var title_f41_29_42448="Tumor bleeding 14c";
var content_f41_29_42448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Postembolization angiogram of one of the left intercostal arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Occlusion of the left intercostal artery (arrow) after embolization is demonstrated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42448=[""].join("\n");
var outline_f41_29_42448=null;
var title_f41_29_42449="Prosthetic mitral valve four chamber echocardiogram";
var content_f41_29_42449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/75409/4chpromv_conv.mp4?title=Prosthetic+mitral+valve+four+chamber+echocardiogram\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prosthetic mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 234px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view of 2-D echocardiogram shows a normally functioning ball-cage prosthetic mitral valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42449=[""].join("\n");
var outline_f41_29_42449=null;
var title_f41_29_42450="Patient information: Bloody stools (The Basics)";
var content_f41_29_42450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15403\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/33/44575\">",
"          Hemorrhoids",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"           Colonoscopy",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29661\">",
"            Amount of fiber in different foods",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/7/6267\">",
"             List of foods and drugs that can make a childs bowel movements look bloody",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/2/43041\">",
"         Patient information: Constipation in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/15/41202\">",
"         Patient information: Hemorrhoids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/31/44529\">",
"         Patient information: Anal fissure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/10/17569\">",
"         Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/11/10418\">",
"         Patient information: Bloody stools in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/47/40689\">",
"         Patient information: Hemorrhoids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bloody stools (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bloody-stools-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H32751911\">",
"      <span class=\"h1\">",
"       What are bloody stools?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Stools&rdquo; is another word for &ldquo;bowel movements.&rdquo; If you have bloody stools, you might see bright red blood:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        On the toilet paper after wiping",
"       </li>",
"       <li>",
"        In the toilet after you go to the bathroom",
"       </li>",
"       <li>",
"        On the surface of or mixed in with your bowel movements",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases bloody stools look like black tar rather than like they have blood on them. Stools that look like tar are usually caused by bleeding high up in the digestive system (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751918\">",
"      <span class=\"h1\">",
"       What causes bloody stools?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The two most common causes are not usually serious:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hemorrhoids &ndash; These are swollen blood vessels in the anus (",
"        <a class=\"graphic graphic_figure graphicRef73076 \" href=\"mobipreview.htm?43/33/44575\">",
"         figure 2",
"        </a>",
"        ). (The anus is the hole where bowel movements come out.) Hemorrhoids can itch or hurt.",
"       </li>",
"       <li>",
"        Anal fissures &ndash; These are tears in the skin on the anus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, bloody stools are serious. They can be a sign of cancer or other problems in the digestive system.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751925\">",
"      <span class=\"h1\">",
"       What other symptoms should I watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These symptoms can show what is causing your problem and if it is serious:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Itching or pain in the anus",
"       </li>",
"       <li>",
"        Feelings of ripping or burning during bowel movements",
"       </li>",
"       <li>",
"        Fever, weight loss, and heavy sweating at night",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Feeling like you need to have a bowel movement, but not being able to go",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Bowel movements that look black or dark red",
"       </li>",
"       <li>",
"        Changes in how often or how hard or soft your bowel movements are",
"       </li>",
"       <li>",
"        Bleeding that goes on for a long time or that comes back again and again",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751932\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you notice any blood with your bowel movements. Most cases are not serious. But anyone with bloody stools should be seen by a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751939\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation.",
"     </p>",
"     <p>",
"      Here are the most common tests doctors use to find the cause of bloody stools:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rectal exam &ndash; Your doctor will look at the outside of your anus. He or she will also use a finger to feel inside the opening.",
"       </li>",
"       <li>",
"        Anoscopy &ndash; In his or her office, your doctor will put a small tube into your anus. The tube goes a few inches into the rectum (the lower part of the large intestine). It has a light on it so the doctor can see inside.",
"       </li>",
"       <li>",
"        Sigmoidoscopy or colonoscopy &ndash; For these tests, the doctor puts a thin tube into your anus. Then, he or she advances the tube into your large intestine. The large intestine is also called the colon. The tube has a camera attached to it, so the doctor can look inside your intestines. During these tests, the doctor can also take samples of tissue to look at under a microscope (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"mobipreview.htm?4/46/4834\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751946\">",
"      <span class=\"h1\">",
"       How are bloody stools treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what is causing your bloody stools. You may not need treatment. If you do, treatments might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fiber supplements and medicines to keep your bowel movements soft",
"       </li>",
"       <li>",
"        Sitting in warm water a few times a day for about 15 minutes",
"       </li>",
"       <li>",
"        Creams and medicines that go on or inside your anus. These help with pain, itching and swelling.",
"       </li>",
"       <li>",
"        More serious medicines for diseases of the digestive system",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751953\">",
"      <span class=\"h1\">",
"       Can bloody stools be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have hemorrhoids, you can reduce your chances of getting bloody stools again by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Drinking plenty of water",
"       </li>",
"       <li>",
"        Eating lots of fiber. Fiber is common in fruits, vegetables, and breakfast cereal (",
"        <a class=\"graphic graphic_table graphicRef52349 \" href=\"mobipreview.htm?28/61/29661\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751960\">",
"      <span class=\"h1\">",
"       What if my child gets bloody stools?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In children and babies, bloody stools can be a symptom of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tears in the anus (anal fissures) from large or hard bowel movements",
"       </li>",
"       <li>",
"        A condition that makes it hard to digest milk or soy",
"       </li>",
"       <li>",
"        Infection by a virus or bacteria, or food poisoning",
"       </li>",
"       <li>",
"        Diseases that affect the digestive system",
"       </li>",
"       <li>",
"        Foods and medicines that look like blood but aren&rsquo;t (",
"        <a class=\"graphic graphic_table graphicRef61276 \" href=\"mobipreview.htm?6/7/6267\">",
"         table 2",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you notice blood in your child&rsquo;s diaper or bowel movements, take him or her to see the doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32751967\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/15/41202?source=see_link\">",
"       Patient information: Hemorrhoids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/2/43041?source=see_link\">",
"       Patient information: Constipation in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=see_link\">",
"       Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/11/10418?source=see_link\">",
"       Patient information: Bloody stools in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/31/44529?source=see_link\">",
"       Patient information: Anal fissure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/47/40689?source=see_link\">",
"       Patient information: Hemorrhoids (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/29/42450?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15403 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42450=[""].join("\n");
var outline_f41_29_42450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751911\">",
"      What are bloody stools?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751918\">",
"      What causes bloody stools?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751925\">",
"      What other symptoms should I watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751932\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751939\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751946\">",
"      How are bloody stools treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751953\">",
"      Can bloody stools be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751960\">",
"      What if my child gets bloody stools?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32751967\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15403\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/33/44575\">",
"       Hemorrhoids",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"        Colonoscopy",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29661\">",
"         Amount of fiber in different foods",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/7/6267\">",
"          List of foods and drugs that can make a childs bowel movements look bloody",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/31/44529?source=related_link\">",
"      Patient information: Anal fissure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=related_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/11/10418?source=related_link\">",
"      Patient information: Bloody stools in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/47/40689?source=related_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/15/41202?source=related_link\">",
"      Patient information: Hemorrhoids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42451="Sarcoptes scabiei";
var content_f41_29_42451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoptes scabiei and eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42451=[""].join("\n");
var outline_f41_29_42451=null;
var title_f41_29_42452="Eletriptan: Drug information";
var content_f41_29_42452=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eletriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/21/12629?source=see_link\">",
"    see \"Eletriptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Relpax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Relpax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acute migraine:",
"     </b>",
"     Oral: Initial: 20-40 mg (maximum: 40 mg/dose); if the headache improves but returns, dose may be repeated after 2 hours have elapsed since first dose (maximum: 80 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If the first dose is ineffective, diagnosis needs to be re-evaluated. Safety of treating &gt;3 headaches/month has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F164505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosing adjustment needed; monitor for increased blood pressure.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F164506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relpax&reg;: 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of migraine, with or without aura",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain/tightness (1% to 4%; placebo 1%), palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 7%; placebo 3%), somnolence (3% to 7%; placebo 4%), headache (3% to 4%; placebo 3%), chills, pain, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4% to 8%; placebo 5%), xerostomia (2% to 4%, placebo 2%), dysphagia (1% to 2%), abdominal pain/discomfort (1% to 2%; placebo 1%), dyspepsia (1% to 2%; placebo 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4% to 10%), paresthesia (3% to 4%), back pain, hypertonia, hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, allergic reaction, angina, arrhythmia, ataxia, confusion, CPK increased, depersonalization, depression, dyspnea, edema, emotional lability, esophagitis, euphoria, hyperesthesia, hyperkinesia, hypertension, impotence, incoordination, insomnia, lacrimation disorder, liver function tests abnormal, myalgia, myasthenia, peripheral vascular disorder, photophobia, polyuria, pruritus, rash, seizure, shock, speech disorder, stupor, tachycardia, thrombophlebitis, tinnitus, tongue edema, tremor, urinary frequency, vasospasm, vision abnormal",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to eletriptan or any component of the formulation; ischemic heart disease (angina pectoris, history of myocardial infarction, or proven silent ischemia) or in patients with symptoms consistent with ischemic heart disease, coronary artery vasospasm, or Prinzmetal's angina; cerebrovascular syndromes (including strokes, transient ischemic attacks); peripheral vascular syndromes (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist; management of hemiplegic or basilar migraine; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Drug clearance may be reduced leading to increased plasma concentrations; dosage reduction is recommended. Contraindicated with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use not recommended within 72 hours in patients taking strong CYP3A4 inhibitors; use caution in patients taking moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions). Consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce eletriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended. If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for treatment of acute migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic or basilar migraine. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Eletriptan.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Eletriptan.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F164499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: High-fat meal increases bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11310537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eight women were given a single dose of eletriptan 80 mg. The amount of drug detected in breast milk over 24 hours was ~0.02% of the maternal dose and the milk-to-plasma ratio was variable. The presence of the active metabolite was not measured.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Relpax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (6): $213.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (6): $213.72",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elle (PK);",
"     </li>",
"     <li>",
"      Relert (BE, CR, DO, FI, GT, IL, NI, PA, PT, SV);",
"     </li>",
"     <li>",
"      Relpax (AT, AU, BG, BR, CH, CN, CO, CZ, DE, DK, EE, ES, FR, GB, GR, HN, IE, IT, MX, NL, NO, NZ, PL, RU, SE, SG, TH, TR, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 138 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; forms one metabolite (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~50%, increased with high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~4 hours (Elderly: 4.4-5.7 hours); Metabolite: ~13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1.5-2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42452/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8517 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42452=[""].join("\n");
var outline_f41_29_42452=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164501\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855134\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164525\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164504\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062899\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164505\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164506\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164482\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164470\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164483\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164523\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164473\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164519\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164477\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164499\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164479\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164488\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164508\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11310537\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164487\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164489\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164472\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164485\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8517\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8517|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/21/12629?source=related_link\">",
"      Eletriptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42453="Lithium and the thyroid";
var content_f41_29_42453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lithium and the thyroid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42453/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42453/contributors\">",
"     Martin I Surks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42453/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42453/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42453/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42453/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/29/42453/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antithyroid actions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    were first investigated in detail when it was noted that patients with psychiatric disease treated with lithium carbonate developed hypothyroidism and goiter. Animal and human studies subsequently revealed that lithium increases intrathyroidal iodine content, inhibits the coupling of iodotyrosine residues to form iodothyronines (thyroxine [T4] and triiodothyronine [T3]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], and inhibits release of T4 and T3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    inhibits thyroid hormone release is not well understood. In vitro, lithium decreases colloid droplet formation within thyroid follicular cells, a reflection of decreased pinocytosis of colloid from the follicular lumen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/5\">",
"     5",
"    </a>",
"    ]. The efficiency of proteolytic digestion of thyroglobulin within phagolysosomes also may be impaired.",
"   </p>",
"   <p>",
"    This topic will review the clinical effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    on thyroid function. In addition to inducing hypothyroidism, the magnitude of the lithium-induced inhibition of thyroid hormone secretion is sufficient to make lithium useful in the treatment of some patients with hyperthyroidism or thyroid cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THYROID DISEASE IN LITHIUM-TREATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    can cause goiter and hypothyroidism, and its use has been associated with both thyroid autoimmunity and hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/6\">",
"     6",
"    </a>",
"    ]. Because of the high incidence of thyroid dysfunction that occurs during lithium treatment, patients should have a careful thyroid physical examination and determination of serum TSH and antithyroid peroxidase antibody titers before lithium treatment is begun. Patients with normal thyroid function initially should be reevaluated every 6 to 12 months for several years, and thyroid dysfunction should be treated if diagnosed. The development of thyroid dysfunction does not typically require discontinuation of lithium. If thyroid function is abnormal at the initial evaluation, lithium can still be given, if necessary, but the thyroid dysfunction should be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goiter is the most common thyroid abnormality in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    treated patients, occurring in approximately 40 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The inhibition of thyroid hormone secretion that occurs during lithium treatment results in decreased serum T4 and T3 concentrations, a compensatory increase in pituitary secretion of thyrotropin (TSH) and, in a new steady state, secretion of a normal amount of thyroid hormone by an enlarged thyroid gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/2\">",
"     2",
"    </a>",
"    ]. Thyroid enlargement may also occur as a result of lithium induced alterations in the function of insulin-like growth factor, tyrosine kinase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    signalling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In affected patients, the thyroid is enlarged to about twice the normal size, and the goiter is usually diffuse, although nodular goiter has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/12\">",
"     12",
"    </a>",
"    ]. The goiters usually occur within the first two years of treatment.",
"   </p>",
"   <p>",
"    The treatment of goiter in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is the same as for goiter of any etiology. Ultrasound evaluation is typically performed to assess for diffuse versus nodular enlargement. Further evaluation of nodular thyroid disease with fine needle aspiration biopsy may be indicated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     Levothyroxine",
"    </a>",
"    (T4) treatment may stabilize or reduce thyroid enlargement in patients with lithium-induced goiter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/10\">",
"     10",
"    </a>",
"    ]. It is unusual for lithium to cause large obstructive goiter, but in such cases, surgery is an alternative treatment. The approach to the patient with thyroid nodules and goiter is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/0/22535?source=see_link\">",
"     \"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32742?source=see_link\">",
"     \"Treatment of obstructive or substernal goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism is also common in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -treated patients. In a review of 11 reports (over 1700 patients), the prevalence of hypothyroidism ranged from 6 to 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, a meta-analysis of eight case-control studies showed more hypothyroidism in patients treated with lithium than in controls (OR 5.78, 95% CI 2.00-16.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/13\">",
"     13",
"    </a>",
"    ]. Hypothyroidism may occur in the presence or absence of goiter, and it is usually subclinical; ie, the patient has a high serum TSH and normal T4 and T3 concentrations. A few patients have overt hypothyroidism with all of its usual symptoms and signs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .) As with goiter, hypothyroidism usually occurs during the first two years of lithium therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/14\">",
"     14",
"    </a>",
"    ]. It occurs more frequently in women over the age of 45, and the risk of hypothyroidism increases with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When hypothyroidism develops, it should be treated with T4 according to the usual therapeutic guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    treatment need not be discontinued and should not be discontinued without consultation with the patient's psychiatrist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic autoimmune thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that many patients who develop hypothyroidism during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    treatment have underlying chronic autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/1,2,12\">",
"     1,2,12",
"    </a>",
"    ]. They have a greater prevalence of antithyroid antibodies before lithium is begun than those lithium-treated patients who remain euthyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/17\">",
"     17",
"    </a>",
"    ]. However, whether lithium itself can induce thyroid autoimmunity is unknown. In one study, the incidence of antithyroid antibodies was higher in depressed patients who were treated with lithium than in depressed patients who were treated with other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/18\">",
"     18",
"    </a>",
"    ]. Other studies show fluctuations in antithyroid antibodies, both up and down, in patients pre- and post-lithium therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two retrospective studies, the frequency of hyperthyroidism in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    was more than two to three times greater than that of hyperthyroidism in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one study, among 14 lithium-treated patients who developed hyperthyroidism, eight were thought to have Graves' disease, three toxic nodular goiter and two painless (subacute lymphocytic) thyroiditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study of 300 patients with Graves' hyperthyroidism and 100 patients with painless thyroiditis, the odds of lithium exposure were higher in patients with painless thyroiditis as compared with those with Graves' disease (odds of exposure 4.7, 95% CI 1.3-17.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of hyperthyroidism in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    -treated patients depends upon the cause. Treatment is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LITHIUM TREATMENT OF THYROID DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its ability to inhibit thyroid secretion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    has been used in the treatment of several thyroid diseases. However, it is not used as first-line therapy because of side effects and the availability of other antithyroid drugs (eg, thionamides).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    (in a dose of 600 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is effective therapy for patients with hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Its effects on thyroid hormone secretion are quantitatively similar to those of iodide, and it therefore may be given in place of iodide in patients who would benefit from rapid correction of hyperthyroidism but are allergic to iodine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .) It also may be useful in patients with intolerance to thionamides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    may prolong the retention of radioiodine within the thyroid gland, which could increase the effectiveness of radioiodine therapy. In a retrospective cohort study, the cure rate was slightly higher in patients given lithium (900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 12 days starting five days before radioiodine (91 versus 85 percent; P = 0.03) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/24\">",
"     24",
"    </a>",
"    ], but there was no difference in a randomized trial of radioiodine alone versus radioiodine plus lithium (900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/25\">",
"     25",
"    </a>",
"    ]. Lithium given coincident with radioiodine can prevent the transient increase in serum thyroid hormone concentrations following radioiodine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/26\">",
"     26",
"    </a>",
"    ]. Because of inconsistent data and the toxicity of lithium, we do not recommend its use in conjunction with radioiodine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    alone has been used to prepare patients for thyroidectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This treatment led to a decrease in serum thyroid hormone concentrations and clinical improvement; subsequent surgery was successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients with thyroid cancer are treated with 131-I, it is sometimes helpful to increase retention of the isotope by cancer tissue.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    can prolong 131-I retention by thyroid tissue. In one study of 15 patients who had diagnostic 131-I scans before and then again after receiving lithium for one to two days, 131-I retention was higher and more prolonged during lithium administration in metastatic lesions and the thyroid remnants in most patients, so that the estimated 131-I dose to the metastases was higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/29\">",
"     29",
"    </a>",
"    ]. Whether these findings will result in improved eradication of metastases remains to be determined. In a study of 12 patients with metastatic differentiated thyroid cancer who had previously received radioiodine therapy without lithium, and who did not have a response despite radioiodine accumulation in metastases, treatment with lithium immediately prior to another dose of radioiodine did not have any beneficial effects on the clinical course (assessed by thyroglobulin levels and radiographs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/30\">",
"     30",
"    </a>",
"    ]. In the absence of clinical trial data showing a beneficial effect, we do not suggest using lithium as an adjunct to radioiodine. This approach is consistent with the American Thyroid Association clinical practice guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42453/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6382623\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      increases intrathyroidal iodine content, inhibits the coupling of iodotyrosine residues to form iodothyronines (thyroxine [T4] and triiodothyronine [T3]), and inhibits release of T4 and T3. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      can cause goiter and hypothyroidism, and its use has been associated with both thyroid autoimmunity and hyperthyroidism. Goiter and hypothyroidism are more common, occurring in approximately 40 to 50 and 20 to 30 percent, respectively, of patients treated with lithium. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thyroid disease in lithium-treated patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the high incidence of thyroid dysfunction that occurs during",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      treatment, patients should have a careful thyroid physical examination and determination of serum TSH and antithyroid peroxidase antibody titers before lithium treatment is begun. Patients with normal thyroid function initially should be reevaluated every 6 to 12 months for several years, and thyroid dysfunction should be treated if diagnosed. The development of thyroid dysfunction does not typically require discontinuation of lithium. If thyroid function is abnormal at the initial evaluation, lithium can still be given if necessary, but the thyroid dysfunction should be treated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thyroid disease in lithium-treated patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of its ability to inhibit thyroid secretion,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      has been used in the treatment of several thyroid diseases. However, it is not used as first-line therapy because of side effects and the availability of other antithyroid drugs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lithium treatment of thyroid disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/1\">",
"      Bagchi N, Brown TR, Mack RE. Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta 1978; 542:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/2\">",
"      Berens SC, Bernstein RS, Robbins J, Wolff J. Antithyroid effects of lithium. J Clin Invest 1970; 49:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/3\">",
"      Burrow GN, Burke WR, Himmelhoch JM, et al. Effect of lithium on thyroid function. J Clin Endocrinol Metab 1971; 32:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/4\">",
"      Spaulding SW, Burrow GN, Bermudez F, Himmelhoch JM. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab 1972; 35:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/5\">",
"      Williams JA, Berens SC, Wolff J. Thyroid secretion in vitro: inhibition of TSH and dibutyryl cyclic-AMP stimulated 131-I release by Li+1. Endocrinology 1971; 88:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/6\">",
"      Barbesino G. Drugs affecting thyroid function. Thyroid 2010; 20:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/7\">",
"      Perrild H, Heged&uuml;s L, Baastrup PC, et al. Thyroid function and ultrasonically determined thyroid size in patients receiving long-term lithium treatment. Am J Psychiatry 1990; 147:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/8\">",
"      Bocchetta A, Bernardi F, Pedditzi M, et al. Thyroid abnormalities during lithium treatment. Acta Psychiatr Scand 1991; 83:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/9\">",
"      Lee S, Chow CC, Wing YK, Shek CC. Thyroid abnormalities during chronic lithium treatment in Hong Kong Chinese: a controlled study. J Affect Disord 1992; 26:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/10\">",
"      Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/11\">",
"      Rao AS, Kremenevskaja N, Resch J, Brabant G. Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur J Endocrinol 2005; 153:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/12\">",
"      Bocchetta A, Cocco F, Velluzzi F, et al. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 2007; 30:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/13\">",
"      McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/14\">",
"      Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health 2006; 2:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/15\">",
"      van Melick EJ, Wilting I, Meinders AE, Egberts TC. Prevalence and determinants of thyroid disorders in elderly patients with affective disorders: lithium and nonlithium patients. Am J Geriatr Psychiatry 2010; 18:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/16\">",
"      Kirov G, Tredget J, John R, et al. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005; 87:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/17\">",
"      Myers DH, Carter RA, Burns BH, et al. A prospective study of the effects of lithium on thyroid function and on the prevalence of antithyroid antibodies. Psychol Med 1985; 15:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/18\">",
"      Wilson R, McKillop JH, Crocket GT, et al. The effect of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease. Clin Endocrinol (Oxf) 1991; 34:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/19\">",
"      Lazarus JH, McGregor AM, Ludgate M, et al. Effect of lithium carbonate therapy on thyroid immune status in manic depressive patients: a prospective study. J Affect Disord 1986; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/20\">",
"      Barclay ML, Brownlie BE, Turner JG, Wells JE. Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clin Endocrinol (Oxf) 1994; 40:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/21\">",
"      Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 2001; 55:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/22\">",
"      Kristensen O, Andersen HH, Pallisgaard G. Lithium carbonate in the treatment of thyrotoxicosis. A controlled trial. Lancet 1976; 1:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/23\">",
"      Ng YW, Tiu SC, Choi KL, et al. Use of lithium in the treatment of thyrotoxicosis. Hong Kong Med J 2006; 12:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/24\">",
"      Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 2010; 95:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/25\">",
"      Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 2002; 12:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/26\">",
"      Bogazzi F, Bartalena L, Campomori A, et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2002; 87:4490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/27\">",
"      Takami H. Lithium in the preoperative preparation of Graves' disease. Int Surg 1994; 79:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/28\">",
"      Mochinaga N, Eto T, Maekawa Y, et al. Successful preoperative preparation for thyroidectomy in Graves' disease using lithium alone: report of two cases. Surg Today 1994; 24:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/29\">",
"      Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/30\">",
"      Liu YY, van der Pluijm G, Karperien M, et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin Endocrinol (Oxf) 2006; 64:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42453/abstract/31\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7843 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42453=[""].join("\n");
var outline_f41_29_42453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6382623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THYROID DISEASE IN LITHIUM-TREATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic autoimmune thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LITHIUM TREATMENT OF THYROID DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6382623\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/0/22535?source=related_link\">",
"      Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32742?source=related_link\">",
"      Treatment of obstructive or substernal goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42454="Hydrochlorothiazide: Pediatric drug information";
var content_f41_29_42454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrochlorothiazide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"    see \"Hydrochlorothiazide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/20/10565?source=see_link\">",
"    see \"Hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Microzide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydro&reg;;",
"     </li>",
"     <li>",
"      Bio-Hydrochlorothiazide;",
"     </li>",
"     <li>",
"      Dom-Hydrochlorothiazide;",
"     </li>",
"     <li>",
"      Novo-Hydrazide;",
"     </li>",
"     <li>",
"      Nu-Hydro;",
"     </li>",
"     <li>",
"      PMS-Hydrochlorothiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Thiazide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bronchopulmonary dysplasia (BPD); diuresis, hypertension:",
"     </b>",
"     Oral: 1-2 mg/kg/dose every 12 hours (Albersheim, 1989; Chemtob, 1989; Engelhardt, 1989)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"      see \"Hydrochlorothiazide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bronchopulmonary dysplasia:",
"     </b>",
"     Infants: Oral: 3-4 mg/kg/day in 2 divided doses (Albersheim, 1989; Engelhardt, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Edema (diuresis):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants 2-6 months: Oral: 1-3 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants &gt;6 months, Children, and Adolescents: Oral: 1-2 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum daily dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children &lt; 2 years: 37.5 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-12 years: 100 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: 200 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1 mg/kg/day once daily; may increase to maximum 3 mg/kg/day; not to exceed 50 mg/day (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum daily dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children &lt;2 years: 37.5 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-12 years: 100 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: 200 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypercalciuria:",
"     </b>",
"     Limited data available: Oral: Initial: 1-2 mg/kg/day once daily; titrate until goal urinary calcium excretion goals reached and symptoms resolve; treatment usually continued for 1 year; maximum daily dose: 100 mg/",
"     <b>",
"      da",
"     </b>",
"     y (Copelovitch, 2012 ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Nephrogenic diabetes insipidus; congenital:",
"     </b>",
"     Limited data available: Oral: 2-3 mg/kg/day in combination with amiloride; dosing based on a retrospective descriptive analysis (n=30, age range 1 month to 40 years) and a pediatric case-series (n=4). (Kirchlechner, 1999; Van Lieburg, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Edema (diuresis):",
"     </b>",
"     Oral: 25-100 mg/day in 1-2 doses; maximum: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 12.5-50 mg/day; minimal increase in response and more electrolyte disturbances are seen with doses &gt;50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     ACC/AHA 2009 Adult Heart Failure guidelines suggest that thiazides lose their efficacy when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microzide&reg;: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 12.5 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food  or milk; administer early in day to avoid nocturia; if multiple daily dosing, the last dose should not be administered later than 6 PM unless instructed otherwise.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F15125969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light, moisture, and freezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); keep container tightly closed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Management of hypertension alone or in combination with other antihypertensive agents (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Use in pregnancy should be reserved for those cases causing extreme discomfort and unrelieved by rest; should not be routinely used during pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Treatment of edema due to heart failure, hepatic cirrhosis, estrogen, or corticosteroid therapy (FDA approved in infants, children, and adults); treatment of various forms of renal dysfunction, including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure (FDA approved in infants, children, and adults); management of hypertension either alone or in combination with other antihypertensive agents (FDA approved in infants, children, and adults); has also been used for bronchopulmonary dysplasia (BPD), idiopathic hypercalcuria, and congenital nephrogenic diabetes insipidus.",
"     <b>",
"      Note:",
"     </b>",
"     Use in pregnancy should be reserved for those cases causing extreme discomfort and unrelieved by rest; should not be routinely used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F179654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HCTZ is an error-prone abbreviation (mistaken as hydrocortisone)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydrochlorothiazide may be confused with hydrocortisone, Viskazide&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Microzide&trade; may be confused with Maxzide&reg;, Micronase&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esidrex [multiple international markets] may be confused with Lasix brand name for furosemide [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esidrix [Germany] may be confused with Lasix brand name for furosemide [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     With capsule formulation, adverse events were observed at doses &ge;25 mg in adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, photosensitivity, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, cramping, diarrhea, epigastric distress, gastric irritation, nausea, pancreatitis, sialadenitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Glycosuria, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm, paresthesia, restlessness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (transient), xanthopsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis, renal dysfunction, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory distress, pneumonitis, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions, necrotizing angiitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic myocarditis, eosinophilic pneumonitis, hepatic function impairment, hypercalcemia, lip cancer (Friedman, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrochlorothiazide or any component; cross-sensitivity with other thiazides or sulfonamides-derived medications; anuria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe renal disease due to decreased efficacy and may precipitate azotemia. Use with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy. Use with caution in patients with prediabetes or diabetes mellitus; may alter glucose control. Use with caution in patients who have a history of gout; may cause hyperuricemia and in certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated. Use with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with hypercalcemia or parathyroid disease; thiazide diuretics may decrease renal calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling; however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hypokalemia; increased risk associated with aggressive diuresis (eg, concurrent loop diuretic use), severe cirrhosis, or after prolonged therapy; alterations in adequate oral potassium intake may also increase risk; monitor serum potassium concentrations at baseline and periodically; correct hypokalemia prior to initiating therapy. Other electrolyte disorders, including hyponatremia, hypomagnesemia, and hypochloremic metabolic alkalosis, may occur; monitor electrolytes. May cause acute transient myopia and acute angle-closure glaucoma possibly leading to permanent vision loss, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy. May cause SLE exacerbation or activation. Photosensitization may occur; patients should be counseled.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peak serum concentrations may be decreased if taken with food; may deplete potassium, sodium, and magnesium. Avoid natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Thiazide diuretics cross the placenta and are found in cord blood. Maternal use may cause may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse events observed in adults. Use of thiazide diuretics during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, BUN, creatinine, blood pressure, fluid balance, body weight, urinary electrolytes (if applicable); serum glucose levels",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium, hydrogen, magnesium, phosphate, calcium, and bicarbonate ions",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Diuresis: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 2-6 hours (Chemtob, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Diuresis: Within 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Diuresis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 8 hours (Chemtob, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 6-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~50% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.6-7.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 5.6-14.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/20/10565?source=see_link\">",
"      see \"Hydrochlorothiazide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Take with meals early in the day to avoid nocturia. A potassium supplement may be prescribed or dietary changes recommended; do not change diet while taking this medication unless recommended by prescriber, especially with concurrent use of potassium supplements or medications to reduce potassium loss. May cause dizziness or postural hypotension. Report palpitations, muscle cramping, or skin rash.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albersheim SG, Solimano AJ, Sharma AK, et al, \"Randomized, Double-Blind, Controlled Trial of Long-Term Diuretic Therapy for Bronchopulmonary Dysplasia,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 115(4):615-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42454/abstract-text/2677293/pubmed\" id=\"2677293\" target=\"_blank\">",
"        2677293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chemtob S, Kaplan BS, Sherbotie JR, et al, \"Pharmacology of Diuretics in the Newborn,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1989, 36(5):1231-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42454/abstract-text/2677940/pubmed\" id=\"2677940\" target=\"_blank\">",
"        2677940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42454/abstract-text/ 12748199 /pubmed\" id=\" 12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Copelovitch L, \"Urolithiasis in Children: Medical Approach,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2012, 59(4):881-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42454/abstract-text/22857835/pubmed\" id=\"22857835\" target=\"_blank\">",
"        22857835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engelhardt B, Blalock WA, DonLevy S, et al, \"Effect of Spironolactone-Hydrochlorothiazide on Lung Function in Infants With Chronic Bronchopulmonary Dysplasia,\"",
"      <i>",
"       J Pediatrics",
"      </i>",
"      , 1989, 114:619-24.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirchlechner V, Koller DY, Seidl R, et al, \"Treatment of Nephrogenic Diabetes Insipidus With Hydrochlorothiazide and Amiloride,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1999, 80(6):548-52.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,\"",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , 2011, National Institutes of Health. Available at file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf. Last accessed: June 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42454/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Vorst MM, Kist JE, van der Heijden AJ, et al, \"Diuretics in Pediatrics: Current Knowledge and Future Prospects,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(4):245-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/29/42454/abstract-text/16898855/pubmed\" id=\"16898855\" target=\"_blank\">",
"        16898855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Lieburg AF, Knoers NV, and Monnens LA, \"Clinical Presentation and Follow-Up of 30 Patients With Congenital Nephrogenic Diabetes Insipidus,\"",
"      <i>",
"       J Am Soc Nephrol",
"      </i>",
"      , 1999, 10(9):1958-64.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13357 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42454=[""].join("\n");
var outline_f41_29_42454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059275\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442602\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059269\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179571\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179556\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059279\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125969\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059278\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179654\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179652\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059283\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059268\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059267\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299455\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179565\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059285\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179567\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179582\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059274\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059266\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059281\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059282\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059273\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13357|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=related_link\">",
"      Hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/20/10565?source=related_link\">",
"      Hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42455="Failure to thrive in elderly adults: Management";
var content_f41_29_42455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Failure to thrive in elderly adults: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     Kathryn Agarwal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     J  Andrew Billings, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42455/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/29/42455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to thrive (FTT) describes a syndrome of global decline that occurs in elders as an aggregate of physical frailty, cognitive impairment, and functional disability (",
"    <a class=\"graphic graphic_figure graphicRef82609 \" href=\"mobipreview.htm?36/14/37103\">",
"     figure 1",
"    </a>",
"    ). The United States National Institute of Aging described FTT as a \"syndrome of weight loss, decreased appetite and poor nutrition, and inactivity, often accompanied by dehydration, depressive symptoms, impaired immune function, and low cholesterol\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/1\">",
"     1",
"    </a>",
"    ]. FTT describes the late stages of decline and may represent a final common pathway toward death unless interventions can reverse the course.",
"   </p>",
"   <p>",
"    For some patients, FTT is caused by a single disease (eg, cancer) and the treatment of that disease drives the management plan. However, Occam's Razor (the concept that the simplest hypothesis is correct) may not be applicable to FTT. In many cases, multiple factors are present and contribute to impairment: medical comorbidities, medications, and psychological factors may interact. Identifying and treating multiple contributing factors can improve quality of life and function in this group of elders; such treatment should be instituted as appropriate and in keeping with the patient's goals of care. A diagnosis of FTT should be considered as a critical point for the clinician to initiate discussions with patients and caregivers about goals of care; considering aggressive interventions cautiously in the face of declining functional status and worsening prognosis.",
"   </p>",
"   <p>",
"    An overview of the management of FTT will be presented here. Evaluation of older patients for suspected FTT and an overview of management of the elder resident in a long-term care facility are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=see_link\">",
"     \"Failure to thrive in elderly adults: Evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42138?source=see_link\">",
"     \"Medical care of the nursing home patient in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MULTIDISCIPLINARY APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of FTT requires a multidisciplinary and multi-faceted approach to treat those identifiable causes that are amenable to treatment. Significant improvements in quality of life can be achieved, even in the setting of a major disease state that cannot be cured, by treating contributing factors. As an example, progressive Alzheimer disease cannot be cured. However, simultaneous pharmacologic interventions for depression and memory, elimination of potentially harmful medications, aggressive social work interventions to increase safety and social interaction, and physical therapy to improve gait instability, may halt the downward spiral of FTT for months to years.",
"   </p>",
"   <p>",
"    While enlisting the expertise of a multidisciplinary support team (social worker; dietitian; physical, occupational, and speech therapist), the clinician should address the role of medical illness and medications as factors. Oral hygiene should be addressed and referral to dentistry should not be overlooked. Reasonable efforts should be made to uncover new treatable medical problems (ie, reactivation tuberculosis, endocarditis, polymyalgia rheumatica, thyroid disease, or malignancy).",
"   </p>",
"   <p>",
"    Management of chronic medical illness should also be optimized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICATION SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications should be carefully reviewed, and all those not absolutely essential should be discontinued with close observation. Decreasing the dose may be beneficial for necessary medications that have known adverse side effects. Attention to dose adjustments is necessary for patients who develop progressive renal failure or hypoalbuminemia.",
"   </p>",
"   <p>",
"    Many medications are considered inappropriate for use in older adults. Medications with anticholinergic properties are best avoided when possible (",
"    <a class=\"graphic graphic_table graphicRef57410 \" href=\"mobipreview.htm?41/32/42508\">",
"     table 1",
"    </a>",
"    ). They have been associated with voiding difficulties, cognitive decline, and worse performance on tests of instrumental activities of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/2\">",
"     2",
"    </a>",
"    ]. Several criteria sets, including",
"    <a class=\"external\" href=\"file://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2012\">",
"     Beers Criteria",
"    </a>",
"    and ACOVE indicators, have identified potentially inappropriate medications for older individuals (",
"    <a class=\"graphic graphic_table graphicRef73834 \" href=\"mobipreview.htm?9/43/9918\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link\">",
"     \"Drug prescribing for older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key component of failure to thrive (FTT) is weight loss and malnutrition. Special attention should be focused on medication side effects, depression, difficulties with chewing and swallowing, dependency on others for eating, and use of unnecessary dietary restrictions (low",
"    <span class=\"nowrap\">",
"     salt/low",
"    </span>",
"    fat) (",
"    <a class=\"graphic graphic_table graphicRef54156 \" href=\"mobipreview.htm?15/36/15948\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/3\">",
"     3",
"    </a>",
"    ]. Additionally, providing favorite foods, varying texture and flavors, and use of finger foods may improve oral intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nutritional supplements and vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In treatment of weight loss, oral nutritional supplements between meals (low-volume, high caloric drinks or puddings) may be helpful in adding protein and calories. A systematic review found that weight gain was greater for patients treated with nutritional supplements plus dietary advice, compared to dietary advice alone (mean difference weight 1.68 kg, 95% CI 0.14-3.32) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/5\">",
"     5",
"    </a>",
"    ]. A meta-analysis of studies of nutritional supplements showed that providing nutritional supplements to older undernourished adults yielded small gains in weight of 2.2 percent (pooled weighted mean weight gain from 42 trials) and a small mortality benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/6\">",
"     6",
"    </a>",
"    ]. However, this review found no evidence of improvement in function or decrease in hospital length of stay with supplements. An important practical tip is that dietary restrictions should be removed or modified to increase palatability of foods.",
"   </p>",
"   <p>",
"    The recommended dietary allowance for protein is 0.8",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    for adults regardless of age. This represents the minimum amount of protein required to avoid loss of lean body mass in most people. However, some nutrition experts disagree with the use of this RDA in older adults and recommend a protein intake of 1.5",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    or approximately 15 to 20 percent of the daily caloric intake to improve muscle mass, strength, and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/7\">",
"     7",
"    </a>",
"    ]. In a 10-year longitudinal study of nutritional status and morbidity, women with protein intakes of 1.20-1.76",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    tended to have fewer health problems than those with protein intake of less than 0.8",
"    <span class=\"nowrap\">",
"     kg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin supplements are suggested for elders with poor caloric intake; macronutrient deficiencies are common in older patients with weight loss. However, studies in nursing home patients do not show clear evidence of benefit from vitamin supplements if the patient has adequate caloric intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enteral feeding via feeding tube did not affect survival at 24 months, compared to those hand fed, in nursing home residents over age 65 with severe cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/10\">",
"     10",
"    </a>",
"    ]. Feeding assistance in nursing home patients may prevent unintentional weight loss. A crossover controlled trial involving 76 nursing home residents at risk for unintentional weight loss found that twice daily feeding assistance (either at meals or snacks) increased caloric intake and maintained or increased weight, while usual care resulted in weight loss over a 24-week period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/11\">",
"     11",
"    </a>",
"    ]. Assisted feeding at mealtime required 84 minutes of staff time per patient per day, compared to 26 minutes for snack assistance, suggesting the latter approach may be more feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Appetite stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of appetite stimulants may be considered, although there are few studies of use of these medications in the population with FTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Megestrol acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    , a progestational agent, has been shown to yield weight gain in patients with anorexia and cachexia. However, its use in older patients with unintentional weight loss should be considered with caution due to limited evidence of benefit and significant adverse effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 26 trials in oncology patients found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      was associated with increased appetite, weight gain, and improvement in health-related quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/12\">",
"       12",
"      </a>",
"      ]. A systematic review of 30 trials in cancer patients similarly found megestrol improved appetite and weight gain but concluded that recommendations for other patients could not be made based on available data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A dose of 800 mg per day of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      was required for substantial increase in prealbumin levels at 20 to 60 days in patients with reduced appetite after hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      800 mg daily for 12 weeks improved appetite and sense of well-being in a group of nursing home residents. However, weight gain was not found to be significant (&gt;4 lbs) until after three months of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective case control study matched 709 nursing home residents with significant weight loss who had received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      (MA) with 1418 patients with similar weight loss and comorbidity who did not receive MA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/16\">",
"       16",
"      </a>",
"      ]. There was no difference in median weight and weight loss and patients who received MA had a significantly decreased median survival from 31 to 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    should be watched closely for edema and worsening of congestive heart failure. An increased incidence of impaired function of the corticoadrenal axis was noted in those who received megestrol acetate in a small trial of patients (mean age 83) with poor appetite post-hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/14\">",
"     14",
"    </a>",
"    ]. Another study found an increased incidence of deep venous thrombosis (DVT) comparing nursing home patients who took megestrol with the incidence of DVT in the general nursing home population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dronabinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    has been shown to improve appetite in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/18\">",
"     18",
"    </a>",
"    ] but has been less well-studied in older adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A limited non-randomized trial showed that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      may be useful for anorexia, weight gain, and behavior problems in patients with advanced Alzheimer disease who were refusing food [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small retrospective observational study (n = 28) compared use of a 12 week course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      or no treatment in nursing home patients with weight loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/20\">",
"       20",
"      </a>",
"      ]. Dronabinol was well tolerated and treated patients showed a trend toward weight gain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    has significant CNS side effects of sedation, fatigue, and hallucinations, limiting its use for most older adult populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHYSICAL FRAILTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of physical frailty involves strength and aerobic training. Exercise, known to be important for preventive health benefits, also has been shown to benefit elders who are already frail with multiple comorbidities. Randomized trials in the frailest nursing home patients have shown benefit from resistance exercise, with almost two-fold increase in muscle mass resulting in improved gait speed and exercise tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/21\">",
"     21",
"    </a>",
"    ]. Participation in moderate to intensive exercise training programs improves functional outcomes and prevents disability in frail older adults in the community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In the Canadian Study of Health and Aging, exercise attenuated the impact of age on mortality for all levels of frailty or health deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/25\">",
"     25",
"    </a>",
"    ]. Those exercisers with the highest degree of frailty had the most improvement or stability in health status, compared with those who did little to no exercise.",
"   </p>",
"   <p>",
"    Referral to physical therapy for evaluation and treatment is a key step in management. Families should be counseled about the importance of ongoing strength and aerobic training after physical therapy treatment has finished. Caregivers should be encouraged to find ways to continue the recommendations of physical therapy indefinitely.",
"   </p>",
"   <p>",
"    Vitamin D supplementation is effective for fall prevention and improving balance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=see_link\">",
"     \"Prevention of falls and complications of falls in community-dwelling older persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anabolic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of growth hormone has been studied as a way to improve sarcopenia and frailty in older patients. A systematic review found that the risks of exogenous growth hormone outweigh potential benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ghrelin, an endogenous ligand for growth hormone secretagogue receptor, holds promise for the future, with preliminary studies demonstrating benefit in oncology patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/27\">",
"     27",
"    </a>",
"    ] and older adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/28\">",
"     28",
"    </a>",
"    ]. However, long-term functional studies need to be completed before recommendations can be made. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testosterone levels decrease with age. Testosterone supplementation increases skeletal muscle mass; however, studies in healthy older men have not demonstrated improvement in functional status, physical function, or cognitive function from testosterone supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A small study in undernourished community-dwelling older men and women did find that combined treatment with oral testosterone undecanoate and an oral nutritional supplement decreased hospital admission rates over one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/31\">",
"     31",
"    </a>",
"    ]. Larger trials are needed to confirm these findings.",
"   </p>",
"   <p>",
"    Adverse effects of testosterone supplementation include lower HDL levels and trends toward metabolic syndrome, erythrocytosis, and possibly prostate cancer in men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4314?source=see_link\">",
"     \"Overview of testosterone deficiency in elderly men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of anabolic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    and nandrolone has been studied in some patients with cachexia related to HIV infection, but use of these drugs in older patients with unintentional weight loss remains to be evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42584?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of tissue wasting in patients with HIV infection\", section on 'Oxandrolone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42584?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of tissue wasting in patients with HIV infection\", section on 'Nandrolone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased environmental support to assist with feeding, self-care, and to provide social interaction is helpful when dementia is a key contributor to failure to thrive (FTT). Patients may stabilize and improve when their living situation is changed to a higher level of assistance and supervision, such as in an assisted living facility or nursing home. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FTT and malnutrition may be inevitable in patients with advanced stages of dementia as they lose the ability to chew, swallow, and deal with their own oral secretions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is a common and reversible cause of weight loss in older adults; the threshold for treatment should be low. The mainstay of therapy for depression is antidepressant medication supplemented by structured psychotherapy when deemed appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The depressive state may be complicated by symptoms of psychosis, anxiety, and mania that should prompt referral to psychiatry. The severity of depression, or associated psychotic features, may warrant hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consideration of electroconvulsive therapy.",
"   </p>",
"   <p>",
"    Trials of pharmacologic interventions for depression have shown most agents to be equally effective in treatment of depression; thus, medications are chosen based on their desired side effect profile. Although tricyclic antidepressants may improve appetite more than SSRI's, side effects limit their use in many frail elders.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    and the SSRIs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    may more frequently yield anorexia or weight loss than other antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    has been shown to increase appetite and weight gain in adults and children taking the medication for depression. Two studies comparing mirtazapine with other nontricyclic antidepressants in depressed older patients showed similar weight gain in both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Thus, the treatment of depression likely had greater effect on weight gain than the specific agent used. The use of mirtazapine for treatment of unintended weight loss is not recommended in the absence of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in severely depressed elders is the use of psychostimulants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    to rapidly improve the symptoms of depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series of 129 medically-ill geriatric patients given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      for depression, 81 percent demonstrated some improvement, which was typically rapid, starting on the second day of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/36\">",
"       36",
"      </a>",
"      ]. Only 8 percent had to stop the drug trial due to adverse side effects.",
"     </li>",
"     <li>",
"      In a small randomized trial comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      plus placebo and citalopram plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      in older depressed patients, patients receiving both citalopram and methylphenidate had an accelerated response at three weeks and a significant improvement in HAM-D depression scores at 10 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small open label study,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      was associated with improvement in the Apathy Evaluation Scale, depression, and functional status in patients with dementia of the Alzheimer type [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    should be initiated cautiously, starting typically with 2.5 mg in the morning, and titrated slowly. Although psychostimulants are not considered to be appetite stimulants, geriatricians find that small doses of methylphenidate may give patients enough energy to eat and to participate in activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1578472\">",
"    <span class=\"h1\">",
"     END OF LIFE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, failure to thrive (FTT) may represent a final common pathway toward death unless interventions can reverse the course. A patient&rsquo;s nutritional status, functional decline, and cognitive impairment may not be amenable to interventions and may not improve depending on the underlying disease state and comorbidities. As FTT in the older adult progresses, it is important to consider a focus on palliative care. FTT or debility are diagnoses used for enrollment in many hospice programs that may provide additional support and benefits for patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Criteria for enrollment vary among hospice agencies and the intermediary companies involved with the management of insurance benefits. Frequently used criteria for determining non-disease specific decline in clinical status that correlate with a six month prognosis may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42455/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss not due to reversible causes",
"     </li>",
"     <li>",
"      Recurrent or intractable infections",
"     </li>",
"     <li>",
"      Recurrent aspiration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inadequate oral intake due to intractable dysphagia",
"     </li>",
"     <li>",
"      Progressive decline in Karnofsky Performance status",
"     </li>",
"     <li>",
"      Progressing dementia by objective measures",
"     </li>",
"     <li>",
"      Progressive pressure ulcers (stage 3 or 4) despite optimal care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consultation with a local hospice organization may be helpful in determining eligibility and discussing enrollment issues with patients and caregivers.",
"   </p>",
"   <p>",
"    Issues related to end of life care are discussed separately in multiple topics in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=see_link\">",
"     \"Legal aspects of end of life care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to thrive (FTT) in elders is a syndrome of global decline, often associated with physical frailty, functional disability, and neuropsychiatric impairment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for FTT involves treating multiple contributing factors, including medication side effects, medical comorbidities, and psychosocial factors. Unnecessary medications should be discontinued. Dietary restrictions should be removed and favorite foods made available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Multidisciplinary approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of weight loss may include oral nutritional supplements between meals and assistance with feeding. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      routinely treating patients with appetite stimulants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      ) due to marginal benefit and potential side effects (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strength and aerobic training can improve functional outcomes in frail older patients. Vitamin D deficiency should be evaluated and treated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical frailty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with depression should be treated with antidepressants. In addition, we suggest a trial of a low-dose psychostimulant (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      2.5 mg) for moderately depressed elders with FTT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Evaluation by psychiatry for consideration of hospitalization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electroconvulsive therapy is indicated for patients with severe depression. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/1\">",
"      Sarkisian CA, Lachs MS. \"Failure to thrive\" in older adults. Ann Intern Med 1996; 124:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/2\">",
"      Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/3\">",
"      Fabiny AR, Kiel DP. Assessing and treating weight loss in nursing home patients. Clin Geriatr Med 1997; 13:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/4\">",
"      Alibhai SM, Greenwood C, Payette H. An approach to the management of unintentional weight loss in elderly people. CMAJ 2005; 172:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/5\">",
"      Baldwin C, Parsons T, Logan S. Dietary advice for illness-related malnutrition in adults. Cochrane Database Syst Rev 2007; :CD002008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/6\">",
"      Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2009; :CD003288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/7\">",
"      Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr 2008; 27:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/8\">",
"      Vellas BJ, Hunt WC, Romero LJ, et al. Changes in nutritional status and patterns of morbidity among free-living elderly persons: a 10-year longitudinal study. Nutrition 1997; 13:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/9\">",
"      Morley JE, Silver AJ. Nutritional issues in nursing home care. Ann Intern Med 1995; 123:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/10\">",
"      Mitchell SL, Kiely DK, Lipsitz LA. The risk factors and impact on survival of feeding tube placement in nursing home residents with severe cognitive impairment. Arch Intern Med 1997; 157:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/11\">",
"      Simmons SF, Keeler E, Zhuo X, et al. Prevention of unintentional weight loss in nursing home residents: a controlled trial of feeding assistance. J Am Geriatr Soc 2008; 56:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/12\">",
"      Pascual L&oacute;pez A, Roqu&eacute; i Figuls M, Urr&uacute;tia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/13\">",
"      Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005; :CD004310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/14\">",
"      Reuben DB, Hirsch SH, Zhou K, Greendale GA. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial. J Am Geriatr Soc 2005; 53:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/15\">",
"      Yeh SS, Wu SY, Lee TP, et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. J Am Geriatr Soc 2000; 48:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/16\">",
"      Bodenner D, Spencer T, Riggs AT, et al. A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss. Am J Geriatr Pharmacother 2007; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/17\">",
"      Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc 2003; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/18\">",
"      Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/19\">",
"      Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/20\">",
"      Wilson MM, Philpot C, Morley JE. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?--a pilot study. J Nutr Health Aging 2007; 11:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/21\">",
"      Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/22\">",
"      Binder EF, Schechtman KB, Ehsani AA, et al. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc 2002; 50:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/23\">",
"      LIFE Study Investigators, Pahor M, Blair SN, et al. Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci 2006; 61:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/24\">",
"      Daniels R, van Rossum E, de Witte L, et al. Interventions to prevent disability in frail community-dwelling elderly: a systematic review. BMC Health Serv Res 2008; 8:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/25\">",
"      Hubbard RE, Fallah N, Searle SD, et al. Impact of exercise in community-dwelling older adults. PLoS One 2009; 4:e6174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/26\">",
"      Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/27\">",
"      Lundholm K, Gunnebo L, K&ouml;rner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010; 116:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/28\">",
"      Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/29\">",
"      Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/30\">",
"      Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc 2008; 56:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/31\">",
"      Chapman IM, Visvanathan R, Hammond AJ, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009; 89:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/32\">",
"      Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/33\">",
"      Goldberg RJ. Weight change in depressed nursing home patients on mirtazapine. J Am Geriatr Soc 2002; 50:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/34\">",
"      Mihara IQ, McCombs JS, Williams BR. The impact of mirtazapine compared with non-TCA antidepressants on weight change in nursing facility residents. Consult Pharm 2005; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/35\">",
"      Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy 2009; 29:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/36\">",
"      Pickett P, Masand P, Murray GB. Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J Geriatr Psychiatry Neurol 1990; 3:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/37\">",
"      Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42455/abstract/38\">",
"      Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2010; 18:371.",
"     </a>",
"    </li>",
"    <li>",
"     National Gerontological Nurses Association Website. file://www.ngna.org/resources/clinical-fast-facts/64-facilitating-the-transition-to-hospice-care.html (Accessed on April 29, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3015 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42455=[""].join("\n");
var outline_f41_29_42455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MULTIDISCIPLINARY APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICATION SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nutritional supplements and vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Appetite stimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Megestrol acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dronabinol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHYSICAL FRAILTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anabolic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1578472\">",
"      END OF LIFE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3015\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3015|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/14/37103\" title=\"figure 1\">",
"      FTT components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3015|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/32/42508\" title=\"table 1\">",
"      Anticholinergic risk scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/43/9918\" title=\"table 2\">",
"      ACOVE quality indicators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/36/15948\" title=\"table 3\">",
"      Causes malnutrition elders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/34/13866?source=related_link\">",
"      End of life care: Stopping nutrition and hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34215?source=related_link\">",
"      Failure to thrive in elderly adults: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14473?source=related_link\">",
"      Legal aspects of end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/9/42138?source=related_link\">",
"      Medical care of the nursing home patient in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4314?source=related_link\">",
"      Overview of testosterone deficiency in elderly men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8393?source=related_link\">",
"      Prevention of falls and complications of falls in community-dwelling older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42456="Surgical issues in HIV infection";
var content_f41_29_42456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical issues in HIV infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42456/contributors\">",
"     Howard Libman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42456/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42456/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/29/42456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potent antiretroviral therapy (ART) has significantly increased longevity among HIV-infected patients. As this patient population grows older, an increased need for surgical interventions, such as coronary revascularization, will likely rise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will address issues surrounding HIV infection in the patient who needs surgery, including morbidity and mortality, the pre-operative evaluation, and post-surgical management. This topic will also address concerns regarding HIV transmission during surgical procedures. Discussions of postexposure prophylaxis after potential HIV exposures are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HIV INFECTION AND SURGICAL MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the data regarding surgical morbidity and mortality in the HIV-infected patient predates the availability of effective antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In the modern treatment era, generally good outcomes have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/6-18\">",
"     6-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 4952 patients who underwent cardiac surgery from 1998 to 2004 at a tertiary care center, 25 HIV-infected patients were identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/6\">",
"       6",
"      </a>",
"      ]. Post-operative complications occurred in 20 percent and operative mortality was 4 percent. These outcomes were similar to a matched HIV-seronegative control population undergoing cardiac procedures within the same time period.",
"     </li>",
"     <li>",
"      In another retrospective study of surgical outcomes, HIV-infected patients were matched 1:1 by type of surgery, year of intervention, gender, and age with HIV-seronegative patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/7\">",
"       7",
"      </a>",
"      ]. Clinical outcomes, length of stay, and number of postoperative visits were similar among the 332 matched patient pairs. Various complications were no more frequent among HIV-infected patients, except for pneumonia.",
"     </li>",
"     <li>",
"      Observational data demonstrate conflicting results as to whether there is a higher risk of postoperative complications (eg, wound infection, endometritis, pneumonia) after Cesarean section among HIV-infected women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/8-14\">",
"       8-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One retrospective study cited a higher risk of pulmonary complications and pneumonia among HIV-infected patients who underwent surgery for lung cancer compared with HIV-seronegative patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational data has been examined to also determine if surgical interventions may affect HIV disease progression. Two case-control studies reported no difference in HIV disease progression between HIV-infected patients who underwent surgery and those who did not have this intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to the HIV-infected patient in need of surgery is similar to that used for any other patient in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General health status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of cardiac and pulmonary risk is important to review. Observational data suggest an increased risk of coronary artery disease among HIV-infected patients compared with HIV-seronegative patients, which may be related to ongoing chronic inflammation, despite viral suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. HIV-infected patients are also at risk for chronic pulmonary disease, since the prevalence of smoking is high (eg, 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/23\">",
"     23",
"    </a>",
"    ]. HIV-infected patients with lung cancer have a higher risk of pulmonary complications compared with HIV-uninfected patients with the same underlying diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/18\">",
"     18",
"    </a>",
"    ]. Preoperative evaluation with a diffusion capacity of lung for carbon monoxide may be helpful for patient selection.",
"   </p>",
"   <p>",
"    Compared with HIV-uninfected patients, the prevalence of insulin resistance, diabetes and hypercholesterolemia is higher among HIV-infected patients, which may be partly related to adverse events of certain antiretroviral medications, lifestyle habits, immunologic dysfunction and HIV itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\", section on 'Insulin resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link&amp;anchor=H2957194#H2957194\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\", section on 'Dyslipidemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HIV disease status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Past medical history should include any history of opportunistic diseases or complications of AIDS. A CD4 cell count and HIV viral load should be performed, if not available within the preceding three months. Clinicians need to be aware that acute medical conditions may transiently decrease the CD4 cell count and increase the viral load, so HIV parameters should be interpreted cautiously in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CD4 cell count is a surrogate marker for degree of immune function and is used to determine whether prophylaxis against various opportunistic infections is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies have found that the incidence of postoperative bacterial complications and sepsis is increased in patients with lower CD4 cell counts, although some have yielded contrary results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/7,15-17,24\">",
"     7,15-17,24",
"    </a>",
"    ]. One study found that a viral load of 30,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or greater was associated with a threefold increased risk of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, for elective surgery, it is preferable to determine what interventions can be accomplished to attain viral suppression; this includes initiation of therapy in the treatment-na&iuml;ve patient or determining whether drug resistance testing or poor adherence may be contributing to less than optimal virologic outcomes in the treatment-experienced patient. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'HIV infection and surgical morbidity and mortality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the patient with established AIDS, it should be recognized that treatment will not lead to immediate immunologic improvement. Furthermore, initiation of antiretroviral therapy (ART) may potentially lead to other complications, such as rash or hepatotoxicity. Therefore, any decision to start therapy in the treatment-naive patient should be made in consultation with an HIV clinician or infectious disease specialist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medication history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the United States Department of Health and Human Services (DHHS) recommended that all HIV-infected patients should be initiated on ART, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, most patients who are aware of their HIV status are taking ART. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have significant drug-drug interactions with many other agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ). A review of potential drug interactions with antiretroviral medications should be performed during the inpatient hospitalization, particularly in preparation for induction of sedation and anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/56/11144?source=see_link\">",
"     \"Pharmacology of integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific questions should be asked of the patient regarding a history of viral hepatitis, tuberculosis exposure, and alcohol and substance use, since these issues are prevalent in HIV-infected patients. A detailed history of sexually transmitted diseases is especially important in women undergoing surgery for possible tuboovarian abscess. Pregnancy testing should also be performed in women of child-bearing age who are undergoing surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional status should be assessed by recent dietary history and comparison of body weights over time. HIV-infected patients with advanced immunosuppression are at risk for wasting and nutritional deficiencies.",
"   </p>",
"   <p>",
"    Lipoatrophy, such as thinning of the extremities and malar atrophy, is also highly prevalent in HIV-infected patients taking antiretroviral therapy and needs to be differentiated from wasting secondary to advanced HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/26\">",
"     26",
"    </a>",
"    ]. Lipoatrophy may also be accompanied by areas of lipodeposition (eg, cervicodorsal region, visceral adiposity), which may be mistaken for simple obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine baseline laboratory studies should include a complete blood count, glucose, liver function tests, serum blood urea nitrogen (BUN), glucose, and creatinine.",
"   </p>",
"   <p>",
"    Pancytopenia may be seen in HIV-infected patients with advanced immunosuppression related to HIV-related myelodysplasia or vitamin B12 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any mild abnormality of serum creatinine should be accompanied by urinalysis to screen for proteinuria to determine if the patient may have HIV-associated nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , a nucleoside analog, has been associated with tubular dysfunction and renal insufficiency, particularly in patients with diabetes or hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determination of platelet count and prothrombin time are important in assessing risk of bleeding, particularly in those patients who have advanced liver disease secondary to hepatitis C or hepatitis B infection. Thrombocytopenia may also be immune-mediated (ITP) related to underlying HIV infection, usually seen in untreated patients with advanced infection. HIV-related ITP is usually associated with mild to moderate thrombocytopenia, but occasionally platelet counts can drop below 10,000 to",
"    <span class=\"nowrap\">",
"     20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    with an associated increased risk of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14522?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5998675\">",
"    <span class=\"h2\">",
"     Advanced directives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical directives and healthcare proxy status should be discussed with the patient prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=see_link&amp;anchor=H5#H5\">",
"     \"Ethical issues near the end of life\", section on 'Advance care planning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral medications should generally be continued through the perioperative period, when feasible. However, if clinically necessary, stopping antiretroviral medications for a few days should not have a deleterious impact on their effectiveness. Viral resistance is more likely to occur when doses of some medications are intermittently missed over an extended period of time.",
"   </p>",
"   <p>",
"    When altered mental status or gastrointestinal tract dysfunction interfere with the ability of the patient to take or absorb oral medications, all antiretroviral drugs should be held. Parenteral alternatives should be sought for agents used for prophylaxis for opportunistic infections (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) if it is anticipated that the patient will be unable to have oral intake for an extended duration of time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liquid preparations are available for many antiretroviral agents for patients who may have difficulty swallowing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H52#H52\">",
"     \"HIV protease inhibitors\", section on 'Resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37495?source=see_link\">",
"     \"Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most postoperative complications, including delayed healing, wound infection, and bacterial sepsis, occur in HIV-infected patients with advanced immunosuppression (as manifested by low CD4 cell count), poor nutrition (as manifested by low serum albumin),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutropenia (eg, absolute neutrophil count &lt;500 cells). One 1996 study identified HIV infection as a risk factor for unplanned postoperative admission to a critical care unit for mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in the era of potent antiretroviral therapy, HIV-infected patients who have achieved immune reconstitution on ART appear to have excellent outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional consultation may be warranted postoperatively if oral intake is inadequate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hypoadrenalism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stress of surgery may unmask previously unsuspected hypoadrenalism, which is seen more commonly in patients with advanced HIV disease who have smoldering infections with Mycobacterium avium complex or cytomegalovirus. Many of the symptoms of adrenal dysfunction are nonspecific. Electrolyte changes (eg, hyponatremia or hyperkalemia) or hypotension may raise suspicion of the presence of hypoadrenalism in the postoperative setting; a cosyntropin stimulation test is indicated in this circumstance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=see_link\">",
"     \"Pituitary and adrenal gland dysfunction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Postoperative fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the HIV-infected patient with postoperative fever is determined by the presence and nature of accompanying symptoms and the level of immunodeficiency as measured by CD4 cell count (",
"    <a class=\"graphic graphic_table graphicRef81432 \" href=\"mobipreview.htm?20/56/21387\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4048288\">",
"    <span class=\"h3\">",
"     Common causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most postoperative fevers in patients with HIV disease are from common causes, such as an infected intravascular catheter site, pneumonia, urinary tract infection, thrombophlebitis, and drug toxicity. In addition to a thorough history and physical examination, evaluation should include a complete blood count with differential, liver function tests, two blood culture sets, urinalysis, and a chest x-ray.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4048295\">",
"    <span class=\"h3\">",
"     Opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration should be given to an opportunistic infection in the febrile patient with a CD4 cell count less than",
"    <span class=\"nowrap\">",
"     200/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    In such patients, routine blood cultures and isolator tubes for Mycobacterium avium complex infection should be performed in addition to the laboratories noted above. Symptoms of dyspnea or headache may also direct additional evaluation for Pneumocystis or cryptococcal meningitis, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7577?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also important to remember that HIV-infected patients with pre-existing leukopenia may not mount a leukocyte response despite the presence of serious infection or bacteremia. An infectious disease consult should be considered for assistance in the diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4048302\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pulmonary infections are among the most frequently encountered in HIV disease. An infectious disease consultation should be considered for assistance in the evaluation and management of the immunosuppressed HIV-infected patient with fever and pulmonary infiltrates. The HIV-infected patient who has dyspnea or cough should undergo a careful assessment that is guided by the clinical presentation and CD4 cell count.",
"   </p>",
"   <p>",
"    The clinical presentation and radiologic appearance of bacterial pneumonia in the HIV-infected patient with a CD4 cell count &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are generally similar to those in immunocompetent patients. A complete blood and differential count, two blood culture sets, chest x-ray, and oximetry should be performed. If the chest x-ray reveals lobar or segmental infiltrates, induced sputum examination for Gram stain and culture should be ordered and empiric therapy for bacterial pneumonia should be started, pending results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15449?source=see_link\">",
"     \"Bacterial pulmonary infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIDS patients with neutropenia are at risk for invasive bacterial pneumonia related to nosocomial pathogens, such as Staphylococcus aureus and gram-negative organisms, including P. aeruginosa, K. pneumoniae, and Enterobacter species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the chest x-ray shows diffuse or patchy infiltrates in a patient with AIDS, an induced sputum examination for Pneumocystis, as well as for Gram stain, acid-fast bacilli stain, special stains for Legionella and fungi, and appropriate cultures, should be performed. Treatment is generally based upon the results of these tests. However, if the patient appears acutely ill or is hypoxemic, empiric therapy for Pneumocystis should be initiated promptly; treatment started prior to the sputum examination will not adversely affect its sensitivity for this infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient at risk for tuberculosis exposure, a PPD should be placed, and multiple samples for acid-fast bacilli should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5997881\">",
"    <span class=\"h1\">",
"     ORGAN TRANSPLANTATION IN HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ transplantation in HIV-infected patients has become more common in the past few years with the advent of effective combination antiretroviral therapy and improvement in life expectancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, only a small proportion of US transplantation centers are participating in a multicenter study of transplantation in HIV-infected patients, so access is still limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/37\">",
"     37",
"    </a>",
"    ]. Also, many insurance companies have declined to pay for such medical interventions. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/61/15321?source=see_link\">",
"     \"Solid organ transplantation in HIV-infected individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5997912\">",
"    <span class=\"h1\">",
"     SURGERY AND HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that identifying the HIV status of patients prior to procedures reduces the chance of accidental blood exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/38\">",
"     38",
"    </a>",
"    ]. Routine preoperative screening for HIV infection in surgical patients is neither cost-effective nor a reasonable alternative to universal precautions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns regarding HIV transmission during surgery have been raised regarding transmission from an HIV-infected patient to an uninfected surgeon or from an HIV-infected surgeon to an uninfected patient, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5998144\">",
"    <span class=\"h2\">",
"     Risk of HIV transmission from patient to healthcare worker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring the true incidence of occupational exposure to infectious agents is difficult because an estimated 50 percent of events are unreported. Surgeons have approximately one dozen percutaneous blood exposures per person-year, which is the highest among healthcare workers, while inpatient nurses average one exposure per year.",
"   </p>",
"   <p>",
"    Between 1981 and 2010, there were 57 documented seroconversions and 143 possible cases of occupationally-acquired HIV infection in the United States (",
"    <a class=\"graphic graphic_table graphicRef60942 \" href=\"mobipreview.htm?32/8/32908\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/40\">",
"     40",
"    </a>",
"    ]. The most common route of exposure leading to HIV infection among these healthcare workers was",
"    <span class=\"nowrap\">",
"     percutaneous/puncture",
"    </span>",
"    injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/40\">",
"     40",
"    </a>",
"    ]. It is significant that no new documented cases have occurred since 1999 and the last possible case to be reported occurred in 2009. However, the reporting system is voluntary so underreporting of cases is possible (",
"    <a class=\"graphic graphic_figure graphicRef54988 \" href=\"mobipreview.htm?31/9/31902\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All cases of suspected occupationally-acquired HIV should be reported to state health department HIV surveillance staff and the CDC coordinator at 404-639-0934 or 404-639-2050. In the event of any exposure, prompt post-exposure prophylaxis is critically important. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5998392\">",
"    <span class=\"h2\">",
"     Risk of HIV transmission from infected healthcare workers to patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5998422\">",
"    <span class=\"h3\">",
"     Large-scale look-back investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall risk of HIV transmission from a healthcare worker to a patient appears to be extremely low; only three cases resulting in eight infections have been documented globally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a widely publicized incident in 1990, a Florida dentist was identified by DNA sequencing as the source of HIV infection in six of his patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Despite intensive epidemiologic investigation, the mechanism of transmission was never established.",
"   </p>",
"   <p>",
"    Following the incident involving the dentist, the Centers for Disease Control and Prevention (CDC) initiated 66 \"look-back\" investigations involving 22,759 patients who had invasive procedures performed by HIV-infected healthcare workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Only 113 (0.5 percent) were found to have HIV infection, most of whom were aware of their condition prior to the time of the procedure. In the other cases, none of the viral strains were found to be identical to those of the healthcare workers based on DNA sequencing. In reviewing the available data, the CDC has estimated that the risk of HIV transmission from a healthcare worker to a patient during a surgical procedure is between 1 in 2.4 million to 24 million.",
"   </p>",
"   <p>",
"    Another investigation was performed in an Israeli cardiothoracic surgeon who was found to be HIV-infected in 2007 when he presented with unexplained fevers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/49\">",
"     49",
"    </a>",
"    ]. The surgeon had advanced HIV disease with a CD4 cell count of",
"    <span class=\"nowrap\">",
"     49/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and an HIV RNA level of &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    A look-back investigation was performed of all patients on whom he had operated during the previous 10 years. Of the 1669 patients identified, 545 (33 percent) underwent serologic testing; all were HIV-seronegative. In addition, none of the patients&rsquo; names have appeared on a national registry of known HIV-seropositive persons. This report adds to the existing body of data, which argue for a very low risk of provider-to-patient HIV transmission in the present era.",
"   </p>",
"   <p>",
"    After receipt of these results, an expert panel recommended allowing the surgeon to return to work with no restrictions on the types of procedures he performed, provided that the surgeon complete additional infection control instruction and adhere to routine HIV RNA monitoring to confirm ongoing viral suppression on antiretroviral therapy (ART).",
"   </p>",
"   <p>",
"    On the basis of the investigation and the published literature, the panel did not require notification of prospective patients of the surgeon's HIV status because of the extremely low likelihood of transmission if these conditions were met.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5998429\">",
"    <span class=\"h3\">",
"     Management of the HIV-infected healthcare worker",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Society for Healthcare Epidemiology of America (SHEA) has published guidelines for the management of healthcare workers who are infected with HIV and other bloodborne pathogens, such as hepatitis B and C viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/50\">",
"     50",
"    </a>",
"    ]. In general, SHEA states that HIV-infected healthcare providers should not be prohibited from participating in patient-care activities solely based on HIV status. Specific recommendations are made based upon the healthcare worker&rsquo;s viral burden and category of clinical activity. The three categories of procedures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with minimal risk of blood transmission (eg, endoscopy, or routine rectal or vaginal examinations)",
"     </li>",
"     <li>",
"      Those with possible risk of blood transmission, but unlikely (eg, endodontic dental procedures, abscess drainage, biopsies under local anesthesia)",
"     </li>",
"     <li>",
"      Those with definite risk of blood transmission (eg, general surgery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines recommend that HIV-infected healthcare providers should not be restricted from Category 1 or 2 procedures if they have circulating virus. However, those with HIV RNA &gt;10",
"    <sup>",
"     2",
"    </sup>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    should refrain from Category 3 procedures. Those healthcare workers who have less than 10",
"    <sup>",
"     2",
"    </sup>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    may be allowed to engage in Category 3 procedures if the following criteria have been met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of prior transmission from the healthcare provider to a patient",
"     </li>",
"     <li>",
"      The infected healthcare worker continues have twice-yearly follow-up with the occupational medicine division regarding maintenance of viral suppression or low-level viremia",
"     </li>",
"     <li>",
"      The healthcare provider gets HIV care from an expert in the field, who communicates with the expert panel regarding the provider&rsquo;s clinical status",
"     </li>",
"     <li>",
"      The healthcare provider strictly complies with all infection control procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from the United Kingdom recommend that patient notification should be decided on a case-by-case basis depending upon the perceived risk of transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42456/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the era of highly effective antiretroviral therapy, surgical morbidity and mortality in HIV-infected patients appears comparable to HIV-uninfected patients. There are also no data to suggest that major surgery accelerates HIV disease progression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'HIV infection and surgical morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pre-operative screening in the HIV-infected patient is similar to any other patient and should include evaluation of cardiac and pulmonary status and routine laboratories for assessment of platelets, hematocrit, creatinine and hepatic synthetic function. Measurement of the CD4 cell count is also important since immunosuppression may increase the risk of post-operative infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Preoperative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A review of potential drug interactions with antiretroviral medications should be performed in preparation for induction of sedation and anesthesia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Preoperative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When altered mental status or gastrointestinal tract dysfunction interferes with the ability of the patient to take oral medications, all antiretroviral drugs should be held. In the patient with AIDS, parenteral alternatives should be sought for agents used for prophylaxis against opportunistic infections if a prolonged duration of poor oral intake is anticipated. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Perioperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most postoperative fevers in patients with HIV disease are from common causes, such as an infected intravascular catheter site, pneumonia, urinary tract infection, thrombophlebitis, and drug toxicity. However, the possibility of an opportunistic infection should be considered in the patient with advanced immunosuppression (eg, CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Postoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine preoperative screening for HIV infection in surgical patients is neither cost-effective nor a reasonable alternative to universal precautions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Preoperative assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of HIV transmission from a healthcare worker to a patient through a surgical procedure has been estimated to be extremely low and few documented cases exist in the literature. HIV-infected healthcare providers should not be prohibited from participating in patient-care activities solely based on HIV status. (See",
"      <a class=\"local\" href=\"#H5998392\">",
"       'Risk of HIV transmission from infected healthcare workers to patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/1\">",
"      Wexner SD, Smithy WB, Milsom JW, Dailey TH. The surgical management of anorectal diseases in AIDS and pre-AIDS patients. Dis Colon Rectum 1986; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/2\">",
"      Burke EC, Orloff SL, Freise CE, et al. Wound healing after anorectal surgery in human immunodeficiency virus-infected patients. Arch Surg 1991; 126:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/3\">",
"      Consten EC, Slors JF, Danner SA, et al. Severe complications of perianal sepsis in patients with human immunodeficiency virus. Br J Surg 1996; 83:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/4\">",
"      Morandi E, Merlini D, Salvaggio A, et al. Prospective study of healing time after hemorrhoidectomy: influence of HIV infection, acquired immunodeficiency syndrome, and anal wound infection. Dis Colon Rectum 1999; 42:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/5\">",
"      Hewitt WR, Sokol TP, Fleshner PR. Should HIV status alter indications for hemorrhoidectomy? Dis Colon Rectum 1996; 39:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/6\">",
"      Filsoufi F, Salzberg SP, Harbou KT, et al. Excellent outcomes of cardiac surgery in patients infected with HIV in the current era. Clin Infect Dis 2006; 43:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/7\">",
"      Horberg MA, Hurley LB, Klein DB, et al. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Arch Surg 2006; 141:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/8\">",
"      Miller FC. Ten goals for the American College of Obstetricians and Gynecologists for the first decade of the next millennium. Obstet Gynecol 2000; 95:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. DHHS HIV/AIDS Treatment Information Service. www.aidsinfo.org (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/10\">",
"      Grubert TA, Reindell D, K&auml;stner R, et al. Complications after caesarean section in HIV-1-infected women not taking antiretroviral treatment. Lancet 1999; 354:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/11\">",
"      Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after caesarean section in 156 HIV-positive women. AIDS 1995; 9:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/12\">",
"      Louis J, Landon MB, Gersnoviez RJ, et al. Perioperative morbidity and mortality among human immunodeficiency virus infected women undergoing cesarean delivery. Obstet Gynecol 2007; 110:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/13\">",
"      European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/14\">",
"      Watts DH, Lambert JS, Stiehm ER, et al. Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of &lt; or = 500/microL. Am J Obstet Gynecol 2000; 183:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/15\">",
"      Guth AA, Hofstetter SR, Pachter HL. Human immunodeficiency virus and the trauma patient: factors influencing postoperative infectious complications. J Trauma 1996; 41:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/16\">",
"      Albaran RG, Webber J, Steffes CP. CD4 cell counts as a prognostic factor of major abdominal surgery in patients infected with the human immunodeficiency virus. Arch Surg 1998; 133:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/17\">",
"      Emparan C, Iturburu IM, Ortiz J, Mendez JJ. Infective complications after abdominal surgery in patients infected with human immunodeficiency virus: role of CD4+ lymphocytes in prognosis. World J Surg 1998; 22:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/18\">",
"      Hooker CM, Meguid RA, Hulbert A, et al. Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg 2012; 93:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/19\">",
"      Astermark J, L&ouml;fqvist T, Schulman S, et al. Major surgery seems not to influence HIV disease progression in haemophilia patients. Br J Haematol 1998; 103:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/20\">",
"      Phillips AM, Sabin CA, Ribbans WJ, Lee CA. Orthopaedic surgery in hemophilic patients with human immunodeficiency virus. Clin Orthop Relat Res 1997; :81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/21\">",
"      Fichtenbaum CJ. Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep 2011; 13:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/22\">",
"      Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis 2012; 205 Suppl 3:S383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/23\">",
"      Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/24\">",
"      Deneve JL, Shantha JG, Page AJ, et al. CD4 count is predictive of outcome in HIV-positive patients undergoing abdominal operations. Am J Surg 2010; 200:694.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on June 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/26\">",
"      Tungsiripat M, McComsey G. Pathogenesis and management of lipoatrophy. Curr HIV/AIDS Rep 2008; 5:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/27\">",
"      Freitas P, Carvalho D, Santos AC, et al. Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy. J Endocrinol Invest 2012; 35:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/28\">",
"      Ryu T, Ikeda M, Okazaki Y, et al. Myelodysplasia associated with acquired immunodeficiency syndrome. Intern Med 2001; 40:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/29\">",
"      Ray PE. HIV-associated nephropathy: a diagnosis in evolution. Nephrol Dial Transplant 2012; 27:3969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/30\">",
"      Ando M, Tsuchiya K, Nitta K. How to manage HIV-infected patients with chronic kidney disease in the HAART era. Clin Exp Nephrol 2012; 16:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/31\">",
"      Rose DK, Byrick RJ, Cohen MM, Caskennette GM. Planned and unplanned postoperative admissions to critical care for mechanical ventilation. Can J Anaesth 1996; 43:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/32\">",
"      Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1987; 82:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/33\">",
"      Shepp DH, Tang IT, Ramundo MB, Kaplan MK. Serious Pseudomonas aeruginosa infection in AIDS. J Acquir Immune Defic Syndr 1994; 7:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/34\">",
"      Tumbarello M, Tacconelli E, de Gaetano K, et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/35\">",
"      Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/36\">",
"      Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/37\">",
"      Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/38\">",
"      Gerberding JL, Littell C, Tarkington A, et al. Risk of exposure of surgical personnel to patients' blood during surgery at San Francisco General Hospital. N Engl J Med 1990; 322:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/39\">",
"      Lawrence VA, Gafni A, Kroenke K. Preoperative HIV testing: is it less expensive than universal precautions? J Clin Epidemiol 1993; 46:1219.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/HAI/organisms/hiv/Surveillance-Occupationally-Acquired-HIV-AIDS.html (Accessed on April 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/41\">",
"      Lot F, S&eacute;guier JC, F&eacute;gueux S, et al. Probable transmission of HIV from an orthopedic surgeon to a patient in France. Ann Intern Med 1999; 130:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/42\">",
"      Bosch X. Second case of doctor-to-patient HIV transmission. Lancet Infect Dis 2003; 3:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/43\">",
"      Centers for Disease Control (CDC). Possible transmission of human immunodeficiency virus to a patient during an invasive dental procedure. MMWR Morb Mortal Wkly Rep 1990; 39:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/44\">",
"      Centers for Disease Control (CDC). Update: transmission of HIV infection during invasive dental procedures--Florida. MMWR Morb Mortal Wkly Rep 1991; 40:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/45\">",
"      Ciesielski C, Marianos D, Ou CY, et al. Transmission of human immunodeficiency virus in a dental practice. Ann Intern Med 1992; 116:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/46\">",
"      Danila RN, MacDonald KL, Rhame FS, et al. A look-back investigation of patients of an HIV-infected physician. Public health implications. N Engl J Med 1991; 325:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/47\">",
"      Centers for Disease Control (CDC). Update: investigations of patients who have been treated by HIV-infected health-care workers. MMWR Morb Mortal Wkly Rep 1992; 41:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/48\">",
"      Robert LM, Chamberland ME, Cleveland JL, et al. Investigations of patients of health care workers infected with HIV. The Centers for Disease Control and Prevention database. Ann Intern Med 1995; 122:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/49\">",
"      Centers for Disease Control and Prevention (CDC). Investigation of patients treated by an HIV-infected cardiothoracic surgeon--Israel, 2007. MMWR Morb Mortal Wkly Rep 2009; 57:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42456/abstract/50\">",
"      Henderson DK, Dembry L, Fishman NO, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol 2010; 31:203.",
"     </a>",
"    </li>",
"    <li>",
"     United Kingdom Department of Health. HIV infected health care workers: guidance on management and patient notification. July, 2005.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3732 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42456=[""].join("\n");
var outline_f41_29_42456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV INFECTION AND SURGICAL MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREOPERATIVE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General health status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HIV disease status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medication history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Past medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5998675\">",
"      Advanced directives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PERIOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hypoadrenalism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4048288\">",
"      - Common causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4048295\">",
"      - Opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4048302\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5997881\">",
"      ORGAN TRANSPLANTATION IN HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5997912\">",
"      SURGERY AND HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5998144\">",
"      Risk of HIV transmission from patient to healthcare worker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5998392\">",
"      Risk of HIV transmission from infected healthcare workers to patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5998422\">",
"      - Large-scale look-back investigations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5998429\">",
"      - Management of the HIV-infected healthcare worker",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3732|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/9/31902\" title=\"figure 1\">",
"      HCW HIV cases since 1985",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/56/21387\" title=\"table 1\">",
"      Causes postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/8/32908\" title=\"table 2\">",
"      Occupational HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15449?source=related_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/56/11144?source=related_link\">",
"      Pharmacology of integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37495?source=related_link\">",
"      Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42457="Laser refractive surgery";
var content_f41_29_42457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laser refractive surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42457/contributors\">",
"     Kraig S Bower, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42457/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/29/42457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/29/42457/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/29/42457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser refractive surgery is becoming increasingly popular as people are turning to alternatives to traditional spectacles and contact lenses for vision correction. This review will briefly discuss the anatomy and principles behind visual problems and correction, and will provide an overview of laser refractive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE CORNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transparent cornea is about one-half millimeter thick and has five distinct layers. The epithelium is the most exterior layer providing the smooth refractive surface and barrier against infection. The function of Bowman's membrane, which lies beneath the epithelium and its basement membrane, is unclear. The stroma, made up of intertwining lamellae of collagen fibrils, provides structure and accounts for 90 percent of the corneal thickness. The endothelium and its basement membrane (Descemet's membrane) form the innermost layers. Endothelial cells, via an active sodium-potassium-ATPase pump, are responsible for the natural corneal dehydration necessary for corneal clarity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REFRACTIVE ERROR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refraction is the bending of light rays as they pass from one transparent medium to another medium of a different density. Refraction is measured in diopters (D). The refractive power of a lens is the reciprocal of its focal length in meters. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=see_link\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In emmetropia (an eye with normal vision), the focusing power of the cornea and lens is perfectly matched to the length of the eye. Parallel light rays from a distant object are brought into focus precisely on the retina and a clear image is perceived (",
"    <a class=\"graphic graphic_figure graphicRef66973 \" href=\"mobipreview.htm?37/40/38543\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Refractive errors occur when light rays entering the eye do not focus properly on the retina:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In myopia (nearsightedness), the most common type of refractive error, the cornea is too curved or the lens is too powerful for the length of the globe. Distant objects cannot be seen clearly because light rays are focused in front of the retina (",
"      <a class=\"graphic graphic_figure graphicRef66973 \" href=\"mobipreview.htm?37/40/38543\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In hyperopia (farsightedness), the cornea and lens are too weak for the length of the globe. As a result, light rays reach the retina before they are focused to a single point (",
"      <a class=\"graphic graphic_figure graphicRef66973 \" href=\"mobipreview.htm?37/40/38543\">",
"       figure 1",
"      </a>",
"      ). A distant object may be brought into focus by using accommodation, but clear near vision is difficult.",
"     </li>",
"     <li>",
"      With an astigmatism, the refractive power of the eye is different in different meridians. Light rays can never be brought to a single point and objects will appear blurry at any distance. Astigmatism may occur with myopia or hyperopia (",
"      <a class=\"graphic graphic_figure graphicRef76303 \" href=\"mobipreview.htm?38/26/39343\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Presbyopia is a different type of refractive error in which loss of accommodation occurs as the lens hardens with age. This results in an inability to bring a near object into focus on the retina and requires the use of reading glasses, typically in patients in their 40s. Presbyopia is not corrected by laser refractive surgery, and the surgery may in fact hasten the development of presbyopia (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CORRECTIVE LENSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrective lenses are the traditional method of treating refractive errors. Myopia is treated with concave lenses with minus or divergent power to focus light rays on the retina. Convex lenses with plus or convergent power help correct vision in the hyperopic eye, and cylindrical lenses are used to neutralize astigmatism.",
"   </p>",
"   <p>",
"    Spectacle prescriptions are used to correct the sphere and cylinder components of refractive errors. The first part of the prescription is the sphere. A plus number indicates hyperopia and a minus number indicates myopia. The second number of the prescription is the cylinder, otherwise known as the astigmatism, either written in a plus or minus. The third number is the axis of the astigmatism. Spectacle prescriptions are then written in increments of 0.25 D.",
"   </p>",
"   <p>",
"    As an example, a hyperopic prescription may read +3.00 &ndash; 1.50 x 180 and a myopic prescription may read &ndash; 4.50 + 2.50 x 090. When treating patients with refractive surgery, the surgeon may also consider the spherical equivalent of a spectacle correction. The spherical equivalent is one-half the cylinder added to the sphere. As an example, the spherical equivalent of +3.00 &ndash; 1.50 x 180 = +2.25 by taking one-half of &ndash;1.50 which equals &ndash;0.75 and adding this number to +3.00.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WAVEFRONT TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a standard eye examination, the refractive surgeon will test for myopia, hyperopia, and astigmatism. However, patients may have irregular astigmatism defined as higher order aberrations eg, coma or spherical aberrations. These higher order optical aberrations can have significant impact on vision. In the past, the ophthalmologist had no way to correct a patient's irregular astigmatism. Spectacles only correct lower order aberrations such as sphere and cylinder.",
"   </p>",
"   <p>",
"    Presently, objective techniques exist for a comprehensive measurement of the optics of the eye. The science of wavefront aberrometry is based upon the shape of the wavefront of light reflected from the eye. A beam of light is refracted from the eye and goes through a micro-lens array producing a spot image array of reflected light. A computer analysis determines the relative displacement of each spot image. The images are then computed to give the local slope and character of the wavefront of light. The analyzed wavefront is then used to derive a correction profile to remove the correct amount of corneal stroma in micron intervals using a guided laser.",
"   </p>",
"   <p>",
"    The information obtained from wavefront technology will enable the refractive surgeon to reduce the natural and surgically induced higher order aberrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The refractive surgery patient may benefit from the correction of higher order aberrations by improving best spectacle corrected visual acuity (BSCVA), night vision, contrast sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/3\">",
"     3",
"    </a>",
"    ], and reducing glare and halos.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THE EXCIMER LASER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excimer laser emits an ultraviolet beam that has sufficient energy to break intermolecular bonds within the cornea (\"photoablation\"). Because there is little or no thermal damage to adjacent tissue, this is often referred to as a \"cool laser beam.\" A computer programmed with the patient's refraction and corneal topography controls the laser beam to precisely remove corneal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first excimer lasers were FDA approved in 1995 and used a broad beam of 4 to 5 mm in width. With improving technology, the width of the laser beam has continued to decrease to less than 100 microns. Some excimer lasers have ablation programs which use both broad beam laser to remove large amounts of corneal stroma and smaller beam laser to remove small amounts of tissue in the same treatment. Each laser pulse removes a discrete volume of corneal stroma. The cumulative ablation is achieved by partial overlap of many laser shots. The greatest corneal stroma removal occurs where laser shot density is the highest. The constantly moving smaller laser beam diameter enables the treatment to avoid revisiting the same site on the cornea for a finite period of time.",
"   </p>",
"   <p>",
"    In addition, laser eye tracking systems are now available that allow precision corneal ablation during eye movements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/5\">",
"     5",
"    </a>",
"    ]. The eye can move during laser treatment of the corneal surface, thereby causing a less than desirable ablation. Eye movements such as saccades, high frequency tremors, and irregular movements can affect the refractive outcome. The speed of the eye tracking systems incorporated in some lasers allows the laser to follow saccadic and involuntary eye movements, so that ablation of the cornea can continue while the eye moves, ensuring accurate pulse placement.",
"   </p>",
"   <p>",
"    In myopia, the laser flattens the central cornea to decrease its focusing power. In hyperopia, the laser indirectly steepens the central cornea by removing tissue from the periphery, thus increasing its focusing power. Astigmatism is treated with an elliptical or cylindrical beam that flattens the steepest corneal meridian.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of refractive surgical procedures can be divided into five broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lamellar procedures: laser-assisted in situ keratomileusis (LASIK), sub-Bowman keratomileusis (SBK)",
"     </li>",
"     <li>",
"      Surface ablation procedures: photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), and epithelial laser keratomileusis (epi-LASIK)",
"     </li>",
"     <li>",
"      Incisional procedures: radial keratotomy",
"     </li>",
"     <li>",
"      Intracorneal procedures: intracorneal ring or corneal inlays",
"     </li>",
"     <li>",
"      Intraocular procedures: anterior or posterior chamber intraocular lens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LASIK, PRK, and LASEK are most commonly performed (",
"    <a class=\"graphic graphic_figure graphicRef53888 \" href=\"mobipreview.htm?15/24/15752\">",
"     figure 3",
"    </a>",
"    ), and are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laser-assisted in situ keratomileusis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser-assisted in situ keratomileusis (LASIK), now the most commonly performed refractive surgery, is an effective treatment for low, moderate, and high myopia with and without astigmatism, as well as hyperopia with and without astigmatism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/6-12\">",
"     6-12",
"    </a>",
"    ]. LASIK is an outpatient surgery performed with topical anesthesia. A microkeratome, which works like a carpenter's plane, is used to raise a corneal flap about the size of a contact lens. This flap usually averages 160 microns thick and is folded back to expose the underlying stroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The excimer laser is used to ablate a precise amount of corneal stroma and the flap is irrigated and replaced. The cap is stabilized without sutures by the natural corneal dehydration created by the endothelial pump. Flap stability and adherence to the corneal stroma are checked after surgery and patients are usually sent home on topical steroid, topical antibiotic, and topical nonsteroidal drops. The patient also is instructed to use an eye shield overnight with follow-up typically scheduled on postoperative day one and then at one week. The patient is usually seen again at one, three, and six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LASIK has significant attractions for the patient. It causes little pain, provides quick recovery of vision, and has the potential for treating higher levels of myopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/10\">",
"     10",
"    </a>",
"    ]. LASIK has also been found to be safe and effective to treat both eyes on the same day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/14\">",
"     14",
"    </a>",
"    ]. LASIK enhancements are more easily performed, at least within the first 6 to 12 months, by lifting the original flap and retreating the stromal bed to correct any residual refractive error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/15\">",
"     15",
"    </a>",
"    ]. LASIK produces less stromal haze than PRK and does not require continuous steroid therapy.",
"   </p>",
"   <p>",
"    Ten-year outcomes for patients with moderate myopia, in a retrospective (nonrandomized) study that compared PRK and LASIK in patients with similar baseline visual acuity, were slightly more favorable for LASIK, with a lower retreatment rate and similar visual acuity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/16\">",
"     16",
"    </a>",
"    ]. The authors note, however, that there have been subsequent technical improvements that might improve results for surface ablation procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sub-Bowman keratomileusis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sub-Bowman keratomileusis (SBK) is a modification of LASIK that involves creation of a thin (90 to 100 micron) flap in the corneal stroma, at or just beneath the level of Bowman's membrane. It is proposed as a hybrid between LASIK and surface ablations (PRK, LASEK, or Epi-LASIK) and is made possible by the predictability and accuracy with which the femtosecond laser can create corneal flaps.",
"   </p>",
"   <p>",
"    The procedure has the advantages in the immediate postoperative period of decreased pain and better vision when compared to surface ablations. Visual acuity is also superior at one month, but by three months and beyond, there is no significant difference in visual outcomes between SBK and surface ablations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The primary advantage over LASIK is improved biomechanical stability of the cornea, reduced risk of corneal ectasia (iatrogenic keratoconus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/17,20\">",
"     17,20",
"    </a>",
"    ] and perhaps less risk of dry eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Photorefractive keratectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photorefractive keratectomy (PRK) effectively treats low to moderate myopia, myopia with astigmatism, and low to moderate hyperopia without astigmatism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. PRK is performed as an outpatient procedure using topical anesthetic. First, the corneal epithelium in the ablation zone is removed or pushed to the side to allow a more accurate ablation of the corneal tissue. The laser treatment is then applied to the exposed corneal stroma&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/25\">",
"     25",
"    </a>",
"    ]. Immediately after the laser is completed, the ophthalmologist applies topical antibiotic, topical steroid, and a topical nonsteroidal antiinflammatory drug. Then a disposable bandage contact lens is placed over the operated cornea.",
"   </p>",
"   <p>",
"    In the early postoperative period, patients may have significant tearing, photophobia, blurred vision, and discomfort because of the central corneal abrasion. With the use of the bandage contact lens and topical nonsteroidal antiinflammatory medications, postoperative pain is usually mild to moderate; however, patients occasionally require systemic analgesia for more severe pain.",
"   </p>",
"   <p>",
"    The contact lens remains in the eye until the epithelial defect is healed, averaging three to four days. Antibiotics are usually continued for two to three days after the defect has healed and topical corticosteroids may be continued for up to three months postoperatively. Visual acuity improves once the epithelial defect heals, usually within one week postoperatively, and typically fluctuates for several months after the surgery before stabilizing at around three months. Glare, halos, and dry eye symptoms are common in the first month following surgery, but usually diminish or disappear entirely by three to six months. Patient follow-up is variable, but a typical schedule is postoperative day one and three and then again at one week if the cornea is not reepithelialized. The patient is then reexamined at 1, 2, 3, 4, 6, 9, 12, 18, and 24 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laser epithelial keratomileusis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In laser epithelial keratomileusis (LASEK), preincision of the corneal epithelium is performed using a special microkeratome with a 70 micron depth calibrated blade. The trephine leaves a hinge at the 12 o'clock position, and a few drops of 20 percent alcohol solution are instilled inside the marker and left on the cornea for approximately 30 seconds. The treated area is then washed with water and dried. Next, the excimer laser treats the underlying stroma just like a LASIK treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 12 randomized trials comparing outcomes between LASEK and PRK in patients with myopia found no difference in visual acuity at any time point after surgery (up to two years), healing time of corneal epithelium, or postoperative pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/27\">",
"     27",
"    </a>",
"    ]. However, patients undergoing LASEK had significantly less corneal haze at one and three months after surgery.",
"   </p>",
"   <p>",
"    The benefit of LASEK over LASIK is that the flap is very thin. Having a thin corneal flap avoids the complication of corneal ectasia, which may result when the residual corneal thickness after treatment is less than 250 microns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/28\">",
"     28",
"    </a>",
"    ]. Without the proper stromal support, the cornea bows anteriorly (ectasia), causing permanent changes in the patient's refraction. Apart from the avoidance of corneal ectasia, LASEK offers other advantages compared with LASIK. LASIK requires the use of more complicated equipment with the risks of higher intraoperative surgical flap complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/29\">",
"     29",
"    </a>",
"    ]. The potential risks of infection are also theoretically easier to manage and treat with the relatively superficial flap.",
"   </p>",
"   <p>",
"    Patients who risk trauma to the cornea postoperatively during recreational sports or professional work also benefit from the LASEK procedure. A dislocated or lost LASIK flap may cause a permanent decrease in vision. In contrast, a LASEK flap complication will only cause a large epithelial defect. LASEK also lowers the risks of diffuse lamellar keratitis because the flap is not located in the stroma.",
"   </p>",
"   <p>",
"    However, LASEK has some disadvantages compared with LASIK. Due to the thinness of the epithelial flap, it may dislodge postoperatively causing greater pain. Another disadvantage is the slower optical recovery time compared with LASIK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/30\">",
"     30",
"    </a>",
"    ]. LASEK also can cause stromal haze in treated high myopic patients similar to PRK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Epi-LASIK procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial laser-assisted in situ keratomileusis (Epi-LASIK), a hybrid technique, is a newer procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Rather than using alcohol solution to separate the epithelium from the underlying stroma, Epi-LASIK utilizes an epikeratome, which is a mechanized blunt blade on a handpiece similar to the LASIK microkeratome. The laser ablation is then performed on the surface and the epithelial flap is retained, similar to LASEK.",
"   </p>",
"   <p>",
"    It has been suggested that this results in less post-operative pain and haze when compared to other surface ablation procedures, to include LASEK. An additional benefit of the procedure may be that there is less damage to the underlying cell integrity when compared to alcohol treated eyes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Additional techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mitomycin-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitomycin-C (MMC) has become a useful adjunct to a variety of ophthalmic surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. It was first used in glaucoma filtering surgery to reduce the risk of scarring of the filtering bleb, thereby improving the success of the surgical intervention. More recently, interest has turned to its use as a dilute solution in the prevention of haze in post-refractive surgical patients.",
"   </p>",
"   <p>",
"    The primary use has been in conjunction with PRK, but it has also been expanded to LASEK as well as post LASIK complications. Postoperative corneal haze is not well understood, but is most likely a complex multifactorial wound healing response, where activation of stromal keratocytes and deposition of ground substance and abnormal collagen may result in haze.",
"   </p>",
"   <p>",
"    MMC modulates wound healing by increasing keratocyte apoptosis and reducing keratocyte reactivation. Although preliminary studies suggest efficacy and safety in dilute applications, the long term effects associated with MMC have not been well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Phakic intraocular lenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phakic intraocular lenses have become a promising surgical option for higher degrees of myopia, astigmatism, and hyperopia, where the use of excimer laser surgery has been limited by lack of predictability, regression, corneal ectasia and reduced quality of vision postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review including three randomized trials of patients with moderate to severe myopia (-6 to -20 D), phakic intraocular lenses were associated with less adverse effects and similarly effective for visual acuity compared to excimer laser surgical correction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of a phakic intraocular lens has been shown to preserve the corneal asphericity thus eliminating postoperative corneal ectasia. Phakic lenses also provide a better postoperative quality of vision (improved best corrected visual acuity, improved contrast sensitivity, etc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phakic intraocular lenses may be classified as either anterior chamber or posterior chamber. The former may be further subdivided into angle versus iris supported. The angle supported anterior chamber phakic intraocular lenses have fallen out of favor because of their higher association of complications such as pupillary ovalization, endothelial cell loss, and decentration. The iris supported anterior chamber and posterior sulcus supported intraocular lens are the leading techniques utilized today.",
"   </p>",
"   <p>",
"    Despite the increase in their popularity, there are still several complications, such as endothelial cell loss, chronic or increased intraocular inflammation, pupillary ovalization, pupillary block glaucoma, cataract formation, intraocular lens dislocation, and retinal detachment, which warrant consideration and may limit their use. Nevertheless, advances in technology (eg, anterior segment imaging technology to properly size the intraocular lens) appear to be decreasing the complication rates significantly. Moreover, newer intraocular lens designs reduce the surgical incision size and reduce risk of damage to intraocular structures.",
"   </p>",
"   <p>",
"    With the technological advances in refractive surgical procedures, we expect to see an increase in the number of phakic intraocular lenses being implanted with excellent reliability, predictability and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bioptics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bioptics is a refractive technique that combines more than one refractive surgical procedure, typically combined phakic intraocular lens implantation with excimer laser refractive surgery. It has also been used for clear lens extraction followed by excimer laser refractive surgery.",
"   </p>",
"   <p>",
"    This appears to be an encouraging technique (or combination of techniques) for the management of extremely high levels of ametropia. The results are showing good levels of predictability, reliability, stability, and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not every patient is a candidate for excimer laser treatment. Age, high refractive error, ocular, and medical disease may prevent a patient from obtaining a predictable refractive outcome. A study of Lasik surgery for presbyopia compared patients aged 60 to 69 years with patients 40 to 49 years, demonstrating a trend toward higher retreatment rates and more myopia post-procedure in the older age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the procedure was comparably safe for older patients and outcomes at one year were comparable for both age groups.",
"   </p>",
"   <p>",
"    Proper patient selection is critical for a successful surgery (",
"    <a class=\"graphic graphic_table graphicRef72987 \" href=\"mobipreview.htm?4/53/4956\">",
"     table 1",
"    </a>",
"    ). The patient's eye must be healthy and the refractive error must be stable over a one year period of time. The surgeon must select the correct surgical procedure based upon the patient's expectations and ophthalmologic examination with an accurate refraction. After the surgery is scheduled, the surgeon will perform a detailed and accurate surgical plan to include verification on the refraction prior to programming the laser. The surgical plan also includes the detection of complicating factors to maximize the results while minimizing the risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are systemic and ocular contraindications to refractive surgery. Autoimmune, collagen vascular, and immunodeficiency diseases all affect corneal healing. Women who are pregnant or nursing have fluctuating visual acuity due to refractive changes of the eye secondary to corneal hydration. Patients with abnormal wound healing such as keloid or abnormal scar formation may have abnormal corneal healing. Systemic medications such as oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    can aggravate dry eye symptoms, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    can leave transient corneal epithelial deposits.",
"   </p>",
"   <p>",
"    Ocular contraindications include severe dry eye from keratoconjunctivitis sicca, exposure keratitis, neurotrophic keratitis, and lid disorders affecting the tear layer. A patient with a history of herpetic keratitis is at risk of virus reactivation and corneal scarring following laser refractive surgery. In addition, any patient with an abnormally shaped cornea such as keratoconus, pellucid marginal degeneration, or keratoglobus may worsen after refractive correction and will not have a predictable refractive outcome.",
"   </p>",
"   <p>",
"    Patients also may present with anatomic problems that prevent the proper placement of the microkeratome such as deep set eyes, very narrow palpebral fissures, abnormal lid position, or severe acne rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical workup includes a complete medical and surgical history. The ophthalmologist reviews the general medical history particularly looking for a diagnosis of diabetes mellitus, collagen vascular diseases, and immunocompromise of any etiology. The surgeon must also have a detailed ocular history before performing refractive surgery, paying special attention to previous ocular surgery as well as conditions such as glaucoma, strabismus, amblyopia, and dry eye syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Contact lenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to refractive surgery, patients want to remove their contact lenses, which can temporarily change the shape of the cornea. Soft contact lenses should be discontinued at least two weeks prior to an examination and following treatment. Rigid gas permeable (RGP) lenses should be discontinued at least three weeks prior to an examination and demonstrate a stable keratometry and refraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Eye examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial patient visit includes a testing of uncorrected visual acuity (UCVA) and a measure of the current spectacle prescription with BSCVA. The patient's refractive error must remain stable for one year, defined as no more than a 0.50 D change in either the manifest cylinder or manifest spherical equivalent. The ophthalmologists will review all previous eyeglass prescriptions, prior medical records, and measure the current spectacle prescription on the initial preoperative evaluation.",
"   </p>",
"   <p>",
"    The initial evaluation will include a manifest refraction with BSCVA based on the least minus prescription needed to read the smallest line. The manifest refraction is repeated at least once to confirm the results. The laser treatment is then based on the manifest spherical equivalent and manifest cylinder. The initial visit requires a cycloplegic refraction to paralyze the eye's ability to accommodate. The patient will return on another day for a repeat manifest refraction if there is a greater than &ndash;0.50 D difference between manifest and cycloplegic refraction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slit lamp examination &mdash; A slit lamp examination evaluates the lids for evidence of blepharitis, meibomian gland dysfunction or infection, and the use of cosmetic makeup. The conjunctiva and sclera may reveal injection from chronic irritation or abnormal pooling of the tear film. The cornea may show superficial punctate keratopathy indicative of dry eye syndrome, epithelial irregularities such as epithelial basement, membrane dystrophies, scarring from previous trauma, or vascularization into the cornea from previous disease. The cornea may show signs of Fuchs endothelial dystrophy, which can lead to corneal decompensation and poor flap adhesion. The anterior chamber may show signs of inflammation from chronic uveitic processes. The iris may have abnormalities and the lens may have cataractous changes, which will affect the postoperative visual acuity.",
"     </li>",
"     <li>",
"      Pupil size &mdash; Pupil size evaluation is determined in the initial refractive surgery screening. The pupil is measured with a device called a pupillometer that measures the pupil using infrared light in a dark room. Large pupils are associated with a higher risk of postoperative glare, halos, and night vision difficulties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A typical myopic ablation has an optical zone of 6.0 mm; patients with a pupil size greater than 7.0 mm in dim illumination are at the highest risks for these postoperative complaints. The goal of the ablation is to treat the cornea overlying the pupil in the dark in order to prevent light from entering the eye at the edge of the treated and nontreated cornea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dry eye evaluation &mdash; The risk of dry eye symptoms increases after laser refractive surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/45\">",
"       45",
"      </a>",
"      ]. Thus, the ophthalmologist must rule out a diagnosis of dry eye before performing surgery. A patient with dry eye syndrome will complain of intermittent blurry vision secondary to poor tear film, sharp intermittent pain, or foreign body sensation.",
"      <br/>",
"      <br/>",
"      The examination for dry eyes includes a basal tear secretion test using Whatman #41 filter paper, 5 mm wide and 35 mm long, placed at the lateral one-third of the lower eyelid with one drop of topical anesthesia. After waiting five minutes the amount of wetting on the strip is measured; any amount greater than 10 mm is considered normal. The tear breakup time (TBUT) evaluates the oil secretions of the meibomian glands. The tear film must remain intake for greater than 10 seconds. Rose bengal stain is also used to stain conjunctival epithelial cells that are inadequately protected by a mucin tear coating secondary to chronic inflammation or dry eye syndrome.",
"     </li>",
"     <li>",
"      Intraocular pressure &mdash; The screening examination also includes intraocular pressure (IOP) measurement. An applanation tonometer, pneumotonometer or Tonopen, is used to screen patients and document a baseline IOP. Postoperatively the patient's cornea will be thinner, creating a falsely lower IOP when performing any applanation tonometry. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Glaucoma evaluation and management'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The postoperative PRK patient may develop elevated IOP secondary to topical corticosteroid use. The LASIK candidate with high IOP may have undiagnosed glaucoma.",
"      <br/>",
"      <br/>",
"      The suction required to hold the cornea during creation of the microkeratome flap during LASIK can elevate the IOP to 65 to 70 mmHg. Thus, any patient with a questionable diagnosis of glaucoma will need a preoperative visual field test.",
"     </li>",
"     <li>",
"      Fundoscopic evaluation &mdash; A dilated fundus examination may uncover other eye diseases or causes of decreased visual acuity. The lens may have cataract changes, which can prevent optimal results with any laser refractive surgery. Patients with symptomatic cataracts may need a cataract surgery evaluation instead. The patient's vitreous may have opacities such as posterior vitreous detachments that cannot be corrected by refractive surgery. The optic nerve may show signs of atrophy or glaucoma; this will prevent patients from seeing better postoperatively. The refractive surgery candidates may have macular diseases such as macular degeneration or inherited retinal dystrophies. The peripheral retina may have signs of lattice degeneration, retinal tears, retinal holes or retinal breaks needing further evaluation and treatment prior to undergoing refractive surgery.",
"     </li>",
"     <li>",
"      Evaluation of the cornea &mdash; The reshaping of the cornea is the fundamental principle of laser refractive surgery. The ophthalmologist must calculate certain corneal measurements. The steepness or flatness of the cornea is defined by keratometry. The shape and contour of the cornea is measured using topography or videokeratography. The keratometry and topography will rule out corneal diseases such as keratoconus or posterior corneal ectasia. The thickness is measured by a pachymeter. Pachymetry is useful for identifying unusually thin corneas and calculating the depth of the ablation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glaucoma evaluation and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmologists have become increasingly aware of the role corneal thickness plays in the evaluation and management of glaucoma. Many clinicians managing glaucoma have incorporated corneal pachymetry into their practices. As such, it is important to record corneal thickness before and after refractive surgery, including an estimate or measurement of the amount of tissue ablated during treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=see_link&amp;anchor=H16#H16\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\", section on 'Pachymetry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also important to record intraocular pressure before and after refractive surgery, since corneal thinning will falsely lower the results of applanation tonometry. Nomograms that adjust intraocular pressure for corneal thickness will also aid in this regard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications may arise from errors in the planned ablation, intraoperative mechanical factors, postoperative medications, and wound healing (",
"    <a class=\"graphic graphic_table graphicRef52037 \" href=\"mobipreview.htm?18/4/18508\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/46\">",
"     46",
"    </a>",
"    ]. The most common subjective complaints in one LASIK study were night driving difficulty and glare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Visual acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undercorrections and overcorrections can occur if the excimer laser removes an incorrect amount of corneal stroma. Undercorrections occur more frequently with increasing amounts of myopia. An undercorrection for a myopic patient would leave residual stroma, thereby leaving the patient myopic postoperatively. Enhancements are usually performed within the first year after the original procedure to remove additional corneal stroma and correct for postoperative refractive error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/15\">",
"     15",
"    </a>",
"    ]. In a prospective study, LASIK retreatment was required in 10.7 percent of eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overcorrections occur when too much corneal stroma is removed and are harder to treat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regression of the postoperative refraction toward the preoperative refractive error can occur over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/48\">",
"     48",
"    </a>",
"    ]. Regression may occur due to discontinuation of topical corticosteroids, abnormal wound healing, and pregnancy or other hormonal imbalances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a 0 to 3.6 percent loss of two or more lines of BSCVA reported with laser refractive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/21,47,49,50\">",
"     21,47,49,50",
"    </a>",
"    ]. As an example, a patient who sees",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    with glasses will have a small chance of not seeing any better than",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    with glasses following refractive surgery. There are",
"    <strong>",
"     rare",
"    </strong>",
"    case reports of visual loss and corneal perforations secondary to laser ablation through the corneal stroma or from microkeratome complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Presbyopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are approaching the age at which presbyopia occurs or who are already presbyopic should be educated that correction of a refractive error for clear distance vision may result in an inability to focus and read near objects, which they were able to do before surgery by removing their spectacles. Some patients may be able to avoid this problem by undergoing \"monovision\" correction, whereby one eye is surgically undercorrected for distance, so that the patient is left with one eye for distance and the other eye for near vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/52\">",
"     52",
"    </a>",
"    ]. However, not all patients can tolerate monovision. In one series, 35 percent of patients initially treated with monovision LASIK underwent a subsequent procedure to enhance the other eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients can undergo a trial of monovision with contact lenses prior to refractive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Dry eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry eyes are very common following laser refractive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/45,54\">",
"     45,54",
"    </a>",
"    ]. During creation of the LASIK flap, the superficial corneal nerves are cut with the microkeratome. The corneal nerves will reinnervate the corneal stroma over a six-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/45\">",
"     45",
"    </a>",
"    ]. The few months post-LASIK may require a patient to use nonpreserved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    . In moderate to severe dry eye, the ophthalmologist may place temporary or permanent punctual plugs into the eyelid punctae to prevent tears from being pumped into the lacrimal system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients may experience a foreign body sensation, fluctuating vision, or decreased vision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=see_link\">",
"     \"Dry eyes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other ocular complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Astigmatism &mdash; Induced astigmatism occurs with decentered ablations or excessive patient movement during the ablation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/56\">",
"       56",
"      </a>",
"      ]. Retreatment of postoperative astigmatism can be corrected with glasses, contact lenses, or repeat laser treatments with newer corneal custom ablation profiles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Irregular astigmatism (central islands) &mdash; In some cases, laser treatment or an abnormal healing process may result in astigmatism that is \"irregular.\" This includes \"central islands,\" which are irregular elevated areas in the treated cornea. Such irregularities may result in decreased visual acuity. These \"central islands\" may not be correctable with laser, and the decrease in visual acuity may not be correctable with glasses or contact lenses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glare, halos, diplopia &mdash; Glare, halos, and monocular diplopia can occur postoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]; night halos can remain a persistent problem for many years after PRK [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/59\">",
"       59",
"      </a>",
"      ]. The etiology is thought to originate at the interface of the treated and nontreated corneal stroma. Patients with large pupils in dim illumination may develop symptoms as light rays are refracted differently at this junction, thereby causing glare symptoms at night, halos around bright lights, and the perception of double images out of one eye.",
"      <br/>",
"      <br/>",
"      The newer generation excimer lasers have ablation profiles with larger blend zones to minimize the transition of treated and nontreated cornea in an attempt to reduce these symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loss of contrast &mdash; Some postoperative patients develop a loss of contrast sensitivity following laser refractive surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/61\">",
"       61",
"      </a>",
"      ]. A patient may see Snellen acuity equal to",
"      <span class=\"nowrap\">",
"       20/20,",
"      </span>",
"      but the sharpness and clarity are decreased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/62\">",
"       62",
"      </a>",
"      ]. Further research to include wavefront testing is ongoing in order to understand the causes of decreased contrast sensitivity.",
"     </li>",
"     <li>",
"      Stromal haze &mdash; PRK patients also tend to have a higher incidence of stromal haze and scarring, especially when treating myopic patients over &ndash;6.0 D [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/59,63\">",
"       59,63",
"      </a>",
"      ]. The haze peaks between 6 to 12 weeks and then declines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Epithelial defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRK leaves a large epithelial defect postoperatively that causes postoperative pain with delayed corneal epithelial healing. &nbsp;This can cause corneal scarring, corneal melting, and irregular astigmatism.",
"   </p>",
"   <p>",
"    Since the epithelial barrier to infection is removed, patients also are at higher risk of corneal infections. Infectious keratitis can occur after LASIK and can be vision-threatening. The estimated rate is between one in 1000 and one in 5000 procedures, and can involve bacterial, mycobacterial, or fungal organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Flap complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creation of the LASIK flap also presents unique risks. During creation of the flap the microkeratome may create a thin flap, incomplete flap, buttonhole flap, or free flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/29,65,66\">",
"     29,65,66",
"    </a>",
"    ]. These complications may require the surgeon to stop the procedure and allow the cornea to heal before another attempt at refractive surgery, an average of nine months postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/67\">",
"     67",
"    </a>",
"    ]. Postoperatively, the corneal epithelium can grow underneath the flap requiring another procedure to lift the flap and remove the underlying epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. The corneal flap may also dislodge spontaneously or with trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Diffuse lamellar keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sterile inflammatory response without an unknown etiology called diffuse lamellar keratitis (Sand's of Sahara Syndrome) may occur at the stromal interface beneath the flap. Diffuse lamellar keratitis is treated with topical corticosteroids. Severe cases require the ophthalmologist to lift and irrigate the flap postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other keratopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases have been described of noninflammatory central corneal opacification occurring within two weeks of surgery and regressing two to eighteen months postprocedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/71\">",
"     71",
"    </a>",
"    ]. Lamellar keratitis preceded the corneal opacification in 18 of 19 patients; opacification did not respond to systemic or topical corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can reasonably expect to have a 90 to 99 percent chance of achieving",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better UCVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/47,72\">",
"     47,72",
"    </a>",
"    ]; 57 to 79 percent achieve",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    or better UCVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/6,49,70,73\">",
"     6,49,70,73",
"    </a>",
"    ]. The results of every study are based upon each patient's refractive error and the amount of astigmatism. Approximately 85 percent of patients see",
"    <span class=\"nowrap\">",
"     20/25",
"    </span>",
"    or better UCVA, which enables them to perform the majority of activities without corrective lenses. Patient satisfaction rates after LASIK are generally high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors that affect refractive outcome include low versus high myopia, myopia versus hyperopia, and astigmatism. Patients with low myopia without astigmatism have the best results, whereas high hyperopes with astigmatism have the least predictable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/6-11,24,75\">",
"     6-11,24,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of additional factors also may affect the surgical outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The type of procedure such as PRK, LASIK, or LASEK",
"     </li>",
"     <li>",
"      The surgeon skill level and experience",
"     </li>",
"     <li>",
"      The laser center's equipment, quality control, and maintenance are crucial for accurate corneal ablations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The laser characteristics also determine refractive outcomes. The newer generation small flying spot laser beams (less than 100 microns) with eye tracking systems theoretically offer better predictability than the older generation wide beam (4 to 5 mm) without eye tracking systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/5\">",
"     5",
"    </a>",
"    ]. However, large randomized controlled trials comparing different lasers have not been published.",
"   </p>",
"   <p>",
"    The surgical nomogram is also critical for a predictable result. The surgical nomogram is a calculation of the amount of corneal tissue to ablate for a desired refractive correction. This nomogram is developed by clinical trials and by numerous treatments performed at a specific laser center. The surgical nomogram analyzes such factors as laser settings, refraction, and surgical technique.",
"   </p>",
"   <p>",
"    Outcome in a second eye treated with LASIK may be correlated with the results in the first eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/76\">",
"     76",
"    </a>",
"    ]. As an example, one study found a relatively high correlation between the outcomes in the two eyes of patients who had same-session bilateral LASIK and, after controlling for baseline visual acuity, calculated an approximately 20-fold increase in the risk of uncorrected visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or worse in an eye treated with LASIK if such a result occurred in the other eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review included six randomized trials (417 eyes) comparing outcomes with PRK and LASIK for myopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/78\">",
"     78",
"    </a>",
"    ]. Visual recovery was faster with LASIK, but refractive accuracy was similar. At six months, a nonstatistically significant greater number of eyes treated with LASIK achieved a visual acuity of",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    or better (odds ratio 1.62, 95% CI 0.75-3.50). In addition to the wide confidence intervals around results, there was significant heterogeneity across studies for some outcomes. No randomized trials were available to compare LASIK with PRK for hyperopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/79\">",
"     79",
"    </a>",
"    ]. It remains uncertain whether long-term visual outcomes differ between PRK and LASIK.",
"   </p>",
"   <p>",
"    Long-term outcome studies for PRK and LASIK are difficult to accomplish because the patient population is largely young, mobile, and generally doing well, resulting in loss to follow-up. Additionally, outcomes related to new technological advances are not reflected in studies of procedures done ten years earlier.",
"   </p>",
"   <p>",
"    However, ten year outcome studies have been published for PRK and LASIK in patients with mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/80,81\">",
"     80,81",
"    </a>",
"    ] and with more severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/82,83\">",
"     82,83",
"    </a>",
"    ] myopia. These studies, involving a combined total of 785 eyes, demonstrate stability for refraction and best spectacle-corrected visual acuity and overall excellent safety. Myopic regression was more likely to occur in the first two years following surgery, with slower rates thereafter. Retreatment was performed in 20 to 45 percent of patients, commonly beyond two years from the initial treatment, and was well tolerated. In another series of 779 eyes in 402 patients followed for five years following LASIK procedure, best corrected visual acuity remained unchanged, compared to one month post-operative, in 98 percent of patients; 17.5 percent of patients had undergone additional surgery at a mean of 2.5 years after the initial procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient satisfaction following LASIK surgery is high, compared with other elective surgical procedures. In a systematic review of 19 articles reporting patient quality of life and satisfaction after LASIK procedure, the overall patient satisfaction with surgical outcome was 95.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/29/42457/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A standard eye examination tests for myopia, hyperopia, and astigmatism. However, patients may have irregular astigmatism that is not readily detected and cannot be corrected by spectacles. Using wavefront technology, guided laser surgery can remove corneal stroma in micron intervals to correct higher order visual aberrations, resulting in improved visual acuity, night vision, contrast sensitivity, and reduced glare and halos. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Wavefront testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'The excimer laser'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two most common types of refractive surgical procedures are lamellar procedures: laser-assisted in situ keratomileusis (LASIK) and sub-Bowman keratomileusis (SBK); and surface ablation procedures: photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), and epithelial laser keratomileusis (epi-LASIK). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper patient selection is critical for successful surgery (",
"      <a class=\"graphic graphic_table graphicRef52037 \" href=\"mobipreview.htm?18/4/18508\">",
"       table 2",
"      </a>",
"      ). The patient's eye must be healthy and the refractive error must be stable over a one year period of time. Contraindications to refractive surgery include active autoimmune or vascular disease, use of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , severe dry eyes, keratitis, and other eye conditions. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative evaluation should include slit lamp examination, computerized corneal topography, fundoscopy, dry eye evaluation, and measurement of intraocular pressure and corneal thickness. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complaints following refractive surgery are dry eyes and difficulty with night driving and glare. Surgical complications include over- or under correction and infectious or inflammatory keratitis. Ten year outcome studies for PRK and LASIK demonstrate stability of visual correction, following the first two years, and high patient satisfaction. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Risks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/1\">",
"      Netto MV, Dupps W Jr, Wilson SE. Wavefront-guided ablation: evidence for efficacy compared to traditional ablation. Am J Ophthalmol 2006; 141:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/2\">",
"      Krueger RR. Introduction to commercially approved wavefront-guided customization: third year in review. J Refract Surg 2005; 21:S767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/3\">",
"      Kaiserman I, Hazarbassanov R, Varssano D, Grinbaum A. Contrast sensitivity after wave front-guided LASIK. Ophthalmology 2004; 111:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/4\">",
"      Alessio G, Boscia F, La Tegola MG, Sborgia C. Topography-driven photorefractive keratectomy: results of corneal interactive programmed topographic ablation software. Ophthalmology 2000; 107:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/5\">",
"      McDonald MB, Deitz MR, Frantz JM, et al. Photorefractive keratectomy for low-to-moderate myopia and astigmatism with a small-beam, tracker-directed excimer laser. Ophthalmology 1999; 106:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/6\">",
"      El-Maghraby A, Salah T, Waring GO 3rd, et al. Randomized bilateral comparison of excimer laser in situ keratomileusis and photorefractive keratectomy for 2.50 to 8.00 diopters of myopia. Ophthalmology 1999; 106:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/7\">",
"      Dulaney DD, Barnet RW, Perkins SA, Kezirian GM. Laser in situ keratomileusis for myopia and astigmatism: 6 month results. J Cataract Refract Surg 1998; 24:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/8\">",
"      Buzard KA, Fundingsland BR. Excimer laser assisted in situ keratomileusis for hyperopia. J Cataract Refract Surg 1999; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/9\">",
"      Yoo SH, Azar DT. Laser in situ keratomileusis for the treatment of myopia. Int Ophthalmol Clin 1999; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/10\">",
"      Salah T, Waring GO 3rd, el Maghraby A, et al. Excimer laser in situ keratomileusis under a corneal flap for myopia of 2 to 20 diopters. Am J Ophthalmol 1996; 121:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/11\">",
"      Zadok D, Maskaleris G, Montes M, et al. Hyperopic laser in situ keratomileusis with the Nidek EC-5000 excimer laser. Ophthalmology 2000; 107:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/12\">",
"      Lindstrom RL, Linebarger EJ, Hardten DR, et al. Early results of hyperopic and astigmatic laser in situ keratomileusis in eyes with secondary hyperopia. Ophthalmology 2000; 107:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/13\">",
"      Gimbel HV, Penno EE, van Westenbrugge JA, et al. Incidence and management of intraoperative and early postoperative complications in 1000 consecutive laser in situ keratomileusis cases. Ophthalmology 1998; 105:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/14\">",
"      Gimbel HV, van Westenbrugge JA, Penno EE, et al. Simultaneous bilateral laser in situ keratomileusis: safety and efficacy. Ophthalmology 1999; 106:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/15\">",
"      Durrie DS, Vande Garde TL. LASIK enhancements. Int Ophthalmol Clin 2000; 40:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/16\">",
"      Ali&oacute; JL, Ortiz D, Muftuoglu O, Garcia MJ. Ten years after photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) for moderate to high myopia (control-matched study). Br J Ophthalmol 2009; 93:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/17\">",
"      Durrie DS, Slade SG, Marshall J. Wavefront-guided excimer laser ablation using photorefractive keratectomy and sub-Bowman's keratomileusis: a contralateral eye study. J Refract Surg 2008; 24:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/18\">",
"      Slade SG, Durrie DS, Binder PS. A prospective, contralateral eye study comparing thin-flap LASIK (sub-Bowman keratomileusis) with photorefractive keratectomy. Ophthalmology 2009; 116:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/19\">",
"      de Benito-Llopis L, Teus MA, Gil-Cazorla R, Drake P. Comparison between femtosecond laser-assisted sub-Bowman keratomileusis vs laser subepithelial keratectomy to correct myopia. Am J Ophthalmol 2009; 148:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/20\">",
"      Dawson DG, Grossniklaus HE, McCarey BE, Edelhauser HF. Biomechanical and wound healing characteristics of corneas after excimer laser keratorefractive surgery: is there a difference between advanced surface ablation and sub-Bowman's keratomileusis? J Refract Surg 2008; 24:S90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/21\">",
"      Hersh PS, Brint SF, Maloney RK, et al. Photorefractive keratectomy versus laser in situ keratomileusis for moderate to high myopia. A randomized prospective study. Ophthalmology 1998; 105:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/22\">",
"      Pop M, Payette Y. Photorefractive keratectomy versus laser in situ keratomileusis: a control-matched study. Ophthalmology 2000; 107:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/23\">",
"      Shah S, Chatterjee A, Smith RJ. Predictability of spherical photorefractive keratectomy for myopia. Ophthalmology 1998; 105:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/24\">",
"      Corones F, Gobbi PG, Vigo L, Brancato R. Photorefractive keratectomy for hyperopia: long-term nonlinear and vector analysis of refractive outcome. Ophthalmology 1999; 106:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/25\">",
"      Seiler T, McDonnell PJ. Excimer laser photorefractive keratectomy. Surv Ophthalmol 1995; 40:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/26\">",
"      Rouweyha RM, Chuang AZ, Mitra S, et al. Laser epithelial keratomileusis for myopia with the autonomous laser. J Refract Surg 2002; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/27\">",
"      Zhao LQ, Wei RL, Cheng JW, et al. Meta-analysis: clinical outcomes of laser-assisted subepithelial keratectomy and photorefractive keratectomy in myopia. Ophthalmology 2010; 117:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/28\">",
"      Seiler T, Koufala K, Richter G. Iatrogenic keratectasia after laser in situ keratomileusis. J Refract Surg 1998; 14:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/29\">",
"      Stulting RD, Carr JD, Thompson KP, et al. Complications of laser in situ keratomileusis for the correction of myopia. Ophthalmology 1999; 106:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/30\">",
"      Teus MA, de Benito-Llopis L, Garc&iacute;a-Gonz&aacute;lez M. Comparison of visual results between laser-assisted subepithelial keratectomy and epipolis laser in situ keratomileusis to correct myopia and myopic astigmatism. Am J Ophthalmol 2008; 146:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/31\">",
"      Pallikaris IG, Kalyvianaki MI, Katsanevaki VJ, Ginis HS. Epi-LASIK: preliminary clinical results of an alternative surface ablation procedure. J Cataract Refract Surg 2005; 31:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/32\">",
"      Pallikaris IG, Katsanevaki VJ, Kalyvianaki MI, Naoumidi II. Advances in subepithelial excimer refractive surgery techniques: Epi-LASIK. Curr Opin Ophthalmol 2003; 14:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/33\">",
"      Lee DH, Chung HS, Jeon YC, et al. Photorefractive keratectomy with intraoperative mitomycin-C application. J Cataract Refract Surg 2005; 31:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/34\">",
"      Gambato C, Ghirlando A, Moretto E, et al. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology 2005; 112:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/35\">",
"      Lovisolo CF, Reinstein DZ. Phakic intraocular lenses. Surv Ophthalmol 2005; 50:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/36\">",
"      Olson RJ, Werner L, Mamalis N, Cionni R. New intraocular lens technology. Am J Ophthalmol 2005; 140:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/37\">",
"      Chang DH, Davis EA. Phakic intraocular lenses. Curr Opin Ophthalmol 2006; 17:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/38\">",
"      Barsam A, Allan BD. Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia. Cochrane Database Syst Rev 2012; 1:CD007679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/39\">",
"      Igarashi A, Kamiya K, Shimizu K, Komatsu M. Visual performance after implantable collamer lens implantation and wavefront-guided laser in situ keratomileusis for high myopia. Am J Ophthalmol 2009; 148:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/40\">",
"      Ghanem RC, de la Cruz J, Tobaigy FM, et al. LASIK in the presbyopic age group: safety, efficacy, and predictability in 40- to 69-year-old patients. Ophthalmology 2007; 114:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/41\">",
"      Wilson SE, Lin DT, Klyce SD, et al. Topographic changes in contact lens-induced corneal warpage. Ophthalmology 1990; 97:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/42\">",
"      Hersh PS, Steinert RF, Brint SF. Photorefractive keratectomy versus laser in situ keratomileusis: comparison of optical side effects. Summit PRK-LASIK Study Group. Ophthalmology 2000; 107:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/43\">",
"      Bullimore MA, Olson MD, Maloney RK. Visual performance after photorefractive keratectomy with a 6-mm ablation zone. Am J Ophthalmol 1999; 128:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/44\">",
"      Holladay JT, Dudeja DR, Chang J. Functional vision and corneal changes after laser in situ keratomileusis determined by contrast sensitivity, glare testing, and corneal topography. J Cataract Refract Surg 1999; 25:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/45\">",
"      Battat L, Macri A, Dursun D, Pflugfelder SC. Effects of laser in situ keratomileusis on tear production, clearance, and the ocular surface. Ophthalmology 2001; 108:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/46\">",
"      Melki SA, Azar DT. LASIK complications: etiology, management, and prevention. Surv Ophthalmol 2001; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/47\">",
"      McDonald MB, Carr JD, Frantz JM, et al. Laser in situ keratomileusis for myopia up to -11 diopters with up to -5 diopters of astigmatism with the summit autonomous LADARVision excimer laser system. Ophthalmology 2001; 108:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/48\">",
"      Chayet AS, Assil KK, Montes M, et al. Regression and its mechanisms after laser in situ keratomileusis in moderate and high myopia. Ophthalmology 1998; 105:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/49\">",
"      Kawesch GM, Kezirian GM. Laser in situ keratomileusis for high myopia with the VISX star laser. Ophthalmology 2000; 107:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/50\">",
"      Watson SL, Bunce C, Allan BD. Improved safety in contemporary LASIK. Ophthalmology 2005; 112:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/51\">",
"      Hori Y, Wantanabe H, Maeda N, et al. Medical treatment of operative corneal perforation caused by laser in situ keratomileusis. Arch Ophthalmol 1999; 117:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/52\">",
"      Garcia-Gonzalez M, Teus MA, Hernandez-Verdejo JL. Visual outcomes of LASIK-induced monovision in myopic patients with presbyopia. Am J Ophthalmol 2010; 150:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/53\">",
"      Braun EH, Lee J, Steinert RF. Monovision in LASIK. Ophthalmology 2008; 115:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/54\">",
"      Benitez-del-Castillo JM, del Rio T, Iradier T, et al. Decrease in tear secretion and corneal sensitivity after laser in situ keratomileusis. Cornea 2001; 20:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/55\">",
"      Wilson SE. Laser in situ keratomileusis-induced (presumed) neurotrophic epitheliopathy. Ophthalmology 2001; 108:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/56\">",
"      Krueger RR, Saedy NF, McDonnell PJ. Clinical analysis of steep central islands after excimer laser photorefractive keratectomy. Arch Ophthalmol 1996; 114:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/57\">",
"      Tamayo Fernandez GE, Serrano MG. Early clinical experience using custom excimer laser ablations to treat irregular astigmatism. J Cataract Refract Surg 2000; 26:1442.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2007/safety07.htm#LADAR6000 (Accessed on June 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/59\">",
"      Rajan MS, Jaycock P, O'Brart D, et al. A long-term study of photorefractive keratectomy; 12-year follow-up. Ophthalmology 2004; 111:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/60\">",
"      Endl MJ, Martinez CE, Klyce SD, et al. Effect of larger ablation zone and transition zone on corneal optical aberrations after photorefractive keratectomy. Arch Ophthalmol 2001; 119:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/61\">",
"      P&eacute;rez-Santonja JJ, Sakla HF, Ali&oacute; JL. Contrast sensitivity after laser in situ keratomileusis. J Cataract Refract Surg 1998; 24:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/62\">",
"      Mutyala S, McDonald MB, Scheinblum KA, et al. Contrast sensitivity evaluation after laser in situ keratomileusis. Ophthalmology 2000; 107:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/63\">",
"      Ali&oacute; JL, Artola A, Claramonte PJ, et al. Complications of photorefractive keratectomy for myopia: two year follow-up of 3000 cases. J Cataract Refract Surg 1998; 24:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/64\">",
"      Karp CL, Tuli SS, Yoo SH, et al. Infectious keratitis after LASIK. Ophthalmology 2003; 110:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/65\">",
"      Tham VM, Maloney RK. Microkeratome complications of laser in situ keratomileusis. Ophthalmology 2000; 107:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/66\">",
"      Lin RT, Maloney RK. Flap complications associated with lamellar refractive surgery. Am J Ophthalmol 1999; 127:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/67\">",
"      Leung AT, Rao SK, Cheng AC, et al. Pathogenesis and management of laser in situ keratomileusis flap buttonhole. J Cataract Refract Surg 2000; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/68\">",
"      Walker MB, Wilson SE. Incidence and prevention of epithelial growth within the interface after laser in situ keratomileusis. Cornea 2000; 19:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/69\">",
"      Wang MY, Maloney RK. Epithelial ingrowth after laser in situ keratomileusis. Am J Ophthalmol 2000; 129:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/70\">",
"      Linebarger EJ, Hardten DR, Lindstrom RL. Diffuse lamellar keratitis: diagnosis and management. J Cataract Refract Surg 2000; 26:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/71\">",
"      Sonmez B, Maloney RK. Central toxic keratopathy: description of a syndrome in laser refractive surgery. Am J Ophthalmol 2007; 143:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/72\">",
"      el Danasoury MA, el Maghraby A, Klyce SD, Mehrez K. Comparison of photorefractive keratectomy with excimer laser in situ keratomileusis in correcting low myopia (from -2.00 to -5.50 diopters). A randomized study. Ophthalmology 1999; 106:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/73\">",
"      Sakimoto T, Rosenblatt MI, Azar DT. Laser eye surgery for refractive errors. Lancet 2006; 367:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/74\">",
"      Bailey MD, Mitchell GL, Dhaliwal DK, et al. Patient satisfaction and visual symptoms after laser in situ keratomileusis. Ophthalmology 2003; 110:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/75\">",
"      Tabbara KF, El-Sheikh HF, Islam SM. Laser in situ keratomileusis for the correction of hyperopia from +0.50 to +11.50 diopters with the Keracor 117C laser. J Refract Surg 2001; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/76\">",
"      Chiang PK, Hersh PS. Comparing predictability between eyes after bilateral laser in situ keratomileusis: a theoretical analysis of simultaneous versus sequential procedures. Ophthalmology 1999; 106:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/77\">",
"      Van Gelder RN, Steger-May K, Pepose JS. Correlation of visual and refractive outcomes between eyes after same-session bilateral laser in situ keratomileusis surgery. Am J Ophthalmol 2003; 135:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/78\">",
"      Shortt AJ, Allan BD. Photorefractive keratectomy (PRK) versus laser-assisted in-situ keratomileusis (LASIK) for myopia. Cochrane Database Syst Rev 2006; :CD005135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/79\">",
"      Settas G, Settas C, Minos E, Yeung IY. Photorefractive keratectomy (PRK) versus laser assisted in situ keratomileusis (LASIK) for hyperopia correction. Cochrane Database Syst Rev 2012; 6:CD007112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/80\">",
"      Ali&oacute; JL, Muftuoglu O, Ortiz D, et al. Ten-year follow-up of photorefractive keratectomy for myopia of less than -6 diopters. Am J Ophthalmol 2008; 145:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/81\">",
"      Ali&oacute; JL, Muftuoglu O, Ortiz D, et al. Ten-year follow-up of laser in situ keratomileusis for myopia of up to -10 diopters. Am J Ophthalmol 2008; 145:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/82\">",
"      Ali&oacute; JL, Muftuoglu O, Ortiz D, et al. Ten-year follow-up of photorefractive keratectomy for myopia of more than -6 diopters. Am J Ophthalmol 2008; 145:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/83\">",
"      Ali&oacute; JL, Muftuoglu O, Ortiz D, et al. Ten-year follow-up of laser in situ keratomileusis for high myopia. Am J Ophthalmol 2008; 145:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/84\">",
"      Kato N, Toda I, Hori-Komai Y, et al. Five-year outcome of LASIK for myopia. Ophthalmology 2008; 115:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/29/42457/abstract/85\">",
"      Solomon KD, Fern&aacute;ndez de Castro LE, Sandoval HP, et al. LASIK world literature review: quality of life and patient satisfaction. Ophthalmology 2009; 116:691.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6908 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42457=[""].join("\n");
var outline_f41_29_42457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY OF THE CORNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REFRACTIVE ERROR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CORRECTIVE LENSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WAVEFRONT TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THE EXCIMER LASER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGICAL TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laser-assisted in situ keratomileusis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sub-Bowman keratomileusis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Photorefractive keratectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laser epithelial keratomileusis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Epi-LASIK procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Additional techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mitomycin-C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Phakic intraocular lenses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bioptics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Contact lenses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Eye examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glaucoma evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Visual acuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Regression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Visual loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Presbyopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other ocular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Epithelial defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Flap complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Diffuse lamellar keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other keratopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6908|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/40/38543\" title=\"figure 1\">",
"      Refractive errors emmetropia myopia and hyperopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/26/39343\" title=\"figure 2\">",
"      Refractive error astigmatic eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/24/15752\" title=\"figure 3\">",
"      LASIK PRK LASEK and Epi LASIK procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/53/4956\" title=\"table 1\">",
"      Pt selection laser surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/4/18508\" title=\"table 2\">",
"      Complications refractive surg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/11/25784?source=related_link\">",
"      Dry eyes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=related_link\">",
"      Visual impairment in adults: Refractive disorders and presbyopia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_29_42458="Velamentous cord insertion";
var content_f41_29_42458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50561%7EOBGYN%2F63304%7EOBGYN%2F76136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50561%7EOBGYN%2F63304%7EOBGYN%2F76136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Velamentous cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The umbilical cord placental insertion site is membranous. The velamentous vessels are surrounded only by fetal membranes, with no Wharton's jelly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eduardo Zambrano, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Velamentous cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 651px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKLAa4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uoor6C+FXw88Ma74H03UNU0sT3cwlLy/aJVziV1HCsB0AHSmlcD59or6tPwo8Fb8f2GAP+vuf/4unr8J/BRXP9hqfpdT/wDxynyk8yPk+ivrIfCbwTt40MH/ALe5/wD4ugfCbwUf+YEBg/8AP3P0/wC+6OVhzI+TaK+t/wDhUngfr/YS4/6/Lj/4ulHwi8DlhnQgB3/0uf8A+OUcrDmR8j0V9df8Ki8DDJOgg+gF5P8A/F0g+EXgfaP+JEM/9fdx/wDF0crDnR8jUV9ct8IfBAIA0Ifjd3H/AMXSL8IfBGPm0MD/ALe5/wD4ujlYcyPkeivrf/hUngjP/IBHv/pdx/8AHKcvwi8Dk5OhLg8Y+1z/APxyjlYcyPkaivrpfhF4GJ/5AS+mPtc//wAcqQ/CDwKo/wCQCp+l3cf/AByjlYc6PkGivsD/AIU/4FKg/wBgDkZ4vJyP/RlKfg74FC7v7BX3H2y4/wDi6OVi50fH1FfYH/CnvApPGhDHr9ruOP8Ax+kb4PeBVx/xIhz/ANPdxx/5Eo5WHOj5Aor7AX4P+BDj/iQjB/6fLjI/8iVE3wh8CqpP9gFj6C7nH/tSjlDnR8iUV9gj4O+BMjOgj3/0u4/+OU8fBzwFx/xIh9Ptlx/8XRysOdHx3RX2Ovwa8BbgDoA57/a7j/45S/8ACm/APU+H/wAPtlx/8co5WHOj43or7Kb4M+AguR4fHPH/AB+XH/xyhfgz4ByA3h/nvi8uP/jlHKw50fGtFfYtx8GvAgjJj0IA56/bLg/+1Krx/CHwLuAbQUP/AG93H/xyjlYc6PkKivshPg14CYDOggZ5/wCPu4/+OU7/AIUz4BIJGgY+t5cf/HKOVh7RHxrRX2R/wprwETx4fH/gZcf/ABykPwa8B8n+wRt/6/Lj/wCOUcrDnR8cUV9kH4M+AsAjQhyf+fy4/wDjlMPwd8BLkHQAT/1+3H/xyjlYc6Pjqivsc/BvwF/0L/Pp9sn/APjlB+DXgIj5dBH43lx/8co5WHOj44or7GPwa8BY/wCQDznr9suP/jlH/Cm/AeD/AMU+M/8AX5cf/HKORhzo+OaK+xh8G/Affw+OP+ny4/8AjlIfg74CyR/YAHt9suP/AI5RyMOdHx1RX2Mfg34CJ40IYx/z+XH/AMcoX4N+Az10Af8AgZcf/HKORhzo+OaK+xT8G/AYP/IBGPe8uP8A45Sf8Kd8Bg4/sDP/AG+XH/xyjkYc6PjuivsM/BzwJj/kAgH/AK/Lj/45Sf8ACnvAeQP7BGe/+l3H/wAco5GHOj49or7APwf8Cc40EcHveXH/AMcpH+D/AIEAH/EhAz/093B/9qUcrDnR8gUV9ej4QeBc86CP/Ayf/wCOUg+EHgbdzoQwP+nuf/45RyMfOj5Dor1/4/eENC8KroB8P2H2P7V9o8799JJu2+Xt++xxjcenrXkFJqw07hX1Z8EWYfDbQ9qk5E5+n7+TmvlOvq74IqT8M9CO0n/XdP8ArvJTjuDO5XBlOCPripkQ54JA71HtIlzgAE4z61YUBQM9KszI1UjOQCD6cUKGLnI4PGKlKkldvT0pVIwcDB7c0AOwOCQM+lPUYHHOKaV6ZxjFL05A5/nQIGOVxg4/lTW+7yNwPQGnjBbnnHqKAoByfwpgIo77RnoM96dgE4xyTTiOu0gDoPrScA9iRSEIVG4DA4PJp4AAPy8jocdaavXgZHTmn/KFI4A7fWgBApJJAAHcYpwT5RjoeOO1NGMAHkf1pR1459fegBQpK7cgY6mnBdw244HXH8VNzjBC9fT1p4Yk4AwcUxCmP5xgE+nNMK4AUqMD0704AFhkfrRIuFAABbPc0AAAC4AznsRSLGQ3DcHjNSLkljjPvTAOR8uBQBMoG4EjBPGPWgY5yMn60h5IzjNKVORg9egFABgBu4A7VKoBBXBJqu7naTnnvmnoQcDJ+tAEr8EgnA7Um8/WhmCjnkevakLbh156UCHYBUnHAqtJGQQFA9fc1MANuN3GajlJQkDdwKQ0OHXG3JAxjPSnMWC8YxnvVMPIhBJAHvUv7xipAyp/hJoCxIJlDEZxjjrTd4U53fhnNQSW4LbiTxyR6mnWsW+WFFY75cAH0pN23GkWIy07CKJSXxnjnNMkQhx2Knp71vJpIspp72O5c/IsaxkDauOp/GsC8uFN3MemWz6c1nCrzOxpOlyJO5MjA5A5P16UuBz7jtUUXO4gbhkZNShj0OMAVqYiEfdAximgcsowB2p3BHJx3oyxJ4Gf5UwGYPQ4A+lOHU9vc0FfToaUjuBgUAAHX1Ipq59RjpTwSDk9eKD1wPyoAY2FAz29qa+OowacTkHjimkDYAVx3oGNAPc884pgyGAyDz3qQsM4JyaY2C3UY689aAA8gYAJHb1pm0FskY9akUjbx2NNC7gQATQAjAFcrwaTCkjBNJO8cC75mSJFHJdgBisuXxHpEO7bcee69RApb9elJuw1Fy2PFf2qiNvhfHrdf+0a8Ar3D9pbVk1P/hHBFA0SxfaeWYEtnyuw6dK8PrNu7ujZRcdGFfWfwMIHwy0M4yQJ+P8AtvJXyZX1r8Cwf+FX6I2OQJwD/wBt5KcdxS2O5YBnBC8Y6GngZxwMD9abklmIBx7U85wDjr2FWZgArMxH+fanRqAegIP6VGMbyP5dqlQDJ54xnimA7IA9RSPwN2Bx1JpfvYOQOaQqPxHAzQAxGYtx68HHWplG49sU3PK4wBTweTjovQikAEAY6ZPFKAP4uh6mo7iaG2tZbi6mSG3iG55JDgIvqT2rl9E8fabr+t/YdHhmmtwfmvHOxT6bF6tz9KTkk0my4U51LuKvbc6wDAHAz6VKBwMgZ/nUDOFcgEYHWnq2/PIx0pmZIuAvzYx0GKUAKMbc46Cmo2MYxk+lOySBkLmmIUADoM/XtTyoxwQKYufxHNOHOV6DsfekA3LYJwMdqa2fvY/Kn7QRg5NKi7lwBigBg37cEdPTihx1xkA1J6HH196dgAE7elAEA3ZA2jrj6VLGSWOewyCKR1wfb1pVGDzgccZpgIDlTyM+3amwnbJgkn2NPXoDjgn2poYB+uRk9KQydiCM8g+9AAwPzpozu4JPGfpUjEBcnr0oJGKQWHH4U5jk49O1MbGfSnkYYYJIxzQAhC7c8kjrnpQcAZOMkYppIHOD/jSOB7k/WmBnahdeTsGwurSBTg42j1rN/tZIrkOhbEbAk44FWdVJwzKcr74rzXX/ABhZaHK8V9NMzn5uLZmUg9ACOMCsp9jopwue5XHiC3u9Nb7LIrAgZPYE1ylzdgXtwrksq9CB0GK5/wCHktveW8xDM7sPOSM8AKehIpfFmt2XhyN9S11ro2zFYl+xxh3JPTIJHFYUabilJs7q9ONmo+p2enShoiAcj3q0VG9ee1eVWfxV0EIBbnXyBjIWzj6e/wA1aUPxP0UndJaeJJkxyPIRMflXVzL+rnn+wkeiHBb3x0NN6NwcGuEHxS0P+HQfETfUqM/lRD8UNMLnHhPX5D2zIKOZB7CR35JwTnpxSrg46cj9a4q3+KlgDtTwTrTMPXDVrW/xFMwUweAdakyM8Rj/AAo17P7hqg31N6RlA4Ix2/OmyMGbPH51LpOvahdzRG68E3VjaE/vJpZULRj12Dk12i21vtysUeD6Chytuhug+5w5UY28E+gqVLC5mwI4HP6AV2whiHSNB/wGlaGNuqA1PtECod2ecahOti0xuUf924Rwi7iCRwD9e1YV/wCInhlZIdJu2YdWfCLjNdJ448N37m6vdAl+x3jAB2ROJY/7p9weh7V5vFosYuXXV7vV5JM7ZFEZI/Eird38JapQWurN+bxDHbW+++vLOyHUon71gP5ZrEvvFhvd40q31SbacA7dua27K28N2AULFEjEgZmjbOfxFbcM9orYjltl/wBnIU1HK3uxc8Y7Q+881/sLWNXlaaXTlhRj/wAvMpc/XFa9p4HmkXF/qJWMdYoBtU49a7r5WHy4P0OaYeWGetCpx66kvETeidj5w/aO0Ky0SHw2lkHzIbkuzNktjysfzNeJV7/+1VwvhYehu/8A2jXgFJ7gndXYV9b/AAMIHwr0TjHE/wD6Pkr5Ir61+Byn/hVWiEf9N+vT/XyU47ilsd0oIjJB707PRTxnkimIPlUcAjtUucYIPbjvVmY1EXdnA44OKkAODxgDgGmxjOT26VIq5TA/DNMCGR/mXBUDtmnKxaTkjPp0pSgLYHBFIQqn3HYDOaQDkcH6U53xkBvm+tV3ZgeuB71SnugpBLL1xjpSbS3GouTsjg/iUq6h4rtLbVLm5GkrCoFiHMcdy2cksR1wcflWfbX8Om+KLS801V+xM6xmGKNVjQH5ctxngdDntWn8RtJm1i4trhbSVBFb7FuXGEVt2R74pvgC2sbfWI49YkikuFUGONkBWdSPvKD1IJrklNRnq9eh9HhIR+rcrjbTXzO8kv43CyQyb4m5RlOQw7HPep4L+A/ILiLzWPCbwCfoK8a+Kt3D4J8Wi2sbiR9Mvv301r5mFiLADMYHTgHI9a5fXPiLpKp9m0/Q7eZ1ACzu5zn1B6irVZy2R5MsIoK8pH0/5oADBvmpfM+UEYJzXgejfEq8toYBbwqsEClry3u5DuUD/nmx6n0FbmofG/S4LXzLPSL2Y4BBkwgx6mrjXgzGphKkHtc9fL5GQBk9Qea5H4l+LbzwvodrJplvFPf3dyLeISZKoT3I7/TNcRonxlOp3bQz6HJAGRnDK+QqgZJOfbmud+JPj7Tta0LR5dPkEsq3plaE/eRQOpH41TmmvdFGhKMl7RaHUp8WNQeOSymtbGxv4VKyTuWaMtjgRp/EfqcCuI1b4jeKLUmWbUbjyWZWjlUBZBg/dZcbf0qZL/TPEWmpHcMjSoAIMKf3bkevYVwQ1P7PBJYPHHNJuPmQ4OMg9AT1rFSlI9J4eFJbb+R69oPxe1t/Oe8sbTUIowP9QfKlYdzt5Feo+DvGWl+LrSWfTPOXyCBLHMuCrMM18veFryCxup3uY1W4RDhXOFOf4Sw/rXWeEPFFn4c8V2LWZ89dUxbXMaPny+flI9cE/ka0jJp2ZjXwsOTnjoz6cUqwBxj8aaQBjHX61V06bzYhwOOetWiQTgD3rc8t6DyMDoBk+nNMk4YZI9+KA4LccjvSSANsbJ9P/r0hIehBOAR+GBUsgAUHgkGqylhI3AznpUzEleVHTPFAWGEc5A6n1px4bJJzj161Hkb+/pT5GB4BIJHWgBx6kg/ge1QzmRWyrDdyDg9qcz4fHzdPWhgVXn5s0gOf1K0mlBIlkz07YOa5PU9JM8kcE9uJyik7lXODmu9vLYujAMVcrwfSuTvZdS0UyXdhemCcRlWLpuVwT0xUSN6bvoM8JeH9a068vQLG5khkwUMcZ+76Z/pXU3ng3UtWtCt1axxqSHVZmXgj1HWo7h9Zj8O2mpXmuXb3Mm0m3jxGu1ume4rGtifE+j6jHDeatZeILMkyWc02Sy54ZT3BrmU+Z27HpTcpxvp2Ot0zwTa2UKLcT2MbLyehrSOmeHrZCLrU7VQeoDKK8usPDd1cKC802SPm8x2LZ/E1Zk8Cxu0Uz3EhXaVaPdwf/wBVdXvNaHnvkT1O/kv/AANan95ewSMOwJb+VVZfG/guyP7m18wjuIf6tXK2XguwRAHQOpOdzdxWtB4Y0+FsrbR4x/doUZdWHtILZFp/ippw40zSd5zxn5ePoqmoh8RNfuuLLSolB6ExOf5kVbt9Mt41GyJQe3HNXEjRQOBj6U+TuS63Yyn8TeL5EwtuUJ/2I0/nuqkrauRldA0qOY8tLJK5ZiepIXAro3fcQV9TzSOeu7r6VSVtifbyOYu4fEZUGGWytP8ArgJM4+paqrReLZZcDXp40xwEY4rsXI2DOT9TTDweMBc0uVMPbSOQGn+LGckeIZn9mkfp+Bpr6b4x2t5OuqrMf4nZun1rrmIySCu2lJwOg/OjliHtZHCxWXjqKUv/AGnaSvjgyID/AOy1T1Gx8aXrStqMelXbyjLnYBu/LGDXoqsCTyeKQtnpyRzmjlXQaryR5dpV3qmgSyk+Fo5EcYJ3MSD6j5jitBPGYtyTP4c1JFAwSkzf1GK9AZQTkgAnvTGjiC42LyeTilyW2ZTr33R8y/tA66NbOhstvdW8cbXG1J+oB8roe/SvHq9+/aoWNV8LiNAvN1kAf9ca8BqXuF76hX1t8ER/xabQ92SD5/f/AKbyV8k19a/A8j/hVmgg/wDTf/0fJTjuTLY7oD5hu9OTSu+xQcAkmkyGcjoBSMCrDj6e1aGZKg+XoBk8AU9eSR2xwKRflUE4FJk5yqjOec+nrQA/dtbgDIOfpVdpCHIUDPrinTSrH14PrUdmhupmIz5SDcx/vVE5qCuzSnTlUfKjL1TUWikW3t42lndgiKB1Y9q0NJ8NyWurtLrTecPJ8yEnGwv3UelGhPDNrElwsAWOMMsRIJy57/lxW3rN1bS6Jcm6aRVijZkKqcqwBI4+tcsm5K73Wp7UIRoJQgt931OQ8a+JE0SNtO+yq81yCXU8lffPQDvXhviPXPt2oB4HlcwTIsV3Cu3M3aOMd89/aneKNU1PU4JZVSaWOePZcTFMunouew6H6VctNNm8M6/4OsLhbeR45mumLfcZsZTI9SK4VJ1Pfb0O6UPZJR6nQT6eupeO9Et/FWkrc3sdt5moFm+W1XsWPQ89j71p/wDCD6ZdXk6Q/Zb63MZ8hraD5dxPQP7elVbfXtGuJrpL64ml1i+uC9wu7YIhzhXBxkAYGKs3niO30zwxZw6Tq6LdBhFDbRsqLIxPY9FUetapxnrLpqZNOOx5Z8UZLa0uo9E0u5kmS2fEnmAMQ46jjsK3NI8CQvpWnx3SSxfaFWSa8RWO8En92SeF46etdFaaBZ+Gb7Nq9tearLunnklAcgd9ueMA9z1ro729t4rW2uLSSfy7kKklzJJtjab2U8HtyPSpT9221g5deZ63OB8R+CrS7sL220qaa1uocM8EzZjAOMEN6Y/DiuA8R6LN4cvIlnImm2EFsfIQ3TBH417Vor6peGaRUivo7VHSWYMEM65J4U9doOBXnnjjxNpniO48u2DR2sWDKqAKrEcKF74z3pU6klqtgr0IuVna5z0VpL4cuVEszK4iViq9V3DPHritjwzp9vb6LPr100VyiLJHhl/eQMfuv75qHzLCRov7RvGbeo2fuifK7BWY9arxCbRdM1W1mvITb3vKEc8g5wfStoVG99zXlgrQ7beRzkNpHqF7DH57WsL/APHzJIc4PrjvW7aaLp2n+KraGK6MghC3CSRHLb9w2qw7HPWuWEhulCRNuudyqvv6Y963Ph5p15rPiuM5J2OHnldsYAOefckYrrs7WR48px5/J9T678LhTp5YhuWPU+9be4EADIIP51maPEbbTYEY7Syljg56ntV+NwpwZF3HsSOK32PLer0EbaTxnjqBSBhkk557iuZ1rxxo2jzvHdvctGhw8sUe5QfQdz9azr34neHbKx+2rdSzg4CwxR/Ox/lWbrQXU1WGrfyvXyO34OWHBB704FnXBwOMmuR8Fa1f+N1upbe2m0i0jcCNpVy8q+oJrpBaG1ZFl1WW4kC7WTACk56k/wBKSqplvCzjpLRliQjcOMmmXUxjwVSWQZwQiE02O/8AskXmOke5iRlsH8wTUUPi2Frry/7W0+0Rl2x5ZM7vU/4USqKJUcI3qyrJqsw1MWkum3Sx+Xu8/b8oOelaAmAKKyS8nj92Tn8aqP4q02zu1k1HxBbXK4+/5qnp6KtWbX4maBO8ixXSKqcAuQAf8KyWJinZs2lg7q8YlpbeeY/JCQrdyMAVc/s+wsrbzbq1W5n4wZOVB+lc3q3xO0a0j3y3SFiflWMEg/41ia54zurjT4iYJo4pR5q7/lwo/iYdh6Cs54qL0TNKWBkndo9DvzDqmk3kUixlwoycY/yBXFafayWnjKxvZWEk0aNAewaPrk/Sp/COqH7NerLcIwZd5Zmyc47f7NeW6l42uo/E19eQyMbezbywvUMelZzrKDTaOilQclKKPXnSdNTuXe5SRvO2RxgYIU8ge/HeprIxI8yKuwyHeQcnJ6H6VyWuX39paHB4hs1Zbq3fy38s9AV+8R6A9fY1Fp3iOO5YTFXWRFX7VAGzIo7Ovqpq/bKjU5Xs9UZTwbrU+eO63O15h8pVVn5OM9APQVLaXBmeVWwpjPQdayLO8tpmSUahInyktBMMcY45PU+wqxcQahBdwXdoYWgkx5objK+q+9dMK0ZbHDUwk4muB8uc8joKQgA4xwaqi8iXgnYQcYbjP41O7/vQuQO/rWyaOZwlHdBkBsdTSnB5P4Uxyp+7jdmhsfKT25+lMkezbQO4P8qjcg4/TJpSwGCDnNNbjt9T6UgI3YBQB8w6fSljOFwcHHINNcAng8HqPWnbQOT1PoaBi7hu68n2pM7lJx19e9Dcnch4I60gCtuwSQKYhSRu7H09qRipXmk2gMC3FB75Ge2aBngX7VPCeFhzx9q5/wC/NeAV7/8AtVfd8L897rP/AJBrwCspbmsdgr62+Boz8K9C4zgT/wDo+SvkmvrX4IMF+FOhnPIE/wD6Pkpx3CWx3K43NgcGngHcu45H50xOAAML6c09OCCwBJ7+1aGZIVB6g1GSE3ZAyeeeae74GcdRjrVJt91dLbwjMr8AjtnvUt2KhFydkLbI+o3hSM7Y05lI6D/69X9Y1KzstFnt7RfPupF2jcNvlg9zUH2iHQtOntwm5wei/eY+p71l2UlsLeSSeGUzSOGdyeB75P8AKsfZ8z5pM9enSVNWRu6GXsdPjglEc7mMHghGb6E9az7rUotUbUNPubi606ZI97QkqrFfTd0IPsaWzeLL2+nOs2P3kaMuR749P5VxfxIt7PUohJqi3BuLaM+XMowSc5wMcECortwXMbU4qc7P+vkeYa1aQTyRR2Ycxb2Fw4Y70TPy59e1QaVBeWHxDhWKyvNVt7R1ZV2khJGUbfmPHHXBroodPivpr29spDtWMJIxwOAOB7kccUwatqb29tey4jl3xLKhUrEQmcOffnNebF8m56M48yt2KPxFsBrM/wBmaFU1xVEwuDgCTrvh3Dg46/XiuVtfD97fNb2tleJ9l3COTz1wLfJ5DA9D6Y4969u8P6bHrWjTQ3VxbW84V2me6TbJCGOQw/uhj6f/AFqwvEnh21h+ykapIJQUSOaWPy2Y5+UOB8sik9yO9btTik90c3LTcnZa/Mm1WWwm1dLFVjU2kUdu/RcEDhh1DbvrxWpq0UN0lnc6sbeJ4FwCp3LFGBwqRDp7t1JNcfqFnqlvLHLqY063eBzG0FowbYxbjdx154qzrt/c6MI9Js3lF/0igt4xl5HHys7nOcA84A+tYxqO8os15bpNbnTb70qohUR/aVysFmN0zp7joB7nFY9/4PuNWuZEh0s29nJMGKyMoyF6h3HAHQ8V3vhvQ08N+G3u9amea5aPzLoDhdwGcnHJ+nSuONprOraNe6ldlV/c+ba2MkwhjijJySw/ibGOuB2q5wla73IjWSb5badTlPFOg6dYzTWseqaOofOWD7lXPaub0y00q7hls73VrJrWLgDcV+rA1nfbPLu0imaOezTdcKttGhKt0GTxlfbNWbIjWLU35SC2htyTJIsCq5A4wx6c9OhqUpQ95MvnUtGb0fhjwVbOWSC71e6GwpBbu6q+e5bHC+9drbyWnhiZxpPh+ytmukWOXT5QvyjnLrISSWI/DFebf8JJJpshukuLy0mlja2jjk6ogH97HAx6Cul8J6Q2uXNvctDI85UyfaBcFSo6AKB6+5+tdHtak9EtTB0qUdTr9Jmm8P6Md11evBLOUitIpARATn5UP93nr61ieIPFNvbSLKwuJjKQssTT4OVHG48Y/AnNXLbwh4ysbe4vJNIsrq1TIVvPDuiE/wCsKZGSBziuBi0Nl1U2F3fQWl3euyLfzRiSKRR/vDcrH0GKxqzk377sXSjTu5QSbN281vXtV0SQaL4aD2W4qZ7dPMBPuc5rJ0SPxXNg2WmQkxSbis6qoicccrivSfh7c23ga1OkeLbp4t8peAKzJHIOxU/0rW1nxfYS3Ua6Xol7qMgIRZYEwN3bLkgE+xzWSaX9MG5t2itDipNO+Id/dJd32qRWrOuFWIBQB7VpyeHPEbWludW8S6jsmYJEtmAq+5ZscAVv6tcanqdusmrfZNOLrvj/AHwmdcdAVX5V9epNYq61rStEJnjurSIMOuGX1KjuPaqcrMlJvt/XmVJvh7Yy29yft19fSspJlnnYlCO/B/pXMP8ADy10y0+0XV3HcMU3JmbJbB6+3416dC0cVo8kFwkY8ouyQMPnwPuncDjn0rGtbO31O6hvry0kht40/wBQyn7394j+M/Wqc0VBv7jN0r4fWd3p1vdWkQinuGJnMqkoRjjan9awrfQNL0bWZoNSt7qxBbapZSA5zjKH+Je+DyK9dMqy2kS/aWKbSPlUIEX0A7flXIeLpYbzRAgnaS1ClGLr5oK9gD1Bz6c1E5JK7CnKUny9Cn/Y0umo0y6laSoJMqLiISD2wRggfSk1W9l/tO2lm2+TKBv8lsISOmAeSK42206/gYxx3tzb2kKFttxwrkDO0D71VbPxBqMUSG5jtpVDtGSMBsjqCME8VnCTvzR2NpJLST1PR59IuriaW+sbiBbAIiSwxKd7gnli3GfpWB4ctbK41vWtP1KIiJpWyi/eGD8rL60eBvGFxc+IntoHL6csfl54+Ykck+3aurTS1n0dvEVnZm8kTlljcDzFU449GH5GtJwTacN+plGTWj+RiWOu22g6hJZ28kktg42SJIMEfh9K0rvUdKtrq3eeC8W3PNve2abmjB6o4Hb26VDeW+kaum1vtMAkTPlv8u1z0OcZGemD3FN0PwJrsLpNaauJFU4UMoH5kHk/hWkKnPH2c9bbNA7QfMtLj4PG+h6Yj20mvx3mH3RCW2ZvLP8AtMflrqLfW7e+0ozR3sdtxlZ4ssiHtx6flWNe6NayKY/EOk24lbjz1gwW/wB4d6tWPhSwwG0u5it7qMAFJGXDL/d5rd4ZtXpyT8tjN1IL4zQ8M+Igb149Xktp+32pGUK47Eqelde2raRcbYo7uMEk8kivObmO286SEaPpLmDG8ptLgn/aTaf0NSifQl05j9g1IXifLtQFtw9QOc4rOKxEFZq/3jqU6VV3Wh6PLaFrfzLR435wfn+8faqaTOYy0kbRgHb8w6+9eVSHVI7xG09dR8iY4QOFBUHq3OP61vQap4g0p0eB7nULc5WQuM4Htnj8q6KdWrdKUGcdbAU2vdkr/d/wDvC4yuNp4yeeadxgkk4JrN0bU49Wt/KXT5opxwspTCt9SMjNXZY5IlzIHRv4gy8fge9dMasXoebUws4eY4AZYMOMU8EA5x+HrxVXzUfkHd2yDkVIkiggMAGHODzxWlzmJWLEArxxikG0AYx6mkTGAc5+v+elNcAkccDtTAedo65z1471GTkknIp2R1GMnimtjIORxQB4H+1Ocr4Y+t1/7RrwKvfP2pvu+F+Mf8fX/tGvA6ylubR2CvrT4JsB8KvD+f8Apv8A+j5K+S6+sfgmT/wq7QBntPj2/fyU47ilsd8DjqMnHWpAwX5ivPfNMHpwCB1NQyzeVGSck9MA1ozNalbULtY4z1Lk4VR3rMuIRDBd3moTTxSQofIETEMrHgZ9TTJtSFrcieSMyleUT37VnapqRCRW9xIQbxvMnZesUf8Ajj+YrlnNfEz1sHQajzW3/pjtCgkuB51y0gSYb3eVvnVAM8/571avEluLCR9TuIrW33eYkEfMmztux61jWl9PfXkotZFS3XEXnKPuKew9T0GKsW9rdWUBs9WtCZ5SZ47jP31Bxskb+H2PvWXtk0rLRfmelyWdzSWYrbRvbNI09sdpMQ+Y5GRtP0rlvHGtWUsVxHHLcW07Q/LuO4yMSA2AO9a8WsWqS3VjeyQW17Gii3jB2rI7Hop7sB36GofE0WnaLo4ubiJ55CmbiVGXlxzt+nTpWdV88bp6BFKMrs42K40eTQo47f7XF9kf95K8ZzOjHaHJH+1xUHi2dbOO2AM5ukT7MsanAJx8nH1707TrR9RInmb7HojFZdsjnfPt5CE9gDzWPczzt4hS/SzledXbDH5kj5GJGH44Arlfc362ubngTWLy2v7uCSzeS8kgCxXNxE0pjlHOAnQjrgmtzVka1+zza2WuLxpBK4bmTYD0IHA9gOlbH9r3kaW7Tx2kcgLKxEZEoXGevpzn8a5ieZbxLiSOW8+z+Z5jOibnaQfwKx4C+1bOSceVEa3uZjW4Go79RW4WSQTvLZHJKQEZXfJ/E2cV3ngXQ7fw34etb7XCDrM8YCyAZNvH1C5P5lqb4aszqURuryCaFljzdi4bIUZyq7vQYzii+1GPXNUhhltJrjSI1zCq5/0hgeSe5Tj6VrCHs1d7vYyn7z5V03NOPUBqmo2kF9cLb6YSRAkiZN03qR/c6H3qPxv4bvtXSDSW1C0WxknQySBCpCgfMvHUHvUYv5o9UEy6Q81uysrz3biP7OB/Aq9Sc+ldLbajaXOoRWj3Fs8Rh3kgiPYnuOuSePwpSV1q9TNtp6LQ881rSNLVooNP0i1ubi1Yq7KFVDFnk/7TDtmuLttIfVNZOgw3asJ7tppblOPs8IHO7+HI6V6L46vdOtbNLCLyxvBkWKN9uYyPUc/jXm6jW457m2uHtrVbmATT3YYf6LEvQM3ckduua54xtI2crxuyv4nl0zUo7jbA0um6ZEbOK9hjIUNn77Z4LEZ4rT+HPjuz8PWkUFxFcSxRQm181RgcMTkZ6ZBBx7ViaPrK6pdx6bYwsPC1rKiG1OP38j8eZL6jgn8MVl6Dd2954luJghmEk7+XbvwjNghCcegGTXRG8U7HK2pyT7/ifUjeJtPt9HSX7VG+lyDy5XbL/KRjduHQ1xV/4am1C4tbG4+z6tZIpNr5kJWUJ1BEg9PXrVDwXp0+qeBLaS7VdOd4zZxIGHlOh7lexPJ5ra0nxFd+GdKXSdSkjjuomFtbyBso8fQYPY47Vx+0TfvHSqfIr09zRtEt7HUo5DJ9qjEXlNBIfPEbjowz0NVL6bT15ubm3hbJPmSx7CT9BWvfaCXu4Z9NQZdMvJuA3H+tcVrFi02ttptokd5qAG+QvJuWMf7Xp9KdWMqa0QqTjOWrOjg13S7VkeHULKKJQAyE5B9xx0reS90HVF3WbWs0vfy5OSfXFc/aeCMWMRuFRWbkYAqX/hEiLjMFuH2f3UwfzFEHV6ozqOlfRsuR6bpt5qQH2NECEkwqfnJ/vAf41BDJp2oyvFpSzT29kSsv73Oxs9CB3rO1HTr6zmRyZ2fqjRg+YnuD3+hq34XWe1M6J/Z1tcXTb3I+RpP9oj+Yq41JXs0U4rl5k7mxFLBcWxUpLHM4yq43KBnuT3+lZlzpUUk8X2uC1tBNIH2mQKZsdyua0tXXVbexj3rbyQNIESNF+fJ9D39azdZ02PUEmgnMgVUTbLn5kYf55qqjdu4oeuhHrXhi0ukYNEJ7Zm2uM4A55P8ASuZ8UfDvSNQubN9NvIrOzUn7TbxcNj1T2q9HpfiQsttLqcAtcbpFLEu6D+LHbsMVpRWql4mvNNMVtGmWkySSP7xHXJrCNSzbUbG7jZW5r+hk3HhPRrJIRbQXIhuIllt54G2MSDzu962PCXhRNMupmstUmltb47tjYWMnHzbh2J5z61uTkapZQwxqttbRgCPYhyi9uapRawmkW8y2kBcjPnRtyP8AeH1rq9ypFP7S/Ex5p25TqrXwfpjzAXAWRfJMKoBgKvXA9vSsfUvDUFhYoiardw+UM/KeSPfHesLQPHmrjUryO5tFltbS2afaG/eSZ+4qj3qnq9hrmuoLvWNbTToJVLm0tE+deeQW+lZx/eRXLHcShOErTlp95oX01i7LBcX+62lPzLITgKP4wQfzq4R4NudPe8sruzlmUKhZpyQB6bTXJWHhzw3al5YLS+uHC7mmupyxz3IFQ3Xw+s7/AMPXkVg0J33AnWaIbXVe6sO4rSNGcZXlYubha2qLmna94a0yW6j0+wklkSY4fcNrL/eY/wAhWuvi/UFs5XXSrC2tP4BOwV5B9K5C9+G1uomj0zfPdDGIlnIAHq3p7Vl3fh2Tw3qDrrDT3Q8sGNiTIoJ7entWVb2k5czdi4Km/N+Z3unfEPQTeNDewT6bHCAu9G3JkjJyfT6U/wAQeJfCOnPBHp813qMl2pP2aO4JSQnuf7q14rqRiTVxPPHugOQYhwEP8II74NaENgpkjlhnkuLhhmR9nA/2QR0ArONSps3c0lQp3ulY9XsPGMFjFvlQtcsAq2lvxFF9P6k1JqPxEtHUR3ZMETEZjL7st9RXmsZmTSpDYxnAO6Z+mV74PrVKZUm0meHSLVpbpFMhaT5sMOSB+FVD2kXvYh0YPVo9lltLPxRp09n4euFSWWPzAElKOfVR7+/euI+H/i2+OuXmgak7XE9i7RmSVCjuB1B7Ej9a4bRL2/tJxPpGpiHUFAL2+0jc391f/r1ojxteSaJq15epCt/9qDuCgDhs4bJ65NdFGtJSTl+G33HLWw6nFr/hz31JVaJGRw4blSDTmPUliOORXE2msQaQVgST7Xp6QxyCeM8pu7YrrTJ8oGSAVBx35/rXpQlzJM8KrSdN2ZaVlwAfvfWnEZPp6e1Ug4DKAwPHOelW1yc8kA/pVGZ4L+1P08Membr/ANo14FXvn7U2dvhfnjN1j/yDXgdZy3NI7BX1f8EM/wDCtdA9Ns45/wCu8lfKFfVnwRz/AMK00U4BAWfr2/fyU47hLY7+WQnoSC3Q46Vk6xc7QQuc+1XJptzYPrwMdK5nVrnZ5s7yfKM/Q+1RVnZWKowcnoUb66RJ4Y5rW6uFkYB3hTd5Y7nHrWFqNza32rTyWrMY528pRMxCx44G7HQ+tdG14+n6Q7SL5TmMvcSOeQW4VB6Vzel3t1pEMtvbWVrfwOpDzbd4jYnO4468HFcVXVWbPoaMeTRG7oOmwT6e1rbXFw0kEm6WPGFBHO5PXpkmqQuIZdUmhvlvpX1N1TbvXAwR+8I6Y+lKI7ixhW7mjk3GMQxQs/7pN/3mMnVFIOAKhSAa/YXmoX1wdDsY38vZJGQ4de6Ec46cjrWbd0jVOzuyYWP2O0Sz1hLeAtO6rNP+8aFc4AJHY+tTaF4cW38R3E09xZanIIdyiBT5ZQ9MKeOnU1bSCDXdHlskmjl1AAKksUnKR/32DYO6rHhXSEtrqexuNQmmSyjLJ5hUHaOp3Dse/Nb0aaUl/mZ1J6O7sWPFRgV4Wv8AyBHaoszwwICv+wv5/wBKyNC0kXV5qNvJLsZD5jDcFM12U3IF9Qo5I9abd3NvcabfvfM0BlxLbxxsP3j/APLNG77fu8/WmWU2pR+FrCy0OO2IaXz7rVbtdxEm7LtGOpPYAdutDSlPmFFOMLI6bU5bya2mglW3JmWNrt0j/wBWSMlU79MD8qzTMbq1aK58yHTIm8q2tlj2NPJjA3eijrmmpC8N3bFWvIreJgqqerM3JJXtknPNLq9451WbynzNHH5NnCOMt0aQj68Zq7NrUhJLb+v6/Af4bsrjxFqWoaOtwYdIswPtLDrPJjlB7V6BaWKWdsRFarAURUAQhmCjpx2HtWVpmiXOjaVYWlk8P2t23XcsrgbR1JA6k5qzJJIt7M9pdwR3G3EvnRsxz36HgYreMOQ5qkud2T0EfSprrU5JL+f7Xp+FlhhMe1ojnnLd8+lclqMOmX+r3C2thcRReaPNmSQK8+Rwield1ePKkQtYJ1lkVVWQj5DjqSO2a881nWodLtrx7e1Zry1J2yRgbTHnqP8AaBzXNVaW7NKN2Ute0OC2vZLqwgaYW3l28UT4YCZvuoT3UD5iK80v72zGo65b2E/2u00lTdAPbb1upiQJWf0QZOM9O1eganqo0bw1JczuPs1rC0kKvndLcyjgk98Z/CvJ7SXxJaabcJDatHZRwCd5ZkA3oWyRg8OGP8PtWajFOyLqN2s+hqQ+H9Q8IWl1qOrWctnp00tpcW9yDujmDPkgEfewu7jrXnOn6nPYambixcLLvOxvTJ/+vXR/E/xTJr2owW9vrN7qenwIrBpk8pDIVG4rGOFHbj0pPC3hrS9R083l7LeQLYwvPfF0AQk48lE7/MMkmuhRSTcjz1KUppQ6Hovwz+IltaXgsvEFtGbNnDbpFIa3kX7pI7r6nqM163oEmk+K7G6tIILacmZ5IN+GG1cfMD1A9K8nj8EXviDQrKKZvs11IguJ7iVB5dtG33VUDlnwByaq6Ro+p/DbxXYz22qtcSXMUmwRrhcAZ+cHjH61xuiorRWR6XM3pfU9Lj0nLyafaPcaZdK+JI2JZZVB5I9ARVjQtNt9M8Vy6WLY2BuEMsFxu/4+e2Nx/i9qk03UbnWtAtPEkkJN7JL+9jicZRRxx9OtdpbtY63pkAuIkulz1IAbIHUdwfpWNOF9h1Kjitfn6/13Es9KFm4MbzCeM7/3hzk+tVDK9i/MsgMrYLDPJrWtYXEETafqU0kWPljnHmDHoe+fxqK9vVWNo5oIWAbceo/yK1vy/Focmrfcx9ZTVdSt49l5LE6nCyRqCfpn0rlrrwVqkt3vvLmO7aQZCyRbD+BHQ11a+M4Hu/sVtaK8lqu+eXd+7gB6ZOBknsBXM+J/F2pR3FveQDbHA7AkcAg+vpWU5Qeruzppe1i+VJIoR2Ou6ZJcxw+ZZwodsfmOZGVAOWGeBWvp+ktMsN7qc88l86tHsY547YA7n1NY/h/UNX8QT3Wo3LAWBcAIDw2O49s16HYWtsiyTZAgB44J5Izye5zVUrSVlt5lVZOG+/l+Rk6dZy6brcs0pjktRaCPYwySSf6VPtiu41F4zi7zwU4CjsBWZ4k8QWrJItnGyup2ZP3jk9cfhVNbqWMLKxMSgAnPOaiUkrpEKMpWb0OmS3EkJt47e5lQ8s5k2rx61kXNk97KswtoEt7RXjmZ5BHEgPfJ6kVUbxgtnYmCxgaWaQkIAcs7elYFppZuNatZddL391KW/wBFDN5MWfQdC3uaqmnNqxSi1ds6U6bYWOhwXsVwst1u+S4znzR6flWJaSWV5Lco95NC2dyxkEfRWz71LqIGnvbxo7tFCphhi67Tu/KsqSa/k1NoooVePyi8pV8Owx16dsewrvu4NWRMU2m2zR1aC9jtUe0gjkDAeYQ/Cn09cmqcOoTaX4hgWNpJdOuEAl3HEsXsOxFPimltLOK4t5JFC7lkjdcBx1wo75rIvpHuLrevlASyAJAzcqM8k5PWoqyuro1pxvoztYdbA1dYYwnmsFRmbgTRHpnHcVDrsr3Ntex31u1tZwKXWWYjDEHhV7kjtWB4quJU1OcWkhgkgjSMNAAWZD1Azwv1pmnapNqohFzKzWizCNllbIUgcNn8uaUq/wBhhCjopo6Tw5Z29l4Y069udL065EsWWKruyrZPzMejYPP0rhP7Uih8R6npi20C3EW1oBF8gaLqVYHqR2IrvPCWoRWfhuTRZ2aSeZ5AlmqmWEkMdvzY+UMvauc+L+mWOk6Pp2tzlYdRtpY4ESAA8NnIYDqMY71n9lcoo+7NqfU5nUbySCSaP7KRbum4DgeYD9OKxbPWo1lu9QFhbCIYXyPM2A4GOnfPrVjVNKvbO+khuSs9k5Gx1bDopXIDL2xmsGe28jU4Rqtu0GlyqSkmRtmKnACY9D261hzOT9DqklGNzStdOubySRtNsftAaRWKQy/vEBGSF9e+DmuZvJEvtc1ewk88sItkPmgK5dOivjgt2/CusuvELLC9toNoLUmMs122Y2bB568k+1UbuZL1o7OBQt07FZppowsm1eSxI784zVx9NTKV5q7LHgy5uNQn/se4tWK30ZS42HDRlQSpJ7c16l4Iv76Tw/bx6lta5UEblbdvAOOp78V4BoVrdNdy6na300OZmVSGxle+71r3fw3BcHwXp9zFgyrvSQA8Kc/f+ldmHl7zhfb+rHn4qnzwu+/9fedTGdibpCNxOevWtSFsoAd2fQ9a5WeyGpacbO6kfY20loyVJwc8H61swztBCy4csAMFun4H8K6kzyHE8b/am6eGOe91n/yDXgde8ftPOZIfCzHv9qP/AKJrwek9xrYK+p/goQPhro/0m/8AR0lfLFfUHwbbZ8MtJOcA+aOvU+dJTiDOwvpSQ3+yOcmsSDy59Tso5mRYSxdiwyDtGcfjV+WQFpmnBFv1ZgeT7CsG6tl1O4mjjQtFFGW2KTgexNcc6vNOy1senhcM4rnloV/Dtva67r0lxc3DJbefuWF+A7cnOO4Haug0fSBHqbRs0c1rJIxk8l8EdxtXr9ayNPtGWW0iYxKIxuwWGF9x6VtyXculSyG0tYWeRhukbqM9NvuetTRfdHdO60TJdZ0i2tb28imf/Rr0bFBGY1OOMgdOQBg1iXF1HJCLaaRVMcaxeWz+YfNxxwDheemPxrRl8RXRufIv7O3d2O9mQgqWAHLjtkY/WsCS5sbN5FiuIPPnJaa3JQB/TDHpgk80TinrEqCaXvF+/j8iNIrrUrhLXyQkLAbHnl6uH2joOnpWdpOr3Wq6TqaxRMII3+zwMBhpI/4z7jrzT51ihsU+2xPdX12dsdtb5ZmA6Ko7jHVjxUOl2usX+r2txMraPNaF44LJSCEhx824fxMauEeWRMnfcatiuoJcSl/IiAEcRbOZ26ME7DC8D6mt/wABoujaHb3V1LIUCyJHBI26PrkBR3Y4H5VLdPZ6bbW+nQQfaUWMKuw8o7ZLID6nqT2FWLMWWnPFd3UpnMQzBlcRj1Kr/dzwO5NVTglK/YKk+aNjQtRcX93PqV/DJC8zK8do2Mkgd/QVnasljceILDUbfFvcyoYwVUkKUblF7dasG6mutJ1DWr5J4biMeYiEqIynIAI9c/lWbZn7O8dzCoht5olu7VX+6smP3iDPY9a05k0kYxi73/r0OqlZrqyR3mEN1KXESsxBK9zk060g3RW+mxBoXBBkmj6uvUgn39apPJHc20V+Xje3lXbEigsyN7CnarqUGk28LSS+XtjMUUW75zIejY9uta8yUeZmVnsiz4r1Sa+26Zo7bb68bylfjhf4+fp/nJrzDxv4mt9FYadoNrFcW+ngGViuQ8inuRzzycdOK871nxXq+m6lezX8znVoQYYzGf3ZBP8ArMjjI/ma4o61eSGWUDNxI+9pVzkHtjniuJKc9SnVp0vdPYr3ULLXpdPit5DcaZCrTvK37sXF44yQcjG1RxjHanz6CNYT7ReXULRRosESxRld69x149sVx/w3s5L24mmvdrzXf7q3gY7PMzyW9FUYyT3r0xor/TUjtISktxdzC3tnB+V2x95QegUZ+tc9VPmOyi04Js8q1rwjYTS3114bDS2VoixHzH4kmJx8p+vb616LfaLZWHhOG0GdQuhf2n9pykEnA28Y6AKDtx6Vt2+m21hf2lta2zyLp0jPcovKyTk8KfXA+b8RTtK0z7do10sk/lyXOsNIPK+7IvmKNo/L8q2i3Zpu7MlTjGzjpc6efxBbwQ6jaPGd0F08cxigJCIfmjY9iNpH61jXt9Y69ZSQxx+ZdKu6NPLO89tv4joK7qy08Xd/fpIkaAs0s0mcbdqgAe/Arn7ua006V9QUWiTOu9IgcPIw+6Bjqfes63NCzk9BU+VytFaknwwltv7A1HTI1WUWcnz8bc7h1Pv7VysGqi11NxfzwQ7J2WKf5o2/77GRke9avgl5P+E0vrnVrWHT4tXgDrb+duYOPvFvRvpXL+JpZo/EV7b28okihcqiOrH5T1z61z1J7PzN4QXNLz1PafDuonUbUR3bQuMArPbN1XPBIHT8K0tUMcdvdIyMtxAokyTnePQV4t4T8SjwpcSR32ltFpk2Cs0I3G3bHIIHVD1z2r1uz1TTtZjivrS8guIZYXgEkZyOSGAPoeK6ItTj5nFWouEr20PKr6+msYbi9uIv3cJWedcfenlbjPrtXAA7V2WoWVvLpcwWGSQCHesSrhmduh9TWdNBbyReIIb62LvFOJgGOAyMg2kj0BBrV8I28usWkL/aHjWC3aMsSdysD933GK5478vc3qtWUtrHC6jd3Hhe50vSTlo7mFxK2cKrg8L+FbSjxJpjy+c63UJUbWQ4ZVI9D0z61U8bXkUVxbW408/NepF52flC5x+Gc1sXt6+k+Ixpl3KY4Z7BDAzc723lSM+2RSjFX0ehq5OUU7av8TnYlguL/wAy2jmR8jdHIpBH0z1pdRn+03Edgk/kmaTaHzyP8MVo+JpdRt7uKESmNZY8JN7Z5Oe317Vd0izhs7oyRMwW3jNuJyu5TM3LsCep6DNXGleVmSp+6mMtPCNpp0zLHfKt6zfO8rZJOOgHYVQVba11qEpd7YwCd5BBVh1BH9aIruS+8RM2s6jLbow8lNnyMD0B3dwfzrqbLS9Miaa2e682eSMqqdc47k+vvXdCy+HQzlNx0k73OO1y8Wwmsr67u1Fs5BA2khidxXOORz3rNj1e0uPJWK+SOdgTK3BlYfwjJwAB+JrqxpkS2qTXdwnlQqUWNW9OMnP1rlta0uGT7S/mFoz1KkKQvo2B3pyctyqXK/dGPeF7xJPObbGBsBQs87D+JfRc/SrdmLe+1KTUtRihjtFYSSyMgXDdApHXn06VWsLO304wiG5SO/KFjFOxLrGRwuB0HfFXreWeCzSSa1+12pjMhnwCsc3O3j0+tZxvLVo0lotCj4buLe88VXCXAX+zrzMLsflwp+6c9vamDSDY6nfaZ5DwNYZlDhvvIW+Vs/xZHPtUUYkhjslWxuNRup0WaSK0ZXZFB5D+mfT2rc8Qme/WS/lgWzubWLAhflntn459x1H1PrU8sWtV5/8AAHzWkrdf6/4B2WmmGbSdNvreJcmNRI8bc4Pp6jOa5/X4jfwyWSMl0lxKMbELFB3P1+laun31tBa3iWtxBNaQ2aeQ0HXK4VVHbOOapE3tpNDPKzOGXyYmiUKoZvvsx6j61tb3bGcG07nIfEPTY7nXLeYLLJFJbhEeA7CJE4xnoT7GucGj3bWhfULne29fJt5oiUX+8475BAziu41eM3Vxb6dDf2IkE6rIASpjjP35CT98npWYbabxI8lvcymzt7e6JguDmN2VBwfQggVySpJSZ0qfuJdjg4Xk1SXUUeK5uLhWYpE53YAGQ6k854P1Fc9qdwkHh8Ngz6vflpE2AqIY/wDZ9z3rb19EC3cujG4uzOTHEzxlpMseckYG3njHc1FLbpdNpklnJHPJNb+T9ncbTbmPJdSTxngVUVy3e5nUV/dKsckKWMNjaRmCaHYGLEYb159a9V8O3klj4etLe4V1lv3Mi4BwkS9FBHqea8ZtI01a6iZRIhOA5bIEfuK988T6VcJZ6PdNe+Xb6baBrdIgCkgx83Pr3rOL9nLm6kVIqouRbWLdvOCQSASemCQAK041NyOeB1GDWDp0zXlja3OEzKgb5CcEHpW7ZnbGDj6CvXTufOSVjxr9p0MIPC5b/p6H/omvCK95/agOYvDHpm7/AA/1NeDUnuC2Cvpv4MSj/hAdGjCiVwJmEX97989fMlfTvwIZP+ES0ZZADlZhnuB5r9KW6ZvQSc1c67U9UdbGI29jEbm4JTyXHAI4NYUjy22nTLES8rNtmRRj/IqLxbqbaV4otLu+UrZR7kYx84JGB+tcJceLdYTx9q1tZW8ErFVCWzyAM4AzhOx9cV5tN3m0/wDhtj3HaMYt6XPQpmWwhS5kUyylQhQDIx71mardJawtcxzSGHZ0X5tpPbHfHrTBq892qLe2BsnaJfMDckKecgjis+G4jSeUTAwCM7oXkXIZfqOAc8VpOcXojWEGtWLpcEGrSXpnnaNmQKBksX29XB7DGRiprO402zt7iKWxhmsEUS/aSMkRtz5Zz79qpzm50ly9taSLcynCRSDaSrHJ/DvWjp84Or2j6nZ74lh3pakbvMYD73oTRSlb4hzVzp9IhtrOx/tLXbc27yRieMrnd5f8EY9B6gVTlhuBfWeuLIvlQylYVCkHZJ97f9OKrnxL9shlu7Vi8rY/cTcOAO2P4cflVW21G6Nwgubu2udOUSTeVbEsFcchcfxc9T2rodS7VjD2bV2zR0qxU6trFx55j8P6crL5g5aWZ+X2+54X86xdY1G61JjG1qzyo481YzhYIwPlj9zj9a1kJh0fT9MyECytcXZbgvKSCOO456VFrtlDPBJ/ZN2bK8LK0kbsAB2YtnqT0AHtUVduSP8AX/DbDp73l/X/AA51Whaa0mm2l1qcLXt/KwQx5AghUDcoPqQOp9azteh069mhs9XkuJEdjKot+PKk/hUAdEz61BL/AGpbaHY2s19E8AmLxTbwg28fex71c8QR3Om3Nq9oUnu9Sj+ZCuB6bmPoPSqduWyMre9e/wDX6BpH9ow/aLS2sbu3U/xOyoXUf3CepNcb430/xVFaLLo1vb6bEWIkE8yvOWPO5pG6fQV6RBFdx6JALkpd6hYyDY8R3ruPAyewFYOv+GptQnSWXU4J0tS000M/KSyBcgH/AGalxluxXi3Zux4ro/gXXPEeq3Ed1cxRWKxFpJwfkfGXwCevOCTU+pA/8JVNBa6YghKwosdqvEQKYJPb1/E16HDrRutMmu9YLiO4cRKlvGdvlqM7QB0U4VPfNaUelwoqON0M2oQicM+FWN+Sc+wHGO1Yzd4qxpGHLK5z2owyPYW0FhZ2n2VWFokoGxmwNx+Y/wBPertrevd7tdSaS9stOAt7CMqV82Y8Nj6HAz7VF4lvppxCtvaSWmqPJ5SpIu0R5GBKiH/lngde+a2oIbmyNtZ3sgtdOtoDK0rYG98YD/XPIqIpatmsm2rGBqEmppp8mk6b5hv3YyXlwDtCTscsc+ijj611OnPBoep6b4fO8fvbaGKSH5lbcwdyzdjkY/OsS11+S/keyj8PzahbOpTAbyI5VHCuzHk56kCpL17/AE200+6vXke309hLIiDCysoIXB6nGePXNN1Fa8dv07AottJr/hzTvNZutXv7oadpMkc8V9OZtQu5SkewMQqog+8MZP4VnSBIEunV1l1KbO+6KcInXIH8I7ACk1TWbe6dUj3RLHEBhnyq8d/eptGuN0VlAFPmyHzWbbkhc8Z9u9TyqfvP+mDTikl1Lnh+2kjkg1HUbczskey3THzIT1YjtmsDxbcWtp452wzuXmRJWVjjaT1X866rxR4qtNKlRNOiecSJt3M6jB77q8Z8Wale3WttefabG5bhVgVTwo9/61yN883G92jSz5eZqx6Rf2c8vibTdTs7o26xQMJEVPlfBGFbtznFdqfD9pfKb/RSmmXpVWuLcc285zn5lHQ56Ec15x4M8RtrulS26WoCW+FZDKMbxjkd2HT8q6N7+/tppUCvBEwUvGvMjntgfw/U1opcrfMjncZuyT2NzxNp9/eahLqqAxzfZzbXUIbKAjGxhWjYyPouu3FpJMIY9QhSaNm4VJVGGUfUdq5y0sdSv5IpbWCSeQAvta5OXYjnJ6Va1TW/9A1FdTtFxZ2aKyynLK5bAIPc+9NvXm/rzElzLkWv9KxT8fBri3uIJFdNpQ4A5aTeME+grU8cIHNsj2jvqWn2/wBpiCLkTIwwyL6NxmsKbWGnvdYtp4ftKJbRR+azfNkkNuA9sV0PjLUTBp9tf7ZHmtYskx8k45P5VKXxNf1uW7x5Ytf00jC1LUZNUj0trGN2mubdI4vMGVMh5JHpt6mt2G1trLSZIo7mUtBL5gcHKlz94++ay/Ka/t4buGQR2ZR3tJEGArMhycf7xBrp9Ms7BNJt9P3+dcSIoUqeV4zuP4110tdWZzaiklsYcumsl6Zkt4ow4R9svKj357+1SS28+qeKI7iOFjOU58kkBVHGCfp2q3rx1G01K2ikufMQgvKJkGI/cY/Slz9lsbsaa+yZ8SGRm5fPqe30rZWvZkttpNEPiFHEnlRwRtHGpILfdBxzuFYV/YLHGWjLHzYl3W23gn1U/X8qL+/nu43niEcarHvcqTnOeRg+35Cs6TVJvtS2TtcNj7i89hyd3tSnJK9zSjCSQzw5BOltftb2kkskrhJrqUZdR/d9faukujJF4Y8i3zp8t5MscSlPuhTk4B9eetRy6clo1srXlxMYQG2wjkZ5y3Y89K2TfStE9oIjdPHtjiZwCCTyxJ9qdKm0mmKrU5mmloVNO0620jXXv4bHY1yRuljJ3Pxj5h0FSs1jJqdpclgJmZ4jKuSChGMMD79a05ri8FhE8hg+1EDe0RHljHAUH1rM1BIFjh8+F0UMCZFcBwM8kjuc84rdrTRGSTbv8jPtbSwtNSmg0y1866tX82OGF8J5JHOR7HP8q1G08w38Cs8ipGPMIZztZyemenrV3RLOCyvpiiDYsbGSSP5SS3Q59MZ4qjvmmSMYeaxkf96zg7wAOVA/XIrPboVGTbKl0LOW5vZ7m1gjldcJsAP7xeh/xrmRZ3J0e5UXM4tBG25lfdsLNhgD3z0wK6COUR3ol8pZrZ4uJWXDIemT6cVnaq5jg07S7edljjaTzJEG1WGM8HuaznZu50RutDJ8MaHp9vpmsXNn50GnpBvSLzM/vCDhQe3r7c15eMy6aLYwHzbfN3b4z8yHmRCe/Br2LxLcWFv8PLu0s1KvMIgdg2kDeAVPuQa83i/dyRXELO8khlsljZMKC64z7Y4rH4ZKL6lKKabMueKSaCK4jujHEeqxfxYPGa9ztLuz1rTfD+lOZCbmB12Iv3DjqT2zXigMUFhaoYSC2EVOmTjkn0xXa+A/Ey+fEm1Rdxgi3UttEgHGAT71yz3V9gtJxk47rb8Sz8Onu7OLUNGvA4k026eNSeyHotdvZybRyfm6151qEVxo3xgSG4uJEm1b/SZk/hL7eVx6GvQLbYJMZDZ969fDybgrngYyKVV8vXU8l/acOYvDA7g3Wf8AyDXhNe5ftLNuh8M5HObr34/c14bWr3OZbBX0h8H3kTwTorwECRBKQT0x5z5r5vr6P+EGP+EE0rr92XP/AH+ehGlOThJSXQ7Hxjbxvpc0gC3EZjO4OOfwrxKXwnq2vxRSxPpts0R+TzG8ubYB1L9xXtc/2u60O+iiw/lAgZGeK5VGtJNHsxdqqXByjiQbVC56/WvNqJ067a7H0Uoxq0rS11MXT5vsOn22lQiP+0I4SYZ0lLJOM8qTyOKrXAmh0ubTLyWaEQsfOtJIjuVG5JV+hGcf0rUvbf7G8scUglg25QKwwe46/wA6gs9XWO6/4mVveyQKpEfkvnCHk/XuRXM227bHVZKN7nPWl7fRTtcXV7dTRWkTJCJFKqpPygjPXjvXXeGvEhvS+nQGW8VLdriG4nQxkSqOgIGdp5qnLeabrN3qEFrB5+nTWzwJFyCWXDb1J5GRgEdiDXPabBeyqB4feK0hmcRwRTAh4xjDNuHQdeDXVeSVmzmbT6Hd6MmnXqWayWkn2y5y8sat+7Az1ds5P41Et75Gu2+n6TbQyxRTlpniwMZGAq4rCsYryHSHi0iSOby52iuL+Rm/fDHLcchRyAelVrzV7zTfDcH9kFJo4Zd7zk8nnhQ+Bu/HNNVIpqwNXu+h22sTXFr4h0uSIW32iZQJFkXDoQ3JOeM4rfuHF/asXs3uYNzybvkDMPXJwAevvjtXnmri/n0a2neeS/hfMi+UmZY2bqD3bBNdv4d8S2moaDb2cSXNzeRJ5UjiLy2HB+V+gz1/CqjNXkRKLUVbdGf/AGBHd6lY+bcxtcmdYbDOHSFODtIz8xB79OK3/Fd3c2KxW9zBpl1HZEZnkkKSvk/PwOc+3pXJ3rWcNzNKv2W1hCI5Z1QzRMp++Ao49iTz6UWksFlqEcqkaxeKBcwzS7QEB6MVPB/rQpcu2gct2m+hvWWsQ2GlS+WwRWJkiW3GfKycZPOM49eax/Gc811YrFaahGiXgEIjkGJJfU+oz6mse51ci0vr5ZIZrppmWVmZIip9EUcf1rBMkV/eaQoZ7hp7oMtzz5ZZBkruOAccdKxc3LQr2cVr1Oge8bR9L0PToWmvrp5mjaOEkvMUByUxz985OfSoLjxHJrqXMiNcwXZlKxHGI4wOGKD+LpjBOKytQlaLVCZrl7S5RXgOxh5iK/zOQe2QQufTd7Ve06x+031uJ2Y2ESgukAORGOygdvc9ampLmaSKhHl1ka4tnl0mfXb+Sd7+fFpbzyN8/wAvHC9lXr7mp7ZpUJS8ubdLeNVMkl05eR8Dgkf0OKVkTULxZI5jZ2rx4twV5hUeoIzuNWdP0SyvoZrjU0kjRHBG9sNK46N6Y/Cq5HLoJy5VqY66tKzy+U7eXjIkZT8/b5R2qa/u2e12vO0a4XK7uFHfHvTpLdJw6shDsS77MgY7E/T2rPu7WOK2KqssyTyLvUnayheeD6ev1pqmwlMSxibUkMUaqLUEeY8jD5+4B966nw+iSa66C8jtbSRRE4Ckh17DI5I9ccVzHkFVeGMblJ3jLffB9umK6jwlZv5yXFmFiWRvKeNjg4zyxA6iiG6QpbXZzfxHuLOPT5HsI4iIJcPLH8qlc4GPU1wp8uS2W4iWRXAwGjbnB7cda9K8dNa3+mfYyVj+03eYYomOdg6np8uTXG6be2EdybN7bZIhKspOSfoe9cdSPI2luaq0km+hveD2J1I3mrxoyMyNNOiAMCMY+76jIIPrXqPh2YanDK0AY2YmlQySDYV9FPf/ADmuK07VtNOn7beT7K/dpYTnr90sO31HbFdFpuqfZ2aG4gFo67XK2/76GRQCdycjj8OOlVTlbdmNWDnFuKO08NxxPekxsHhjBCqOF/E+uf5VleINOt7nUkNwu+1Qm6nDDksv3IwP1waj8M3kmn213qMt3byWE7lkgkkG+PPUjjge2Kfaa7a36FxCJlznMak7vTJHIrdyjyJM41TnGbcTidZ8pfFeoRou172W3XcBwVwCyj34rvdR0gXkVtgoiq2N7cKQfvcd/Sss6G2oavY3VwsREsvmsyH5QQNqq34c108lu0t5axRxgwSu8SGRsFgF++fbJxUU42u2aVqnwpPZf8D9DgNSb/hD9QjRR/xILtx5K9RbSnoAf7jdvQ1euXe11AeIdNcRRQRYubYqWWVMZO4/wsO1dzq+h6brWhPa6hCksZbywN3/ACzAxn9M15tqNhd6FD5Nhq81xobTBDFOpZ4geNwYck9sHrV2dMdOpGpo9/z/AOCak8E3ig2d1ZXSrBcAzRuHOH44B757Vl2qzR2Nyju0DRKySgPnof1J9as3dlPFa2kUrSQGMbiN2MjPAPoDViwuIYIpWdVkR1bzUPDn/aXHpXXGN3fqVeystjI1GRBp8NvbQs0pkCxiPkHd29cVpx2bJJNZyOYoPsSFiuQEuHOCoPVawhq4Z2Z7ZorhVGyInIGW+8fw7VctpbiCcJcuGmvVdjFCq/KpHCsecfT6YrLm946PZ+6XdHmu5GNuIblp+ImnZMxkxnOC3Q+hHrVyzguftVxHOxt2kJkkEJDsB3GDV0pNaWVrYWd3PFdRIGmkT5yc9sdhVCy/c+IRshZTMjRu2/Pzfj2NdSi0kmczd7tGjZm1hupbeHzOnm/MTwMYGc9T9KZJLZ3mlwyXRjSZLjIV1yVxyuMd6mie7jmkFtaJHIsZy7P17DJP9Kw55re4uPsRBinUCORxwC3XePUZ/nVc2hXLdm7dXV3BI0rIhW6BXGRwcA9OnesmzMUVnDBblgCGV5PNJ9cjnpmq0DiK28ie6kQQuZZFZAVJwMBTnIPU45qhq5tIpr5TPIc7WcJH87Z5BHYDvXNUq2fNY0pUW9C1fb7bwvCZFzDFcoJGjzkIWxjHtWTHFLLrWrWsd55tqrNEJHYFFXAIQKfU9xUWp6lPBPAbIiaNo/M+z9CQOuRTozFZadazuMfaJPNJJOXZjwu3+6O2alyUtun9fqVZx+ZQ8R2U0jWkEcYaOV/k3tyr5zkHuCB+FYlxP5ls9qIm8uZzh26q4XBA9+orp9Qt72axvr28cyLaOZjbyPgumcER+hXdn3qprljDLZ2MfmY8xo/tBI+5u4Vxjv2rKcbO6KUtked3lzOFktGKBfLWTLAZww557YINT2wc6VY2ks/lyGcTxMUAaBBwpBHXdVfxHprRXl7GV2q8r28MpOQdqglTj2ORUVgZNS1FpQWLQqsUSA9Soxwair7kW3oa4eEqk1FanX7Rcapp2oXWqm5vbS5QFriTBBPB46jI7V6nGTvYc45PSvAp/DsEulS6zHLLp8kM4Q20z7vPdTnIb1r3W2Imt7eVMjfGG9hx0ruwj/do8PM01Vu0eUftKHMPhrnvddv+uNeH17Z+0acxeG/mzzc/h/qq8TrpZ5wV9IfCQkfD7Sj2xKD/AN/pK+b6+kPhKQfh9pHXI83H/f6ShAeg6M0xgv4ljXMinZnucd6841eJkSyhuldrhQyySDr1+7tH869A068azuxKoD/3hnqKS/8ADsepLLqMMvltITs3nH4fWuatRc5XR62DxCatI82iA8zyrmKWMKDuU9MdjU19ahrJWQtsJyWT+ED+VbN/4c1FfMiOI4v4tx+Y+4NYl3az29pEbRGY+Yf3gJOVHUe9c7p2umj0faX2MoWtzYXcV55OCSY4pCeQGGGOadpUsWnpf6QYkjvL2QxLeOD+7DdyT+QNX7jUPK3RaxFdgk4iIAMa+wWmXGnRXN3byXMkogaHbFIozhh0+n40uSNtCbtu8kQafp9rFa6jp0Goi3u9Pk+UW7MQ6nqG3cEev6VXs7rUdL8y5kihkimjJeGLaY58cDbkcVd0+zukupo4ZEadMMZ2QAHHYmotMeVHm0+7uI0SQu0FxIoYLn7yMegPoazkvkaLTTc6XwW88d1by21xhL+Bt0DAARvg87geG7dqv6hax60Yp7iV4rqIBVt0fEiFTkNuHykAZ5PrXLabouoadltFsZDdwgABZQ4mLHqF7NgH867BvEdvB4fjtLt5VuUBQosY3sM9Gz909s0RtLd2QpLW8TjWtLk3ksen+IjbpOzs/mRCV8Y4U9wDzxUIW/1LUrDTZdWmuLGLOzy7UJIZR/Dgt0HYngVBqizavqFp5EcmmyA4e4t0yNvPBx1b3rVg0u1tFMCNcPbzjc9uw/eTyZ4Z3HI+gxUwbfXQqaj0KyaLoFlvurlJtX1Ql1SFpfOEUmeCyKAM+5OPWrVnbyR7r7xJK0/2YCXyVIMcEeclVRRtXJxnH511mk+HtYuhHlbOxGMGKNAqxjoMjuat3/hNNOimtzco0Uy5YRDKkbgW4/pXR7OW6OfnhF2XU8wiaxuPEM+qSeXKLs+ePK+6CONoPoP516idJbR/DVtapAEvtYYSzuF/1UQ5xmsrQ/h7DZeM7nVdRO7R4YFuWjXAVGXopA45xmus1rxG+raVLKgjjjuGPls3yfu1xuGe1VRo2u5df6f+RNSpfljDbr+n+ZzcVipkuLm4xKFYZWTK7ccKM+mO1QNatcJcG5w24jYsfAAz2+lbELfal+ysxZFXIYcg+2O9aEMCxJDwqovBZhyc+ldShFolzcTlpbHy7YuwG1yEDyNk7vQelUNXi8nTEmklXa+4AYGSc8jNdfcRJcMwRf3MZyuV6+5rntV06aaW3juIk+zrkrs7A9zWUqXLF2Gql5K5g6Zoj6m6MHJUKXJDY2qD0Psa9G8MeXb+IJY4JVFt5QwyqDg4xzkc9Olc7ZM6LbQ29xFHJglyq8unG3np07Voz2UTWlzcWstwJivlA+Z8oPfI7emazpRsuZIqo+b3WzgvFr3t7rlwzFGnic7WhQRjH0HFY9x4evdZaPEUYdVLJNExBDDsDjk+1biw3F1fxtDZzefyk6s2Y5yOmD1FXrW48R6Vp09k1orW0r7lk6mAeg9MHvXmSqpycrnQqUtlY42Se70W4S0123likBXMygkMp6Hd2+ldPYxhz/otxOPLAk2LJ8jr9O2asweGrzUNJbE1s1xDnJVyQ+7nZKD69mHINZ2nXk8V6tvLYPBdjHm7v+WZHBHpg8EfU0mk0pRViZ3Ttc7CDSJ9RE7RoLsxP5pjlOyQgjqrDAbjpmprDRdH1W7aVLrU9LvHXAQStH0GMlT1wfrW54PW6SyluoInkREIcMeSnt/OpoLzTvEeY7p4XkgX9yxJUuP9kjoa0jHmV+pzKvKLa1su3+RiJb+NNItZZmm0/V7aJgOBskZR3OOB+Vb+kapfXWm28c9rBG0j8hZlkdhuztz/AA/5NZ+q6bqFnGh0yae6YEb7d22sB6K3f8aztFmg0++Y6j/omqSTAy+aNoKY4GOmeev0qfauErPQ2cY1Y8ySv5L9Dqr6C9tWuGvYjbRszBFD5zuO7Df57VTh1b7VfWsLwxJHCw3OOv4D1963vFF1Hqk0QgINoFyAhHLdzmuFtRD/AGncRpIhuI2ClS3zY65A9K6k9bRd0csYtq8tzqtUvrY64beRAeAJCTldnYYrhLsMj3CSLGkKOV2xqdzDPY9cYrW8Tn+zo7e5dlaS4JXhuw7ZrFe7+33C7XdJMbAG4GO/4VVWfRHXh6aS5ihG6R3iGPfb5QqGc7gV7Dn35rb8OWoM8V3qRSC4K72hPzHOevp0xxUM/lNJGsbCRFX5Soz071BJdv5rbFCyMAC7c/8A66iM0t9TaS5lodRFrCWRuhawS29vK4aS5fh5/YDrirWgapY3z3DzrvUAtHOY9hXtwp6/WuOsopZbdri5tp7q28wIZN+PLA/ur69OtdPrNu3lwiKJzcQrskkXBIQjo34V2Ko5Rucsqcb2CO+kuEdI3DxI2N+OQOgNRalGksLTSp59zAm62UHLccbmHfmspp7e3E4Dy/ZolwTtwc9x+PrRLfjzFuLdFJ2tCsbcELxnnuBS9uuWzNlRbd1sVNVkhfT0UrIbhiJppR8uGHB49MflXPzXk981rIkwjZjiMt0dCP8A61an2triLdOytOVIYKP4c9ao6ZbRS6sF8uV5IjkRL0Cg4/WvNneTSWx6kFGlBuxhXF639o3ESuHKFo4n6AEdQPat1rkSQadbSS+Y8L4MmPmfjOD6AdvWuduZo7TWrwbB9nhuZGDN907sfKvvWjLrMNnal7OJZL12BjH/ADzx3/8Ar1SbjNroc8uVwvbU76e20620hAsm/UEmF1CWGI5S330wexBOa5e0ifbqltcFTc20iQZVvlUbg8be2Vxz68VF4b1OHU7mS5HmmeaJoU3rlYcdsehJ6/SobmQXJe6DrZmaPaF3jMhUncrH3BGK6m09TgUWna55/rl9Lb6SsUuF2Xk0iL/EuVAyfatrwckRvbRrVYJGaHZ5JXIkbH6H3rkdSRrm4eZhIkcjMQr87gpxn8813vgNoIWsJlASeQmFVHOF9ceprjxsrQR6GBjecn0syl4mjvNMt3t71o4FuwW+xMfMRPcN2PtXp/h+bztB05g29fIUenQdap+NtH/tHw6oKwukBZvN24aJu4Y9xTvBqyf8I3pgll3ERAMccE134NJbPoeNnE3Pl07nnH7RJzF4c7jNz/7SrxevZv2h/wDV+Hs+tz/7Srxmu1niBX0n8JR/xbvSDnP+uwP+2z182V9KfCY4+HGj4IzibGf+u0lNAdYvDHIJPfFMkuLqzliuLWMXKxsHMDHjI7j3oiON3OTn8TUoHQ5Ix0wKZUJuDuje/tnR9aVYpJCZp/lMUjbSjd+Ksab4Znk2JOY1towyrGO4zXA63ZxSbJig8+JxIrjggg+tej6FqxvY1+zlGkwD15HHb1rm5JRk5N3PTpVFVhaGjMjWfAqXMLm3dmlZg21hwuOmPSuP1jTm0m7a1AbylAzu5wx5wK9ksL0SziO5RlYnnJ4z2rnvEen28E15NcQhjOcrM4+VT2+n1p3TV0aU5zjLlkebxambi8jNxDGs0yhSgABYjof/AK1a15aab/ZM8y2qrKW+ZNoVX7E47GquoaNLHCk00AyvzBv7zE8YNbHh65aa4igu1RxIjYDHJVvVqhQk7nVJxsmjz+TSY7iKEfap7eZWEamJyrRpnPOP5981e0rS7GD+0ba7vnmvGuB/q3LOsZUbTuPb1PtW/fxSw3BC5gQpIzBeSccf1xWbFYA3E72sCxzykArGckAYwSx9K5Y0rOzNXO+pbWyh0ueCC3Y+WEKn58sR9e31q3plmIrwqLfLHEhJ5DY6YNPsNOVp2mknhLqoBMj7g59vate3hhs7QQyyFrjeSioeSn1PGK76dJLocs6ltL6jJYLm8iezti8TE+aTuwzHsBRZwzRkGdI9m0xPuf5iT149T61JPGlxYyxgSRTQtvCwNk49d3aooRNbQLqoRLhVkWOJW/5bfX6VTjZkc14mr4isvK0GC0hdPLEi3F4rsd8hx8kYx2HUj2rh7t4xbLaFCtqrsRjnY2Qcc9q6htTt/tQg2S299OxZ5LhGbLHrgjjjjArJ1m1d/tluHhdwySb1GB9f8a5py966Lo+77svUS1SWEvEMR3DDMQ6gfU+lbNszxqokkjaZVyQBwp9cVzmiXLTIieaoeMHDtyTjsKv6W9wJ76W9uorh5XzFsjCiNMdDjqa6ISuk0KotWmaMqvLGQOrsGO0cbR1/E1ga7YzSQyoHYws55DY46DFdBEd9o90r4RVVUb8eQBWerRy37I7qtvIdhAyQd3HT0zVySlGxnBtO5Hp9g0vhyNBiK4iXfGdmVA9D74xRqUpTRzZQKPOA82Z2G3bjqQe9U77VALdtOhV4p7UZxvIO8H26j61DHFJDphl1BjdXFxzOAwJ9gK87FVY01yxOmnFt3YN9h0+zt2W6ku75yHaRuBHz0A7Y9avXGp2dzfQyrJJZqxwjKc4c9dw6EGuWu/NiiCyxwxhxtjw24/Rj61JpVm168MF7G8UU7FVYtkhsYyP0NcEZX0SNXCzu3qd3aPvsLp7OGKPU41YPaL92TH8Q9jkGsHWrGbVrSzv9OhR7pHWGaINsZ0bsCe4PT8qXwwLy4vRdNdAXyL5e4qRudcqT9MY+protNs1FrbaLqIePU33E/uyE3AluD2J69aq/O0l/X/DjcVGLf9efyRDoO+0ns4J3msy2N6yrhW9Pm6V09p4Z0eyuFu4kZW84zKnXy3PGAP7pqkttLNCrRlCtvlZQH2sD7g5Vge3Si2mlkhZrOVoN/wAoVsRgn0AYY/Kt4JQdmefOLnrGXqbk9qtzMjODFcxnCuGyGxyBiqHiOWI2SyalbWqzrJl9yg5Q9B6EVQt5dWtZlXzrk5+88ohYfpU+pR6jfR/uoLR1AP3o9xPucHFRKWj0/AqFLlau/wATltSsLYxLd+H7j7AcncIX3ox/vFegFczYWvif+3LswJp15u2FiY9sjrnordvWtm68NzTTM4tWgnHzBrRym0+4PBqj/Y93p0U8sN/fNqUzBhGkSktjoMZ+U+9c6mk7pWPQitHHmv6o6zWfDIvdMQmNZJrb94sIbBU+3rWNrng/UrMwzojyRzlVkOcCPPrjtXNajD46ZRJYJfrdy/KGuJUUL64Vck1Nc+E/EF1NDDqniC9m2qBdQ294zSI5HQHG0fTGRXUpxkrtWIhCUNOdO39f1+J0z+H7fS4x9p1m1t5FQLtGOrHkc9hXNW00st5FFpjJqF5ArbDH/qIggyRu/idugx0qe3+FPh211eO71e+1GZIQzy29zNuEvHygN3PqK9N063h8OWElrp2lxC0Tm3jRwr4x16Hn15rVU1NpR0Rmq/KveV2/6/r8zlo5riKxlW4hEcskiSCRek2eOfQjp+FWZ9btxcPHdIYbkxiMmT7k+OmG6ZrpZRHfxQXmoyW1mjrhYppFLEZ9PXjrXEfEjxJoGkR/ZriZLqVnMkcSkEhj2VRWybhpcim+d2sZev6nbrG/mxsFQHEJcBWb2Pf0rlpdXkmjL/JCY25A5CY6qMVCtt4g1+aGax0uS2s0ciOS8wFj9SB1PWuytPC1jpsAtdS1lprgnKNCqxjp0wf5+1cdXnqax2PThVjS93dmFoaPeXB8pS3ygoQMKAefm9O/HtXUW1qLP7JJDfW0E3Ms0qrueQYOFx6VmanLbaPBKtpbPcRYDyAEgy7eAWI7VFo+qalql1G9zHaWtvLEY1Xy8uI8dj24zWdOSi7PcmpKVRc2yOK8UWt3LapPLcopSVwkPlgBd38RPc+lYvmS2ktvPa4JKsmU7HH6113iSdbq5khDhoYZhtBUNu+XAAH0rklkXy0t2DhgwIKjHfv+FaepDu7m1DMUtYJceRN5vlNHGecYBA/r+dbGpRrJpPlTwqkchZ/3n3sgD5R+dY1gl/eMby4S3jtLScoSDhAfVsd/Q11VzqekraWi2jNqUaOxMzoSS3cgeo9+1aGGtzyZ3G64RCWAbkEfdJJJx6Crfh+4eDUoWZ5EjiyVweQTTJ1WG+uBFgoHYMRzn0b6HrVCOPzpY4o32zb+MelRUjzxaZvRqOnLmR774M8Q/wBrx3WlXFwryMuY4RGPnGOQaXS4/JtEiMaosbEBF424PSvH/D14+k68LhrgWyxsC7OeX5+6v1NeuaXcQ3qzSWwz+9O/59439Tz3961y9yjaL18zz84pxXvR8jzH9okAL4fwOM3Hf2irxivZP2hGLJoGezXPP/fqvG69M8EK+lfhPu/4Vvo2AM4mxzj/AJbyV81V9LfCMA/DrRvXE3/o6SmgOpCAEA559CalUNjIOfxPFMaPLZUj+dPCkcgcdBVCKt8N0PzHPYDNV9PvptPwYGYrnopxj6Vav/uoOQvuKoTRfuSw+U9eD0NS1c1pVHTlzRZ6J4TvzqUEgumSRW+7JjB/EVuXel3Q0544HF2rDBjlPb0BryO0lltZYJonkRQ4dwhwXx2r07R/FFvexRrYrmZ/vq/BX8KzcdT0Pbe2d4LXqjkryyl8N2N3nz2sp5A4LMXNu3pj0rHOny2+nXOoPMgmk+aLYc4btnvXr7rbG38q7VXSQEMDyD9a878ZaUdFZby1ikmsX4KHJEJ7ZA/hrlqqcFdPT8jop1ed67mBPbXFyk93dxuJnRQ8qtlGx0XjoO57ms+3WSZXWaUNFGQxZR8r9eQB/KtC8nc2Mi6f80yrukVARGuey0+xgjkto4ljeIheTtw0THqwHfAq6duY2V0myzp0SPE5lgKrGcBFx+Z/+tV6NRPMpl37QB8gYDHpT4LKK0XygVKxgbZF+83HJI7AnmobTQ579luJnVbGL5iyMQXIPSuuzSRzuabbbLd05jsPtd/HL5bShFiDZaU5/lWvdSW95c2aywq0sbKsduhwsKnoxHQ1UudatUuFmkMD3kQC4blUX0UUzw7qMkuuGNIlYE5EnHy+3vT03Zjq1ex0+n6bplpvtETZICXLOcncea4nxBYWlm1xc2PnPvb5yzZz26eldHrmrpbWl1c20g85NyYAzmQnaPwBNZGm/wBnw2afbyXh2YAf70jdzXNP3n6DpKSvJnBAw215LPNC/mMAMh8KPw681u2UMdrbNCTdSwun3CuRHnnk1pJpD6pPJthlQhhtRRyAORk1v6dYS6dbTPf2zJEjb8OA2/346UUVy3TN6tW68zkr+4KRYt1mAhiAdREcLJ2/OqtlZRyvGRdq033pI1fDD0+gz1zXU6ze3d3B51jb3AVz18sLk/WsC88QTWNo4OnwQXHTzFH38evvWVaty7ihdqyRyPj3xGya1Na6YDOqEGV8/IjDqAetR6NbXd7Ir3t21pBKoMTxDcpPuaZJZywWomvlSC3eRmMgIPzE5wR1rp9Bt2ntYo7e3je2zu85v4f90f0Nec4+2m5SOtS9nG0SKTQ3tHjltZPtczHkPj519T6GtMLaSQL8jNcvImyNRyrc559Petyz01I7VpH8z5c7pCQTj6/0qaDTmmsEls41SDJfzNpy+OR1rWNJqPumLmm7tmUtksLGWNFMj5aJ1PIOcsCB710Wk30WrWAF7vBViu58ZyO2ajvNFUS6c8E7IJd8xUHJJIA4HuTVfTNPaKaNDv8AmuJdq9AxUdTQ9GroS1T1GpeC0vpndN7WTYmReRJAcc/UdavapbvNOJYpY5bJxmJsAhQecMvb61UvrdrdptXfc4LNC0SplZosY4HrWR4ZW5tWXzYh9lPEM8W5TCv8KyL3I9ah3i+Rj5IzXtEasdlN+6KQo0ZOVKMduM1oyXyWDeTfJ5IKkiRCQu0dcmqUkn+miGe3CXMw2iaFTJA4HPIBGDWJAdKv7meOO6tonj/dyNBcSQkN/tI+RSfukqlzatmtdtLNcLJY/aFhP3ZAA6kexosdG1qbU4rlfJL24LiVo9yjPTjjJ9s07S7Ccx+XFqtxCfuqsexgB9cUzVvDVpMFW5167mud2PJa62iQenHSs1FSd5L8S+fkfKn+FxNemstFinu9T1pkn2hDAkyx9+yLgAfWsG3+IPhbTosafaz3lwxzNKiEI3uMDn61ur4R061ummstOtopJFzIJcSFj6c54qPU1W3jZo4o40QBQsK7BGPQVpWSpR5r/r+ZpRlGo1Bpv52/Bf5mBqOt3XiU2rWVjG9r5qtJHcRlU2DurEYyM1N4w1PVJrZItHvNKt5fuyGd3woxxjAx+dbehaf9usknunYQbiybj99e3X3rB1s2sl09ppyZmdN08uc7D0wvt71zyxE4Q577nTSpRnU5Evh/rUwtN8FQ6/PEdb1+XUZU2jFtIi4J6g8EgelaN58MNC0tyYI5ba53q8FzK5d1I7bjxz6Vq2fh5JdMFqhjVCN3msQruQOOfSuF0nVPEWhQ3s0N8lwvmmJre5HmQtjqMH+Yq4YhRivaK1zRUvbSajPbp/X+R6lo+naqxlSKa0miH/LSWPLLkdCR6VzR8PWU1vLLPdst2J/3l2QAc5PyEHhR6H86ydI8eeU2Ly2e3IA3GF98JHoR1x/KuguLqyv7b+07WP7RbSoUlEb7maM+3cj0rX2saitHWwLCzpPXZ9Uc/qHh7VftSG2ntruHdmWPzNrqOxC9wPaqd3p93e2FzAkUls6krE8MvyvzyfUH1BFS614euVjtpfDpu5IovmEW85U+q55H0rR0fxvDcGKHXLCF7yP92ZyBHICO7Duf51ipR5rPQ0nRkoqdP3vwa+Rjaeuo2+iIy2Ub3CoQ0TRkvLk7cLjj35rhNahfQdYhgvIZkeLDtvUjfnnAz1HavoDTtWt7+4mggWYqMHycAb/cHrXH+KVEuvnS9TsobyyNv9ot5Jc74PVSetdLqRtZs5oqUpO3qeX6feKtvfT7Xt42kCjYMrv68jOK1rWez+aXy1h1CMrh+igY5IA6np+dbkXh7wzDpl5c3EF3FExEn2dZtu4juc9B6VB9n8PzWOw2kEUA+XBZndvbcT+Zqfax3K9lJuzR53r99Et8ZVVVdW5ERwDn+IduvUVct7BEtftDxo12BlZfM4UHuB611/iPUbG+sFgt9O01VtkJQtDtUEDt3J9zXJTRSahpsEq+TGsKbDLGeRn0Hc0p1E0uV+ovZuLbluZ1zewQ6nZ3N3GkiK4/dvzx3J9zXuWlokUErqqxo8m8AdOR614po+jLqUPlW1v5hhuxG7N95lxks3sPSvaNKeAxstuUCDCnZ93cBjA9K7MK0pcqPKzC7gmzzT9oTO3QM883Az6/6qvG69i/aBzs0DOcZuMZ/wC2VeO16LPGCvpj4RDPw50fHpN/6Okr5nr6a+EAB+HOjfSbv/02koQHXLznJ5HTjrUca5LAtzntUi5B9B6U5FCk44ycVQipeAYUnlc1Xm5TPc1dulzs6MdxxVeRNqnAOQOlICi8gSMhs7h7Z6mql1PcWepWdxaSFbhGLAL/ABADv7VpyISOcDup9PrUbxsmFRQST1qWi4ys7nW6T4ugubeI3i+VMPvIx4BHpXT2F9DcwyI7iZZTwueAPevH7qMNwOee471Z8N67NoepGS4Uz2jLgr/Ev+NCSs0ztp1YzXLLRnWan4bkiuWk0l/LhyS0Rbv6Y9Ku2sCSWpVlCzAgMJOCPXFSwarDcMb1G81HXEi/3RVvRtRhm8zeYpY8/ICfnA/rU06aSdzqbml3Ki6ZOLwhoUW2JCoynJYd8/SsrXtchgs1tzayQ28L+Vtj+Uk/3vcV2rTW9sUQbhn5ZGYZGD29vrWVf6TYpbpLPIDgEq5YEt71qm3scymr3kjzDxPaSfYYbwBJHkJCxx/e9s46ZrOuNSvvDTWF1cWlxBBdoJo7ofNGvYqcdDnrmu2szZ6ZcT3ErOIlOUilwfOc9MfjWr4pv44UsPCSRQSXDW5lumYjMIbk7Qe56VxSTd2nZnTKq9I2ODlCyQz3XmzwhgZQVztds9B6k0nhJNSvbsG6YC1Qq+x2yQecJj1rW1oWEGhws11BDFAPLSNpB93pke+Oa4vTtUm+0rNoUM1xAzfNPIQiqw46dc1yuTjNM6YScotHvFvqOl28cUQnMcqg7hKxDZ9c1Vm1Iu7F9YdSThFVVevL7oaw0Rmu4GjjPJMkgH+RWI/i1LGaWF5YJl6FUQtn6N61vGpKT+FnG6cY6tnvJa+ihVrryihGRcQ4UAf7S9q8n+Ifio32orpmkN58UB33F1Gg5f8Aur7D1rmrTWtU191gur+SDTFBAiDEZH+0a6zTdIs4bfzLS7tURByNw/lRVpzqq2yNKSVN8z1KPhnw0+peXd7ncuPMbzvm3fWu9stHeG2xbIImzy+Mqfwp3hi+gli8l0WAAnns1dWPJSICNg2QcVEcPGmtBVsRNy94x30+S4jVLhlMS4wg+UE+/rV+0juLW2lVEMsD9ee9VxcSRGacogU9Gk6DFVp/F2k2qBLi/tzIf+WaSbsflTSi9nqZc0tuhPGk73MUxj2CJdiKT69MfjVWWY2+pT2h+dY4FWNs5GWY7z+OK5vWvGtvNKBp7yyNnJZUOPoKxYtb13V7nFlClorHLSONzY7Y9h/WlCi2aOtGKvJnXa5rptoDElxEFhILAjA2jtmqOkXV1NapcW9h5qOzfOJQCxPb6VVtfDEbx/8AEyka5bPLSHP6VqW2k2scYRVwh6bSRWrwjlrc5vr0Y6KJLbWeqpvmWBbe3P34mlHJ7VYTw7aeYt9cac0lww+8pBVh/tVl33h8OhNtd3ERbsJCQayZLfxDYRmGDUZGh9HAJzWE8FUta/8AX3G0cfTeu39ep2MGk30rDy1gsmIwjB9xU9+PpWdpfh2fTr6S52rcTHhS7DA9cVzYvfEQy6+R5w43n6elY0+o+IvNzcXA+Xn5FxiuWWXzerWq8zqhmMVeKej8j1iG3kN6Lm8SOF2XBijk3fQt6VF4gs5dRsJLYC2iYKSJI3BYjB7CuB0vXPs8u/Uo76UMOqSA8+hrQn8dyR25t7GylUbs7vLVWI9M+lU8NPl5eX8iFiIKakpLT1NjWpoLPTLO1m1ERy2salI2H33AwB7j3rB0q3uryye50u3ea1uDi4uEjyW7lU9qyLnxHeNdfak0e2N2FKrNcMXwD14qWw8Za/akRfY7RoWP3Y8xhT6gDoazeXznLmkbLMadOPLDd/cdZrFq8ektKYYnAISO2mJR3Pse2K5TWFhn0bUIZLJ49QSI/u7hCoDDsr9M0/U/GuoXMBSbRIJmAIJeQsfwrLvNZ1u9smtbmOB4ZcO4YE8joM1bwE29Ap4+lBJSetzyKx1Fkt5be4tZ0nRtqshwm0noa6Twxqs3ha5mMhe4sJlBmjXgpnpt9/eulkm1F599xZWLrnPlrHgZ9aqNZ3ClzFbI4fJdZOQ2e309KcsLW5vdj+J2081oOny1JN+v/AOotvH08luqWxmlgjTKzSQ4YA+pHX61Q1W/stWtN+r6XJJ5i/uruLADY7Fh0/GuTgOqw6xbXkiQmGJlD24yqugHK/iK6a1h07VJJoIdRudHWdji1kGY2z6N2IpPD1re9/mZRx2GUvc0/Ay9FmujqEV61wWS2k2xAfeQ9iSPSvQPHFrbS7LyaWR5L2OECReu1Byv0J615n4l8NT+F7yJo7iY2d2d5ukYlVYHgEjiu20ya+1Dwhc/agfLtU/d3CkEkHqorD2U1eNtzodW8o1E9P6/UyZUsNXkeK4jfY3d8gLgdiKrXnhefTtNurzWjLHYBQ0UlrHy8fQEk9D61eh1i90yyWOws45nI3LC3XjkZ+tVrOLxB4uSw1LXL5za3f7yO0QlIto4MZHYg/nWlDDSerRGJxXs3yp6HP2KLqd4qDS2t9GjBfzJSSZD0H0BNWNJ0ZtTfUZ9OkjWa3jYxh/lVRjqB0rsr2D7MrxyRySpK21pMZ2AdAB6Vg2WlW0up3ULzvG8cYMMSHy0cZ/j7mnWoSTT6GVLExcG+ph/DjR9Qv4bhLy3uLGxBLGYHDu3faf616VYafb2Fqttax7YlGcHnd7n3qeAtCiLgAAAYz0HtVpRkfLgqfSvZo0VTXmfN1q86zvJ6HjX7RClYvDwPXNzn/yFXjFe0/tFLhPDxGeWuev/AGy5rxatWYhX038Hhn4caPx2m7f9Nnr5kr6b+D7f8W50Yegm7/8ATaShAdkP7wGelKgOMnH6kGncNuwM8Z5pWyCpIIwec1QinOvzcckHoO1V3GEII69f/rmrbHMrLtbAyepprqFUYzk9AQaBFUgMBhQcdSaa8Iwdwyx9CKtEY4OR/FjPSlC7s8k0WGZM8fcYB9jVcW+Tnnd24raePJz6Cq7RBsdsnOMdaVhpmVFLNZKywsyK3VSMg5rOF/eW90xfJgzvBTKlD/UVvzWqyfwDPvVGe0LDO3PPc1Lj2OmliZ09mVpPFVy6G1+1TQrnO9QT+f8AhV3TteuZpkilgS/iDcSxSbTH9UPX8KxHs2TGRjp69a1/CmixC6m1i7QvBZcRIf8AlrO33Fx6DrVU5NaG31jm3R22grY3t4+q39rKtpoyG6laUY3OPuqBXHajqPhO7vZNY8ST28uq3J81tjfOBn5UH0FdD8T5n0fwPb+G0lJ1C/Pn3zDrzztryPTPD8W0fu1xnH3R/OhtJ2tcz9prc6O/8T+F4JWutI0Bp7nokky4Rcf73JH4VmXGo6jqskUUfkafFjc62qhTIT6mtmDQIZIQroe2PX2rRtdFggVRHDgxndyc1nyeSIlXfc5ldFna3KTXl08QyCjyFlz9M1NHocYKxqqOAOi9jXVx2CbCJctkcn1/+vU0NmkTloV257etVymTqXMGDQoxFlIWLccEkA+tW38NRtF90/Nz1Iroo1YAAEjPv71K2dpBwRjFHKTzs5uDRJIiyQzyx4GABIas2djqluVaK/umPVcvkVsCDcQSPYGrUQMS4Izg4odNPcr2klszmL7Rbm6YyXN1cyZPIeXIqaw8OW4AxCjbAMkgV0YiBGxupNTWsAQjYetCgkQ6jMu20qOFWDRcYzjAGa29Ps1gRHRVBH4/lU3lYwSdoA7c4qxbwmYLk4A7d6tRIcnYlSImMnzFVh7HFQMrq+0YI6HFXo4MDjOenNAiG4gZB9KuxCZX2Og+ZcnoG56UsicgkKPwIB4q28ZZOMdOKrtkuVDH8aVh3KQtVYgYXAPQ81nXllDvcNHkjrg4rdkiO87Tjj86rXEJIx/H6Hmk0F2c59it2AjYAEnIHrUUmnRM20AjjqBW4IBuyV6d6ieDAJb8M1HKacxhtYrG4GMgfrSfZY/MPHyjHOBxWs8A65wepqPyyWJ45/Wiw+YqtYwlWY7cnnoOtMS1iXjBH4Z4q+YxwQR3yKaV5yQPTGOtNITkymtlEVOFGQevqKJ7VFi5jX14q6FXOOhNJKm9Ov0zRYEznrnT42GVQjnBx6Vm6npcRjIKgnn+GulZDvKgMAe5qK4t1UjAHTg0WLUmjgHS8sIpo7O4kjikHzxP86H/AICeK6LwNL9o0S602TKkt5sSrwoPdSOwpt9bHkAZz/FjpXOap5+neReWbmOSOQFih4Ze4Nc1elzLmXQ78HXcZcj2f4Hd28EMcchtAj30KMVWX6dB/Sn6OtxdeCNLkRB5rOZmAOMZY7h9Kr6POtx5t6QzLLGPKZCDsyOvv3o8LCSx05tOJZYbKZ4Q7E8qfmUn8G/SkoWSfc3nuXbeZ4rlYpvv9VzzTdetVkure5liQSxjG7GCQe2O9XZbdpbiMmHBjXO7Gc1Bqd/BcGBc/vATkdwMd65ppymo92YOTjeS7fmVl6EsDnGB6Vp2vIX5ckDpjiqVmoeLDEFcYx1q/bgpjjP0xXpo85njf7SK7U8O/wC9c/8AtKvEq9v/AGlNu3w5gY5uf/aVeIUmCCvpr4P/APJOtHB7ibt/02kr5lr6W+ETH/hXejDjGJQfX/XyUIDvI1I43EjGc0kwJbKtjjkUyN2C/KeO3rS8mQqRn8cVZI1QNwIGSRjOKjkO+LbgZHSpwMHoc47elNlDArsU5GKAI2Qu4LY5GPpS7D9fT0pBJl2UADjoD0FSBQQQVyucnnpQAwgEcY4GOKYqAk5JA74zT9h3YIz7UqJxsIYc9aAI5ISWzg5x25zUE0C7Tkj1JYVeQIgKgt9DUV6dsB/iBH457UAc61q0t2I4gHdmAUKvfivQdCsba1uSZCP7N0FTJKT0nuj/ADx0rndGzYwzaps3zqwgskPPmXDcD67eT+Fa3iyVdI0i18PQOGaIedfSf35W6j600rI2WiucPr88+tavNd3DEySsSRnoO1T6fpwCDAy5xxSWkIknLEscc1u2luVAwD2GMfrUpa3IlK2g37PsVSQB+VWUgGzOdwx1/pU7Q7jGrKCOTn1NPS3GDlvTAHHFOxncp+RtICjj05pyw8c8GrhiCgEE4xxk0gTABzg/yptCuQwRbpYlYZyQDjqea6TWL63s9Wu7SHRtNKQysilkckgHv81YSswkDLgEHINOu5JLq4e4lffK5LOcYyaVhpm7p19bXOnalO2kaYHtkRkAjfBJcKc/N71XTV4z10fSwP8Arm//AMVVfSrK8n0/UHgliSBY90yM43OFIIwOT1xz096rxqCAOhx0osDZ0WpXVva/ZRHpWnkzW6THKN1Ocj73Sn6JdwXmoJBJpWnqhVySiMDwhI/i9qwneW4MZlct5aBFz/Co6D9av6PFJ5++K6htpFG0F85O7jAAB7E0WFctrqgxltL0/B9Fb/4qtA31vFpkFyNPsw8kjoRtbHyge/vWRdWb2s8lvcYMiHB2nPNPQO8Kw7iY1JcD0Jxn+QppCubFvfQTPEPsVmAzAH5Gz1+tJfXUUF5PFFp9mQkjKCUbPBI/vVT0yza4uo44XAmY5UueBjn+lS6hbSw3bGeQNK+WJ2MvU89QKpJXGXYLmOWyuZfsFpui2EDa2Dk4PeqEmqRrydOssj/Zb/4qmxSSIkkYfEbgbge+KrPApbHbPc0WFc1ry7ghkhEdjaHzIEl5VupGT39c0lhPBdXZifT7LGxyCEPUKSP4umRUF5p7m1jupbqOSFMRKF3A8dAMqMgetU42MEpeA7JQCAR6EEH9DStoDY5tQQHLaZp+P9xv/iqmuLmFNKgul0yw8ySV0IKNjAAI/i96zHChj19uKuz6bef2co86PYkZuhAT84Q4Bbpjt60mgTZVh1GOS5iRtJ00I7gE7HzgnH96k1a/htNTureLSNNKxyuilo3JIBI5+brVAsVIIY7h8yketVrpnmuHllfc7kuzdMk8k/nRYaZu2d5BLpl/cHStO8yDyyoCNg7mwc/NWe2rwg5/sjS8j/pm/wD8VTp7O6060iR5YTFfDO2OQMDtPdunX0NV9W02TT5YUmaJmliWZfLbcMHPfoenbIpWQXNLWLy3spLZYNI01hLbRzHcj8Flyf4ulGjX0F9dNFLpOmqiwySDbG45VCR/F0yKxLqSWdlM7ljGgiX2VRgD8qt2dld2+nSapDNEkYPkkBwz/MCCMduM9cUWGmVpNeiQE/2LpGf+ub8/+P1oXOo2seiafd/2Ppoe4eVWDRvtG3bjHzf7RqlNoh+wz3kU9rLHAU81Y2Yld3TkjB/Ams+Yu8MMErboYSzRoOgLYz/IUWKuXrLULa91C1gfQtJMUsqox8p+hYA4O+uH8VaVHHqmowLF+486RAmOg3HAH4V2ulaXc3Pn3NrJEhs1NwcuA3y88L1Pbtj3px8N3Oo2MmrPPGqSSOWYrIxB7k7EIA96TSHGTTuee6BqUFrbR2F3utJI8RxTAfIy9t3ofetLQUubK6vtM1O6E7XgdoJMYy6HOB/wE5/CqOuacPKYNHldvOe9YzTanp0MN3EEu7OO5iVo2BMkJGcSKfQDINYzSitTvoVef3WzsYL+eO3kijcmVxs3DovvWdBGchOGkGeeuT60+5SdZXlgjGyKQyht2AVJ6+/0qbS48yl/f8/auej71WT6LQWKfLFJdTStYvKhwRgjkn1qyuQQ5Py4wCRSFCF3EHGOhp6R4VWxwPfvXcjgbPGP2j2Bj8OAEnDXPX0/c14nXtv7SC4j8N9eftJ5/wC2VeJVL3GFfTHwiCt8OdIVuPll5H/XeSvmevpP4Rtt+H2kcjGJf/R0lEdwO2A27gwIx71LHnzF5yP1qu8gJyeg45zUkDrkg9PTOKoROygbjtI75qtKztggH0A/rVtSMccD60hOCCe/0oEVrdVjkkPt0IqfcxyB078c0jczDqOg5xT17ksMdO1MBoKhR1yo5P8AWhWzwSFH86cchTnPHToaaFOCwAbnoB0/z6UAOBA45Ppk1SuGaWVY4hlmO0AdyakmkKhh+Oe1Y2tT35tTb6Mrvqt062tuQMiJnON7em1cke4oKjG7sdFoV3brc3Otysr6ToOba0X+G4vG++49cdPoK56+u5Zy8twxe4nYySH1z2qTVFtbMaf4d09i2maPGA7f89pf4nP1NZTXAutQYMCecHByaqelkaN3ehs6ZHiLcwA46VuwRjAK/nmqVhEFjGFwCB2rWj+VTljkEHGKSMJMZg/Kw3D/AAqVAecLnPb0pWA4OCM+1G35TtPJ6CmIRUYKSTgnqAc4qMkqTkAD61KAwx0JHXHBpGOUZuSDx70AV3JDDA5NPQn+H6mk8sM6DB6jPOMVu3Ohn/hJbjStP3Ns+60h5xtBJJA/pQBBpGoW+nxXayW0kr3EZiYpMEAXjoNp5yKo7cH5OB2Ga15/DN3E7+ZLAiJD5+9t6jbnB425z7EU8+HLqKSYSzW8ccWz94SxVi33QMDP6UtBamfAhPGQAR6Vo6fNHauZWSVmBAR4ZvLZfXnB4NX49CjtbUyXNwpuEuxbsqklSMA4Hy5z79MUmt6ULV7ma2MX2ZJvK2hmLKcZ5z/iad0xWZUvbk3t1NcmFY/MbdtQ8ChBnBU8fWrttpUs1namMoGlWRyXckEKfQLx+Z/Cm3VlJbPArFJBMgdGjJIIP1waafQNRbRlWQF08xD94btv5GrV5cfao4YkG1Il2gFtx/E4H8qcmlSG4NsksRuOrICx2cck8Y/LNTSaTLCrCR4wEQSF23dDx0xn9KLoepkgEPgCmHHI6Ee9bEml/Z7W5knmUTQsAApO0gjPp1NMk0iQyuqvFEu9EG+QtlmGR0UetHMhWKV/e/aEgiSPyooF2qm7PPck+9UJAWfMjKB2HvWp/Y1w0sSoY3Z5GjwrH5WHXOR/jT49BaP7S13cCMCBpYyAwHHHIK5wO4xnmi6Q7MwZt3J/Orj668emvbCPdN5XkGSQqcJ3AwoIH1JqZ9CvRZeedmwIJeN33fXpj8M5pk/hu6F29v59m0oUuyo5YqBjqoG7nPGBSbTBJnPbuASee1I5wCH5pLuJrS9kgdgShwQFZf0YAj8RSOwIOKYGlf6jbXVjZ2yW0sYtQVDGYNuUnJ/hHfv/ADpNWv4tQW28qCSFoIVgBaYPlVzj+Ec81lADHt/KjIz9D0pWC5LIinjdyecmr1vfwRaNNp/2aRmlYSGQTADcM4wu3p7Z/EVRLjgfzHOKjVfmJ3c+lG4jUm1eL+yZ9PhtpVjk2nEk5kSMg5JQYG0kk55NYe3BwcZ7cVNzzuxz04pmMHlOfYUirmho2oQaf9r8+GWd7iBrc7JQoVGxk/dPPHX9KNI1S30qQXEFm7Xqq6JIZvkO7IG5dvOAfUVkyKEbJJBP6UFDgYxxxk0rFXMzV4S1m5UnpjHQ1kaBcrZagwePfFLGUdc9j3+v+NdHfKWtCB154J5rEtLUC68xiQAO9TJXLhLl1JNbt/sixRwTLNDw0ZQ/Mq45QjuPSrejRbYRn5i35fjSzW42Eg8jvyfpU0IHlj5ipxg1FOkoXt1Kq1XUd2XHYjIY4B6mo2kwQWyfTimCRyo5HHfPBoZxuGWJPpz/AJ/wrUyPG/2jMGPw4Rx/x88f9+q8Vr2r9oskxeHMnJzc5/8AIVeK1DKCvo74Uuw+HujhQcYl7cf66SvnGvoz4WN/xb7Rl74mx/3+koQHZFvlPBz9c1LbMQxLZAIqsjtgAjcB+dPiYBsjBFUI0EYg7uAMfXNPDhl68jnr3qrG4AxwOegJ4qaHB5HrxTETPxIP9rgcf54pQQSMAKfvfQ/40A8jd156ntS8gbzgYGPwpoQMc9FGCPWoWlGwnr7k4x9asEsfm5GeKoXTKBgM2cdjxQCK08mT90DueelVLC/NhaXmrPt+0bmtrJR/eIwz/ULx9TVe+LyeVbQcT3DhF56DNJqCQ3GqW9nE/wDo9khTaBkgDlm+pJ/U04W5rvZG8FZXKyg2mnEyNiWb52Jzn2H9ap6NAzzSOJMbuee9WtQuGuJmTse/p7VZ0iJVIIxyO/eobcncV7I6CztYHkt5wuZ4gVQ5J2561pp8pOTxWfBjgqOnQf1q4mDtOcECrMWWlb72ATzzxUhYKPlGOvJGKgVwUPJ+tKzkbgFJPYUhD4yuWOMEjsaa2PLJ/hzSLNtyM9een+fyqMvlsEk55pjsOHyjg4Yc4JzWj/b2oS3X2hpYlucg+aII1YnGOSFBPHastmz03dMHnFMXiQ4z7UhGqmq3eJQPJjEsZjcRwIgZfwA/xrSs9dljmd70vcB9i7AUUEL0yCh/MYPvXPxtycY9T3qRjh+vsKdhXZtSa1ez3M7K0axzS+cY9gYBhwCMjg47iiTUbq4SaOeTcsknmuAo5bGM9Kx4WIcc5OPSrMTdc456UWDc1rfUrqFIo0lwsSsqAKOA33u3enyXc0wj81ifKXYucDA6is2NhnDAZp4kxG24YAOKYWZuf2pclxJ5gDj+PauTxjBOOfxpsl/OqsCY1WRdjhI1XIznsKyfNwpJ6HkEd6VpiSORx60kBpTandP5u+UMJQA4ZBzgcHpxx6U1tVvGIJkJyyvkqOq/dPT2rLeUDngj1FI0nzrtHB4p2QWZoHV7wYIlIYSGUEAD5j1PT9Krf2xdJKXQxKWUowEKAOD1BAGD+NZ8kvUrg4OTVWSZwxJ3DuADzj/Giw0jVn1O4kjWKQxsgXapeJSVHoGIyPwqtLq1y17LeSmKSd8BmeBH6cDAIwOg6VlzXAY5B59KYZBtbA4Pv0paAT391Lc3kk905klcgs7DBP8AhxUTOeOcg/hVaU45wAT6d6A+On4UwZbDDbk8YqMsAMg4+tRufkye3rxUZbPI3Y9KBF0sV285pCwB4PPpUG5sryRTmkwM5yPSkOxKDnGAuDnvTd5GcYzTDIN64ZQPrUTPnJU9Dnp/KkFrCsWLAYJzwBjNKpwxP0NQMCSc7TnkDPQemaEILFQeRz0osUPlOEIxn6DmqsSKkg2gbSeOP8//AF6lIViAcjjrmiNR83zEtj04BoAc4C4bbx0PB/l6/wAqiLNtYLggHPHb/P60p+bB5zioy3XJyDwMrxSAkUjYuWJGc4A6f59Kjcnoq4Pc802Nhg5LZzjGOn+fWntt8sHed2cY64FAzxr9oI5TQBuzg3HbHaKvHa9i/aD4GgjHe4Oeuf8AVV47UMYV9FfCjH/CA6T1HEvPb/XPXzrXc+HPiJfaFottpsNlayxQFtrSF8ncxbnB9TQgPfd4UkA9O4pVdvMXPQn8q8SHxb1RQNum2GR6mT/4qlj+LurIcjTdO/8AIn/xVO4WPcQCj4BJyeMnFWIGO7qOOa8IPxf1YnJ03T8/9tP/AIqkHxe1YEEadp4wc/8ALT/4qi4WPoBSAASpJPep1IPRcnqDngV8+j4za2Bj+z9OPpnzP/i6cPjTrY4Gnab+Un/xdPmQrHv0sh2nAzzxzWZdOjhiAAqjnmvEn+M2tOm1tO03GOwkB/8AQ6gk+LOpShw+nWeG67Wcf1ockCR7PYXaWNrfa7OmREDb2inoZCOT+AqhBGLLT2cqfOnO+QsefYZ/HP415HcfFO+uIIIpdOtvLgbdFGsjhc+rDPJ/Kif4p31x/rtNtCMk4V3HX8aV0lZGratZHp0G+Sf5xgE8Hsa6Cxj2qPlJFeHx/FG9jxs02046Fnc/1q1H8YdXiBEem6cMjv5n/wAVQmkRLU9zjcgleRzxVlJm4GQTjlTXgn/C49Yyc6dpxB4IIk/T5qQfGHV1KkadpwI/66f/ABVVzIix9EQOpT5TuY84z0pDLKfmQbgB27CvnqP4y64gb/iX6Zk9PlkGB6ffqT/hdmvDO3T9LAPqsv8A8XRzIOVn0BlpIgCGUnpVd5Gjk27Txnr3rwb/AIXXr/8A0D9L65+7L/8AF04/GzXjn/iXaVzx92X/AOLo5kPU91N0clivIpyTYyzHA56dq8Fb4064wGdO0s+uVk5/8fo/4XRrmMf2dpe302yf/F0uZCse9RXiocMTg96spciTDAn8e1fPjfGjW2JJ03SuueEk/wDi6b/wuXWu2m6WP+Ayf/F01JByn0fbyZG7cD7VPC2XIGCT79PevmtfjTri/wDMN0rHfCyj/wBnpy/GzX1+7YaUB/uy5/8AQ6OZByn0w7IB82CRweaqyTFGG0A+lfOEfxs8QoTus9Mb/gEg/wDZ6ePjdr2DnT9M564WT/4unzoFFn0dBcnaQ74we55qeScFQSw/E18z/wDC69fJ5sNLP/AZf/i6WP42a6pz/Z+mbj6LJj/0OlzIOU+lDdKSd+B/s56f/XqIzI5+THpXzj/wuzXjjOn6ZjHICyf/ABdIPjZr4/5cNL/75l/+Lp86Cx9EXE21xkkAdh6etVxK8kpC7WXoCO9fP3/C6teIwdO0o/VJf/i6aPjPrg+5p2ljt92T/wCLo50Fme93G6NiR3z36VIhYoASDx0JrwA/GfXGU7tN0pj7pLj/ANDpW+NOunB/s/Sxg9lk6en36XOgabPdpnP8R4H61E067wQOgrw0/GfWznOm6Uc+qSH/ANnpP+FyazuJ/svSsZzjZJ/8XT50HKz3R7uMj06d6WKZSwUtx0rwdvjBrDddL0jj/Yk/+Lpw+MWrg/8AIM0wD2Emf/QqXOg5T6CLKQuGB+lOMg6sQSeoHSvnwfGbW1PyadpgGPSTP/odK3xl1tm/5B+nAZ54k6f990cyCx73LKu7jg/SkJJAfk49+grwBvi/rD7t+nacSfTzf/i6lX4za0o+XTtN/ESf/F0cyHY963MJHzu284yKar7MbsnI457V4QfjPrZyTp+m5IxwJP8A4ukHxm1kD/kHadn1/ef/ABVHMgse8B/m5YfjTgdoAVsE968DHxk1nJ/4l2m/lJ/8XTz8Z9azxpum4z6SdP8AvulzILHu+8dWGT2I71C3zAA4zmvCj8Y9ZPTTtNHtiXH/AKHQPjFrPJ/s/Tcn0En/AMXT5kFj3SMYTOVAJ7d6R3+VlyBjkV4X/wALg1nB/wBA0/Pb/Wf/ABdI3xe1c5zp2n5P/XTH/oVLmCxpfH1t6aCc97j/ANp15DXS+MfFt14p+x/a7eGH7Nv2+WW53bc5yT/dFc1UsYV3nhr4Zaz4h0S31SyutOjgn3bVmkcMNrFTkBCOqnvXB19PfBof8W60b5c58459P30lCBux5h/wpbxHkj7ZpOf+usn/AMRSn4K+I84F5pJPtNJ/8RX0Qg9RjsRmh1A7D6VVkTc+dW+C/iQHH2nSic4wJn/+Ipw+Cfic9J9Lx6+e3/xFfQpwsoPQdQasRSsSA4yKEkFz5zHwS8UHpNpmfTzn/wDiKX/hSPinJAm0wkf9Nn/+Ir6RZir/AC4+n9KdvQryAecEU+VC5j5q/wCFJ+KM/wCt0z/v+3/xNOHwQ8VlciTTD/23b/4mvpJX/eqyHOfep1dg5JBA/I0cqDmZ8y/8KQ8WYzu03Gf+e5/+Jpf+FH+K9uTJpg/7bt/8TX0qZcnKjkds80sQkLbgAVz69fpRyoOZnzT/AMKP8V5AD6Yf+3g//E0f8KP8W9B/ZxP/AF8H/wCJr6e5Cg8AAdxRFIjZx6d+1HKhczPmBvgh4sXOTp2P+vg//E0v/CkPFmM7tNx/18H/AOJr6eVlxhmIPfmmBiCQScjj/PvT5UPmZ8yf8KP8WltqnTifac//ABNL/wAKO8W9zpo9vPPH/jtfSslwEbjLsenJ/CljkEzFmyFxwOeKm0Q5mfNX/CjvFfGX0wf9t26f9802P4IeKnGQ+m4zj/Xt/wDE19NlQRtJ/T+tP8raSMcNxwKfKhc7PmD/AIUj4pwD5mmYP/Tdv/iaU/BDxZjIOnNzjic//E19QhBGDxwec56U5MqpAYcnof5UcqDnZ8uD4H+LCPvab/4EH/4mlX4H+K3OEk0xm9BOw/mtfUbgAryqhv7oqGIY3FNw55J/wo5UPnPmIfA3xeei6fj/AK+Ov6UN8DPGAz8mn4Hf7R/9avqZGHlg4wc9ff8Az3qVSMY7gdu9PkQudnyp/wAKM8YYyU08c4wbj/61A+BnjAkAJp//AIE9vyr6tGV3bQM9PrQrAeufTFHIhc7PlH/hSPikkqs2mFv7vnOD+qYpT8DPGAAO3Tzn/p5/+tX0zqMOyUOuOe2KnsLgsrIw57DGKORD5mfLw+BvjDH3dPx/18f/AFqd/wAKM8Y4GY7Dn/p5/wDrV9VB8BufzPFOyVKlf/rijkQc7PlIfAzxhkDbp4z63H/1qB8DfF+cEacD6faP/rV9VjPzFjyOnuKYjoy/Kcd6ORBzs+Vz8DfFwYj/AIl3188//E0o+BfjAgkDTsDv9oP/AMTX1O7hGAIVuOdtQM/zBSMBm49qXIg52fL/APwozxhjO3T8f9fH/wBam/8ACjfF/ddPGMf8vH/1q+qymYz0GOvHWgA555xz07U+RBzs+Vj8DPF46jTsYzn7Qf8ACk/4Ub4uwP8AkHYPf7Qf/ia+qCBjGcHt/wDWpoIVsNjIz24+lHIhc7Pln/hRvi7dgf2dn/r4P/xNB+Bvi8ZyNPGP+ng/4V9S55Hp6gdKXABHPPr70ciHzs+W/wDhRfi7Gc6b2/5eD/8AE00fA3xcev8AZw+twf8ACvqgKOmMcnPFMDMMgjPOaORBzs+Wv+FG+L+mNO/8CD/hSf8ACj/FuSP+JcMdT55/+Jr6ob3444ppw6cED29aORBzs+Wj8DvFwAI/s4jPac//ABNL/wAKN8Wg8tpg4zzOf/ia+oOenQd8d6bIpGD0wBxmjkQc7PmAfA/xYRndpuPX7Qf/AImg/A7xWGI36Z9ftDf/ABNfT0ZJVeRgHjjig5B4wVo5EHOz5hHwP8Vf89dM/wC/7f8AxNK3wO8VjP73TD/23b/4ivp3KrgHqTxSMRk5UHPGPajkQc7Pjnxx4H1XwZ9i/td7Vvte/wAvyHLY27c5yB/eFcrXvP7UONnhnA73X/tGvBqzejLWqCvqH4N5Hw10cjGMTfn58lfL1fUnwY/5JrovPG2fj/ttJQgZ2Yyemc9c07aMH0HJx/npSqvygHpTxgg4PGOtWQRbCRkkj0qZFKkZVtvXNIo4Ab7w544qbDEKc5zzg0AKRzuA54zg0IjM3CjvkCpFXO0YyR+lPZcAlcZwfxpiuVTGNpIOBnr1p7n5OpyO+OtOUcNnj054zSr+8CjKhgOe4pARjd5nU9ewp4k2Ap6HjnmpMKW44OKaIl25y3HT60wuBkMi54yMH8KEbEgH8RHGR0p8Uafu8gkY6k0FV+4qgc8CkBIA4GQQcdh1ojG8FCB7ZpGcJuaTAAHPHWmrcwiXa7AfLuyTtH/66mU1HcuFKdT4UJJCvmjfkHsc05YxtIXGffpxUsWydkMbh1PoP61bSzEhY2jpM6r8wIwRUqpB9S3h6q3RV+ULhTuGOO9IXIZVIOCfvAcCnbXCkFXAX+6M4NNyu5o2YqSc4IPIrS6MXFx3Q8kbeTwRnnnFNjT94gLEbT93HWmWsjTRB5IinH3G6/jVjaqsuAT2pk7C7TuPPI59fxqLaQrk/NzxirORnGCQc5INQnAiPB55wB3oBDbdskjAC/rVkAnBz24qhI+x1yME+nNWoWY9MYOT15p3Bk7MQw3MDSb8E8Zx/EKTqc4Gc4zimtggdAcY5oELNGHQZHXpVQRyNcBztYg46dP/AK9XAuQOTx6Gs+4ZgdqZZjQNF5W3LkgD296az4A3P9PQ1SUz+aQccYBAFTxwMcgkgdenQ0XAYb4ISshYe1KLgyfdAGB16UssCYzgeYchSR0xTpgEHyKPmwM4qdR6BCzNkvtxgdO3rUpUfKR0z/8AqqiZWjlBYDHVsDNXVZyrZWmncTBXJJJUYB45p7cqrbhk9P60gUkMc46HApBuAAz1/nTEKSCAR09KY2N+Q+f1p24ocE//AF6aWCt1I9aAH7gQARxTF4UFiSOe3enDH4dScc0AE+3bB9aABc5GU7/nQVUkHGCTmnMBxke3So+Cq5bnOCcUAI2CPcfrUS4DE4Pr9PanqAWOcnt0pMEMSnOe1AxAyjdyQD1JNDEFeDg9qa524JBK59O9YWueIrPTAYXl2TAZwBuIGeDjtmpnNQXNJ6F06cqklGK1NpWVANxwvUHOOKck0U2fJkjkCnDbWzz6GuAv7SfVdRsp5vtM7w5dY1fAIbgbgOPcV1ltBDptzBb2cOyNhl8jbg9/rXJDGc9RRS0OutgnRp88pa9jV7ZOOlRkk5B789elPfhRgZOaZkA8Hnpiu04Twv8AaibdH4XOMDN1j/yDXgte8ftP42eGQoxzdH/0TXg9Zy3NY7BX1J8Fxn4b6LyB8swyR/03kr5br6l+DIP/AArXQyAMHzgT/wBt5KI7jlsdysfQ56ccU7yyOhIznJP8qUDavTjuRTyN20L1znnvVGZFGp3Z/Q1ODgDbkknrTCwVyWAA6EVIFwozz7DOKYCo3AyDk98UrcDAPAzimk4xhhj0PPrSblU5Ve5yaAEZiD936DNSJGEwTgZGevrSK3yA4yAfXpVGXV4hcpaQgyTMcf7I9jUynGGrLp0p1HywVy8+xV+YqAvXcaggv7e4laG3mSWRFwNvTPYGoJnjfJkIuJUP3eqE+w7mqVhCrTu8kaQlxtAUYBOefxrGVbXQ9ClgNLzZtrNGZBFPdxRTjohP3iPSld4kjaVp1FsBlpAeh9MdzWDNaWmlyvNfGGTPABPzqPelkSJUiaVohaH51Tefl9zTlVUVbqbxwUJO9tCy+s2k1wq2iSyGSQLESCcAdWasW9u7LV2kMuoBIImbC4KliOpU96k1TxbpNupgEUd4XiJ8q3Ug8dmPYe5rk7jUdQ1a3hW3trbTY3BSBFTz+T2I449686tiY33TPTo4bkV1Fo27bVLoqzW0dxBaoSm9zuZvQ+n4U241jWbJlms79WiAyJYR8w/2WU9PxrI0Xw7fXywWuoGSGeIN55hIUSn32nt6VrWnheWFnEN1cMxAKSAjb7pyOfxrGVSLtZFOMXJ81vzNU+KPFcLxSz6fYeWy5JgYh5Bjg+mfaui0/wAY2clhG+qq8ErjLq6bzH+I5qlbJex2mZLS0WUYAVHxuA9e35Vmvpd5cM6y2cAu3yylSWQL6Enqa0nWUdU2cvsufRpfedjBqejajEv2K9t3Knkq+0/iDV6HT1eIPHvK9N0bBx9eK8uj8IRXOr+dqAWOFDt+UYDt9KXwTZrqK3k+jXF5Yz2c5hkgeUwsp6jPXtzipp42Vrr9TOrgYdV+R6TIPJyVdXQgjpg5+lNVtwG1QR0IzVX7JrF00byXZdbfh49oxKSO7d/wqwLC7tpkMNxHJCFMjxkfP+BzXZDFTavY4p4GlsnZlO5iKKW+dV3Y6YqTT5xKWIO5h+OKnW3n1WCWeO9SG23bQQgJPvz3qu9n/ZF3ARO1/lcurKBI/wBMVSxdrOa07mUsD0hK77F3hiAfY0uBuIwT9Oa0D9layM6+WsG3dg4GB6E15zqHi+4k1mew0eyN2sSZkIJ79FznCsevrxTqY2MFtcmhl9Su2ou1jt4gFwWBGabIw3jPGTxxwK5rQFENzKkqXMUsn73EztIW/wBkVuW9pqkrGUhI4znCkfMM9OlTTx6mvhZVXLZU3bmX9feXBggnGMcHdSbxgcg5B5zxWVqFhfxW0qSyDypBtPmsABnvk1FpNlMQIpSs8YXBaNlPP4GlUx/LpGI6eXXV5TRpl2DRkKGiz8zN2GOMVDK7bv8AVOoHGa149OgmhjimaRdv8KnpWXeeIdGt5prJnMjxfeUgYAHqc8Vn9el1iNYFS0i39xG3zEbUzkZ4GTUts7EN8rAqcHcuMkdx7VXj1vQtTsY0vBHDLLgRrC5UsfYjHFXbC9t7eQLJOr2aAjJIDIP9od/rV/XbPbT1E8vdnrr6f8EFI4HAB7CjcDjjnGNtXdQ1PT1jAtSkpI+8gyFHesTU7yG9eO3tkdGkcYkRvmZB14rWWMS2RnDASl1sXSxyNhBGOhNNkBIGMZ71Fp9kupXl2ttPOkEQHljlR1x1P0ptpomqWlyw1HUI5Lfl1lHybV9D2P1pxxd1flCWAcb+8tPUmMnlDPUdMgdD708EZYqc9wPWsK6WK51VJ7XVEMDJsicElS2f4h0x71fnt5LO3Mi3Pmuq4dHbblvQEUfW7PWOhTy+Vl72vzLu/eDuYg9cY/OmI6lPlbvWVJfXBtjLbRPO5GRFJwc4zzWCnjb7NdQWutaXdWRuGxDKBvic9Oo5/CqWLp3s9PkZ/wBn17Nxje3b/Lc7M5wQc5/lTXYKAAcEnvxiqNzrNpb2LXhmUQqCS2cce9ed+K/H0tncRfZjGYjHvkVhuIB6Y7E0q+Mp0bX1b7F4TLa+Lb5FZLds6zxDrrWwlhtJEXahaWZuQgHcDua840Rm1HTmv5L6Rop5gh8xcyTMDlAOOOeOOK5aW41Lxfqtz9kt55XA/fC3mEZCHgLhuCcZrofCOnvZ3AlluGgS1DG008yBinbe+Dy30rzMRWlU1n8ke7h8LDCpxjv1PYPDXk2t+kM0TrNMN7Snozen4Vc1EvLrmDtwq8D0FYWgrqOoTJ5mIyvAmUfd/wD11uS7RqrYcuNmCQc/jWuDleokeVj42je5YC43ZK4Y4601guCaNxIIC4J/L60xj84AzjNeweQeF/tPHKeGhkHBuhkf9sa8Ir3f9qDkeGecj/SgP/INeEVEtzWOwV9VfBYA/DLQhz0nz/3/AJK+Va+q/gof+LZ6HjPAmzj/AK7yUR3CWx2+3+HAHr6UZBIUjAHFIp3IxA5FNx8wJ79aoglYAMMYDZ+7jn605jwG6A84PApiAAbjgZ6cdKkLAEDdgdSaYCCTPViB3qEszZWLLOD1zgAVJt3/AHQxQnBK9hzzUFzdxpIsMEscTnjJ7/8A165quIUdFudWHwsqur2H+Vhv3jbUX73H86puQk8jWMKSvt2/J1/CobqxuGlVlv0mjdwkiDt74rznxp450TS9dvNLhvtRW1hIUfZAEaRh13E9s9q4pzkne12e5Qo04R3SX9fiem+H44Bdy/aZ2S5dd2WwoQehzUXiHxPpGlvLZpdLJdOoKiIByD68flXhmr+NrDVk+yaTazIoUDD73lkY8HLD+VUpdVbTLqE6TZX93iRXkldMFto4Qd8A5/Ss51ajXKo2Or2NKf7zmuvLX8rnq+uak9vpxvL2weRQQC8TCQ4PqOo96u6Noes6paSSwXnlwTpxJldqIV6rnn2rwn/hYHiDTdX+1W6G3+Uo0UqlgQeuc1kaj4s12/uXludSuYYyMCKBiqKvooBwKI4erNJz/P8AyOapjacPdgtvL/P+vI+gdM8J6RoeiSMdTjeW7YJcTdZYkzzlf4f1zWZo1x4b0m4uriXUUi8ssUCzjyip7gH5lPA+XmvE2XU7y28261G8kPAI3MR9M1ctfBNxfSsovIlYbdzu2Rk9BnufYVKoLm96S+7/ADNniK84OUYt380j2K3+KWkW+pR23h61+2z3AKGQgqF7/L6Hj8a6228dQyaVbRyRxb5SxDMNojAPUj+97V4L/wAID9kWKNtWhaRnGzarKVf/AAqa/jms4VD6sBLDGVMcZ3MpJ5C/41nVou9qchUWpx/exV/X/hz6XtvEujAQx3UkTIoBL7wBj396u6vrmjXQSLT5SpKj94hGAO+fevm3wLpdr4l1K5WJJB9mULHCxO5iRy5OfWu+fwlFY2R3m4iAHz4JYH0wKwrVZ026d0/kXDD0pcs9b9ju7m80uFAJA0otyT8p3GbdxjA7/wCFN0e3sm1O91Jna1mfZ9oi6GZkGFZu3TjArkLXw5qMYiNhO0alcrLtx9ODzVu28JahNBJFd3NxcTnJKpIcH8e1c6lUjpY2apWfvHodrqUCxuVu/wDWHaFJHA+nTNN1a6t7aWA6bMZNytvL9QMV5xbeG9Qs2VPKZoN2Xd3ywJ/hroLK1uriMxJEUk+6Q/U4649jXbSqznHllGx59ajShPmjO6Op0O9isvDltM6+ZHCCXAI/ya5qTW/Mup72RGNxPk4wR5SdAM/lmodP06VRLNfvvtrfd5Nrj/WEfxH1GT0q5aaalx5sUjs8JRVfnjfndwfXnFVVUpqN3aw6XJTlJ73ILa2i1fS0+3vKNOaTcqhjGZmU9NvXaCO/Wu0sbOx0/ThFb20MSPlsBccnqR6n1Y1h22makrzTLdRAJ8ifu92xQPujPf3q5KkskIwLh7hxjeVwP/1VdOnpqjKvPmfKpaDreW1sZXmeQNOflU4z8voK07W9WVS7Pg8gJggfj6Vydzo+shJZIb2OCcfKjyHKn8B3p+lWevWtop1C3uJ7hWO6RJgoYeu007OHQzlCE1fmuzdlc6lpLw3/ANnh83KzRH94NoPGKoPoWixmMW8ds4OG3Q/JIfbjpST6rPEkYfSb1xvw8hCuFXHLDHv2rMm1LS5nWPcEZcNtCtH17njisnJddfUqMJr4Xb0NC/XV9OgV/D2o+cA4LwXRDkL3CmuE1/XraS9SHV7F9LkcnfOke5Se5Hv9a6C8vrBIxHCxglU58wfOD+NctrF1OQ4Gr2cvykiJ4WG4n3rGVTW0f6/ryOuhBrWX/B/y+86LQPD/AIXFq02j3kFzPIMuzTfO3oMHp+Fa0duIzcPLGY5OgL4baPT6e9ecaL4ZtxDFezxqZnBysWflHc8VuTaBqem20V1pmqTMucSRsSUbJ469MVtFuX2SaiTl8d/U33urK9kaKeNbecAqRGcLMpHIA/I49qzY477T0WK0xNtYKjsxyqZzgHuazNQkuIHRtZhZWUjlRhX+jV0HhuWO5vVl+2eZaLtCLK4DoxHRv6Gm1Juz0D4Y33JNP1K6tobs36eTbq29ZC/AA55Pb8ab4j1mykszN58i7Y1OzdmMljwferfijw+lzY3ukJ5skd0uZZQcFc+g71xEbTaXZva6rG1/pemptj4AkOByHHt1BqmmnZsVOMJe8t+x2vh7VrGSFo5fLdhwxRQV3r2FWdWkCrDPG4uFddklsHwzZYEsPpjpXDaNLYaoTb6bKltIf35EQwHX3NbE+p2EMskSzQt9mA8xITuOT3qnJJ3vclUpc2xTOqy299LDbBpX84EhcglfTn2rC8d6sv8Awj4SVFX/AEtfKgVyGAJ+Yn39ql1aGa8u1uYpZY7hG3q2eDxwMflWPp8LTaikWo2xvruBftHn4+QZ67ux6dKr2jrq0jqp0o0pKcXsd/ZJBc6rb6UZJPIniDOzICrjHKkHpmofFXg/wqbET+YmnwrKAJAGaMPnv6fyqpoermci/vZBb6QoP77G0SsOo55FYuteK7LWbbUEjt57izZTFFHu8sAdzj+tSqPKrMHVmn7ratvYifw8v9pW91ot1Y3WmQnzCsAOQR3OOWPrXNWGmLP4lXUIpg7RyFAYcopzkjch549DXSaZ4ibSdCh+zaZLZaTEQ08hIdnj9BjkAmoE8T2OvaxDdWFhcQzRISSThsZ+U/7WPQ1lUpJRbiaQrSnpPX+uvzOw0LVdRit2uLlStmXwkkUeCy9Mn0resJoZZN8BBVs5yD1/GuFuvFml31lc2+qu9skylJnVGEb9iD3BrQ8J3NnpNra2T6ibos+YJnfO9CPlXPsK2wicKicnY8nHwbpvlXXodwpUZKAAHpntT8BjjPTrUQQs4Ccr6E9KkXAHzdT617SPBPDf2oeE8MD3uv8A2jXg1e8/tQkbPDAHb7V/7RrwaoluaR2Cvqn4KjHww0ZieMTAf9/5K+Vq+qfgqR/wrDRs9cTD/wAjyU4hLY7WBvkBUHI6H1o8vLAvgk+nQGnIGXjGTgmmSsABkgDtVEE7KBHkenI71LaW73LFthEO386zt4kuo4t+HboM9RV+51DyLaWC5XaR8kboQc+x/wAa5MRX5fdid2HwrlacloOOnQag0XmBhEvBIYru/KrF3NE8Ulla2qQ26AZkZQd34muN1rxpbaVZqbSG4uLkN5axBR973JOAK4jXNc8WeIdLjN6bCwWB/OjMG4sR2z26VyqfKvd1PSjSlJ+9ov66HV+MxpdjbtFp9zIdTkB+WCT73+96D9a4y+iaa1jN9pltKQNwfYMlscknrU2lWaMscjTRmUkZyfve5Na2rXUMVswZFKL0VeAT71DSd3ax3KU6do3uc9oM2mfZZru2Dou4DIiCBfXHfPWtK91SzhupCtrI8SJlmVgpZR6+hrM0VQ9rdoyJC0jmRwwz+XpWlNpkbxv5TN9nePLnOSPYVDilojdVm375mXB0rUNHNyFtWnnHlwwSNlo2J/iNcDe6PDaGaR7pUK5SNTH/ABdj9DzzXSWtxpc2nQW0kTG5BYSOFwYlDYDE9OmOatahNbafvi1JrI2LLtt7jILP6E98fSiKlB3Wopyp1I8r0fcyvhVq39m3giuLWMQvJuYTt8rEDkYPSuzuPEGnR6pvU/aoy+UEFuMxkclVHfPrWdpFpYXlqs0t6ZroMEdREDFsxwSO5x0q/pukaNp93NdqxhLFUhUNlgB1YntmtKs7K7+RjSpx+BXbW/8AX9ablZ7W9vja2mpztO+TIqBdjc5OTjpj0+lJBp1pJpOw6SsziY+WIjufg4AY9uOtWbedIomis3JuZpCXlDGR9p/2uwOOg9a3tJW20tbOKF/3cxCFVPEfOSzd81io87vc6rxw8Ukinb6PeaM9tqumxwxXMXHlxHG9T/Aa9B0O7j1eATQl5Um4eKTrE4+8Ke2nwPELkxErIMjP3genI7CuQvdas/BviKKVku2g1CQQztt/cggcMCazrUb69Uc3t3VZ6La2oILJL8yH5dx5A/rUFncXBu1aBGltWYhpMhNhH15NDarapHBNAU2TcgZz0q5DNDJLHKHjkjI4XPHvWas+pjK8b8y3Na0fCtGUhjzyd5GW/GqeqvhS4aH5VOCTjB+oqa/jSc7jbxSISAVU9v8AGuO8W6Wt3KptDtji+ZggK5Yfwg9PrXTeaj7pxwjTlJczsTXN2sNtGiSsZbjEfmBPuj0Uf1rQnn07SrFprpilnAMAKCQzdwPVj6Vy1qGmx9puhCx4L5yIl9fc1oadqlhcKHs5vtccJK7iMjK/7Pr70U3fWRrW91aHT2XiGyvLeFrKQhZUVjEyEOgboWXqM1Pqd3JplndXTt9q2IWECHbuxyOe1Z2mqpBnMawz3Q3SyDqMf4VYnhtnRxLI/kDnc3VhXS5M4bJy0ON8M+PNW8TXq/8AEnjs9McNvuWf54zngbT3NdzprLJI4LySt93eWzgd8e9YUbaXE9xbWFt9pGQSFJAJ9Se9Ub3V9Tt4pH8y108hvlwN+B9PWsm1vLU2dPmdoKxt3tlrECvHHqgt4S/7qRwACvcAetczqcs0KAT+InKZ4xEvNVL3+0dRQzXN5e3McSlwSuwKOvQdAa27a1tdK0JJZ4Q9/dAEJjcFU+9c8LSlZaI6Je5FNu78jipIbi/uXSyu2nDEKcIA3PfFaMvhrVdOmiKzxyzgjCPGAMe9dBp/2GzklvLg7XAKMwHDE9AB61k6tqKX5KQTzM38GDgZHUZNbKFP5jU5zdugyHxP9nF1FdaebPUdpRbm0xKhPrs9KvaT480G4jMEmqRwXIGxo7qMxNI/ptPqa5a4vjpU0Ba8jV7h9gCoHIx6/wCNXdY0+K+ZBe20b3sjAo1xCuQv4dCe1aqOjbB04N22Ni8v7jWkubKSB4hI2EyowuRjjPH4Vzup6JNo9usf2lWeMB3jY43ID1/DFdN4ZSS4vpEtjN/ZqLt3zd2HHHtWX4jN1+/mvru1ltIfMh81WG+H1555A7d6za5vM1g7StHQwIfiNdO6xB1uJIztCBhyvUYJ9qvXTWmrXr3Eeuwor4eeNzkupGNgx0+tZL+HdI1O2aWxddS2R5PlDy2B/vAjqfY0yw0dbO3spRHbrA0wV3KBWUHoCP0JpNS9TqhCm9lZ/wBdGTzaTDYC6S1tmSJ22+fZlt5Uc4bt+VM/sS61a8jggK2enMQrNGpDEDkfN3J9a7m2NzpPiF7bUIz/AGbdRrHBeLgRxZHIcDoB61dl01dFvrh7ZlfEH7yUEvlRyrKOntUqm3K6+YTxEoqzd21p1/poz5dMj0axE7Mk0sacwk7ifUk+uK4tPFVpLeXKLE8OmOo2MFJG5Ryvvya6PXPE+nx6C9ta2pS7X9yN38LkYBB/HvXnPiPL22m6bpgVIoD5txITwTnOM/XtWilFOy6GVKlJpuS+Zt6tere2ITLyrAQ6xrjEbY6EVRg+0zqyefDDKU3L5kYeNm9D6VSubm7nkMNgqRCVM3DvGd2f7o/xp+napbaVILI2t1dXSJvCNt2jPvWyVzKpJxXkSRI7adJFfXCm6mZoWe0Q+WcdgPxxXMS+F9dsNWiu7m5aGxjcF7qOXLKnQDHr/jXfXB11ZIT+5SyuCrSRxxgFRjoCe9SXcbSP5c1uFKMCvzjbj/a9+9aJLqjjc5PS5zFo6Xxm+03T+ayMptbnlXA6NnvmqGlTWlyDBbIVjjw5j/uOp6oe1aPjJ7n7VGI7YNMf3TFhz5Z6YI4Wo9A0S4hX7TKrFUJGQMELnnIrKcLbP5GkaiV7rXuereDvESaq3lPOryFfkYcbgOox611aZfnkjuK8S0rTTpniGC+ikdow6glTxhjxxXt0IZokk4O4Y/CuzDybvF9Dx8TCMGnHqeG/tO8R+Gee91x6f6mvCa95/ah/1fhj63X/ALRrwatJbmcdgr6m+DJJ+GGjAY487r/13kr5Zr6k+DTY+GOjdP8AltxnGf30lOO4S2O5D7QSCFHrVLebh2VdwA4BHrUeqT+Rbq2/DPwB9aoyS3Vsy29uwSVAGd3bAUdSc1nVny6HRhKHtZXeyN60NtaWF07SI10qjdJx857AHtXjXie81TWPEzadJcGKzQ/cU7Xkxyx9cDpmrWoeLtW8SPdpoUaWdjan95fSpnzCOMovQmo49NezAk1V7l74/vIy7Zk9mP19K4Zrmkr7HtQqct5I3rSxjaDy7a2ONuzDHd+WfX1rRn0ZorIC4dYwikeUw6e/vVTSGuYLXyJD+5bq7dZO4P8A9atO4u2uJlM0kct0VwhKkhV9qq0U9TFyl0Of8pbRmAU/Z2Q4L8BG9Qf6VQuWlmXyJHRhGAxZOC59MV2EJmWAotwHjCMcMmNrdz7/AErzzxiogeyl06B5zH88caHYVYnkH2Paplbp1Nacr6voWPtVvbzOLuQ7XwVXP3j9KuW26ZLwJK3lSR4QJwIx3cse/wDKuGTU5LK8tTeWt2pklJkd0yFXsB+NbWt6Jf6vo8NrYyLHHNcf6ouQAm3knHbJzWfs22k+pvKqknKOthdY0zTNZZfsN1uMCNvuIX4UqOFJ6HJx696p2mjwXfhyS4+zObpQsbiVQ0YYH7q49TzxV3RNOufDUUVhetFJHM28+RldnHr/ABZqJLDUdP1G5ufN+ziZW+yWwbI34zuOen/162cb3imYKTilNrfcu6fp2o6fpf27TnYkL5UvnHzAPUBcDaAeAaQ6nqRvMXekNJbheIo0+Vn/ALx9a3fD9nqNtoKDU4zJJMQGYneHz3JHp61q2tqYmjSIiRYychjyP/rVl7Lm3NlXcHeK3KcL6XLYSXIuLO0vIVwYmfymz/dwf5Uzw5azaslxLqNkls6/djUkE5Gd306c1Pd6bZXD/ar+1WO6AWPE0YIkBOA2BVa6udQ099g2XMcedyGQgkYwOnt2qFG2puq/PGz1Zr36RzQeRp9xewS22NrJMcEn+9nqtc7cR3umSTW1xb3N3aSMXmVnEqSgjnG7lfbpV1NT0DWYJo5JDDKoUPCSY2U/xH3A7Yq7aa3punXU2lX7zG6YF4XmAJdMfKVPQnHrRytPcpNRjtfy/wCCP8F3uj6jfJZbZQFX/RopHI6fwk+o/lXVS6LdtOyRRNAobJAJB69VNcNaXulX1vcPprxpNC++KbaFYN13L9Ohr0bwj4pj8Q6Sdsg/tK2/dzIi5G4dTWHsYN2luZ4ipVp+9G9vMu3Gspo80TXDzC2ACtII9/txjmuW+IPie6m059P8KzRSXSvudzx5YP8AWun1iOO7iMUkIYtwySRmuCtdBt9LupYdOeMS+aWEZbPB6pu6n8c10c1lbocMIRl7zWq+5l3SVKQW9sZPtJiABPUySHlmNXUWwsIZ00+yKXdxIZXCfKiH+8f8KryW8UDKrsU2tu/d/eLelTWcazRMykLOF+ZFG7GfUnjP16VKdtENrmfM9i1Ne3Ygij8xjcFAAqAlfcnAyap3l7IskRvfOnRT90ERID9Dkk1s63ELXS41RC0iqvzM5OwdySD15pdN0K2FtFcXSR7lHK5z/wDrrTlexl7SCV7DdOvrue3kks7Fba35xLcSgKx/Dk1NZ6Td6nvlnktYkIztiTr6cntUWp3KS2hXywgkZk2quAuB96rPhO5lkM/7uTzCmFJI27SPSqvqkZyuo80dCu+h6rBBdbVmkJJQIjYDKBkZFZ0+pNa21tFLHLG0CF23jO4DoB7V0dtr147PlPJmCbXjU7x8vcH3HWudvbwXoltVCS3V2rSFVGXCDq4/ur2FczV5Xgawu/jRl+Ib+UafBLmD7Fu3QYbBGVHLe4zjFc7arcR27SWI3TEb2kduFAPYdOauyppxS7IA8mOT/WMNwJIyQe3HOPwqDSbhebizlZ41PyLMgJc479Pl9q1iv5jpi0k1FFPT5LmTUpv7WMaSRENbsuDtJ55J6GtFm1Ow1qTV72/e7F3Eluvm48yJBz90fzqTUdHmuZIbzTltyEYPdRH5iwzzg9vaqGnzyabr90siO9kZPNR9xyoPRSOvJPatNUtOoJKbvbY6S/nza2E1k8tpYSgyOu47g/O18dx7cc1geHLJTGl1LO++6kN1fR9U88jBAXuOc/WtHUtQW+hlsJmhvL1i22WNfLMKFuFI9qqaJNeCYpvitlQhFVRuLKPvN7VUmloh04tpsfNpa2lveTWUwijlYBJRgKg6EYHWtzw3o72l9exXkr3enXaqBvIJRsdR6VVltL6SUSpK0kZxiJQAWHqo4BIpbjUI1vUMrFLrySEit2xu9WZf4sfpWcrdjqXNKNr7jtL1zTLqLU9OvLkQ6lpxkj3ykH5Mfe2ngrjGRU+gWd5p2gxeZcE6YnzySFuJFf7oz1/D3rltJt109rnU78W8mpXShZImAYHnhyeccVd17xKNUd7HLSSSH7PbyKMAkgZwvbaM8/SoU4t3fQ1lRm7xjrHq+3p95T8TQWM2sw28YNskafa5mAO1uRwD3rmbaa68uaWAW6RNKUiglQ8Engj6jk0/xvOw1q3F88i+QkdsVUfLsxyMfrmt+w00/wDCPQLZ3ctrLLEFEwiDs2TwQCeOOM0pJudkVZQo3lqQSaIuku97rF+JLi7ZUQQgqu4/yp0enzOXMqQ20zORHLKVJAB6j1rmZdbn0rV4tP1OddZWI7QVyrwjvuXv9as32pNc61FqF3JA2lxBoIoSpLtxkkKOuOOeldN3HZHkPmm3fodJ4ge8uJbTyFxboMIx/ib1z39qy4IBGb5557rcTtdnUHJ9Mjj8KhTX7vxet/b6RKLS3sIgVWaIZVz0OR9DVHwbrOqarpl9BqTbo3U+ZKw2biDgFT0pxlJq7VjNwUZct7mHNqiadqMTkm4gZhuIPzL/AJ9K7LRgXiuZftzyW8rbogD0Uj7pB75rgNViZ74qVTy4+I2VsCQ+re9dT4X8uXSZbZpPLny2JP4eD/Sh25WRVTU7G9JcLFpylF2vC2Dt6OBz07EV6zpj/adNt5QwIeNSvuD6V43bTyyRz22RJcMjIp28MTwGzXsWgWr2ei2cGFBjjCkj16VthW3Jo8/GJLlPF/2ngNnhnHrdZ+v7mvCK96/aixs8McjObrj/AL814LXRLc547BX1F8HVz8MtFOMjE3H/AG3kr5dr6d+E8uz4W6LjjiY5/wC28lCBm5rVwRDuTA6qu7+YrA1V31HRpEYSRiNgrSKcMw7/AIVa1O6j+0QQvnGGdvQAd6wPEWqyS2ckFzJGljCVA2jLF+wOK4cRPWz6ns4WnamkumpPIyWumMkMkdrHalEVHYCNmPTI7j6VKlwup6rObuZ7lVQAzR8F+P4fQcVzer6PDd6dDqKeZILILNGFIdnI7Htip5b+eM2xikSzmNuZVVgAOeenp1pX7F2u3c7KOV0vfMYLJaiPdEevzAYwf0q3oupQHfFeBIroDDRAgFCegFec6/rJ16S28O6Ezi2mKPcTxnGFXnAPbnvRdaO8NkJdKcXN3LNieZ2JKsOjN9AKI3S5rA4q9pOx0+t63a6dehNNMhYkq778gHuSP0rj/Et/58FxDbytJdyDdEinkY78dKw/7XvtQmuY45olijAW4uQoAXn+Edc10kdhpsNlbDSGcK4yzTcM7nuT6e1Z8mt2dEJxVP3V8yhHZx29oqG4kaTjYhbI3EfMc+me1dALS+t4rUXE6vZK4laSNSHjYD7o9V7Vu6ZZi5tniaC1iFqoMAdP3kpPU/nVyS9jnZoRbvEbfESK6cDtn8T3pb6sHO1oxI7O+0udElnuY5ZwpZYimGP0/wAarahHbPcB0Eht4AxcMMCQEYx9a0Bc2v2eaJreH7WpwMY3HHQZrDvL46hpGswXNyA6QFg8f31P0+taxbSuZyVjstOkttS0iGK2220tsOYSMYP+FU7FAjFSqEncZGA+7ivPdA1t4EtNQi8+KQIsV4WOc4GAxB5ArrdBaeRp5726Eayr+6C4+6ep/KlG+xTitXc19RiUJ5+SyvtAYc/j+VZuo/Z/NWRQ2x0IZGXBZjW8LQRWnk+exJG4H054zWTqUUr2+7cvLZUqM89OtOUNLsUZa6HF6hDBZ3lveeXHHAmI2GOWX/EVt3g8Oa5DaM8bXkjAIqqD8gz97cf5Vzep6bJdu4a5LMhLGMKeD/Q+9Z2sXN/Z6HCUCGS2JWaNCd5TqpLDpWcJX0Np80bSTNjXvCvh6S5c6etxbzqAvlwvtJPriqfw61G78H67dEyeZbXc0catO+G3ZwN3oDk/lVzwTokXiBY42llsbieNmjkE/mbjnPDdvpWD418GTWtqH0yadoc5nWSQfM4PLCnJNvV2RKlBQ2u+x9L3ct5doklxcI8bkAiHIAHoWoXSo0LSzW8bsRnO3GR7Vx/w41LT7/wvC0El5Lb+UsMkbSZdJVAzk/XvXRajPZxQmS8kukhT/lmjF2bP6VklfV/mck4tPlX5GNf6jp+mzubC0k3HO+5xlE/E1Z0hbeWwkuId0kkfzO5BCsM5PHU/WjwzoT69dSXjL9lsofkjYkOcD+6On1rR1a3gsdsizyKMgIxAUuegHvTUOVc3QdScU+RbmbDc/aS8KJmOVCy5OVGe1b8NvGNM8yRkWTPl89TkdRXL2rvZXzS39hcW0qxGVth3RFc8Nx3qbUJr6+mtHtt8UMEkVwQ2AHA9D68jP1pRklr1M5UW3voXJLiBmtrd3/e7zuYjqAORUFtqIsnuJoGEizQt5bk4wynjis7XJJ31BbezhEc0g3hzyRjnd9O2KhXSw19bp5j+XGu9l/HLGipVs7RNoUU43kzK0fWdX0e/uLe4QTGZPNZcZwzHlm9jxwKz7jxBqeleJL+fTdJi1BnIiuWLZZiB8uOwUDPFV/FF/qP27VZIJFVHeNcKNrQKeAPcmqtvps/lC3inljaY5eTne34+tVFOOxq4KV5SMAyajq1qV08XVpPPO7F7hQsagnJwvt0z6Cuh8KQ3mnGK11OS3kLDEF5nCu391h2+vety18PJHdQSu0jOUyqu5wo+lW9Wt0t9PlZrOEx9SWXK5HQY7VahcOdXK0OrrFc3lozDT70AYjMf+uHfbngg1fvbp7C/061nSOSe5QzIxGRtA6MPX2qGxmtp7uym8lGuUj2oZRlYznlVJ9aiv2mbX1u7qwZVt3PmeTIGSNfU9+e9U2r3QRT1TH+GPssqajLb200RLuyu6/e5OTzWsZrHSPs8UtpLdST/ACrsTeAQOpx0rDu9cgsB9lR1lurl8oqNkFWPB/8ArVNZC6V4r6z1IwLEx+0RzLu3x9Mn0I6inza6BrZs6nUrCeTS0m02TytQiAeLzT8q+oYVwl5bTPOs+oIL2+y482NSqwqf4QR1xzzXSw3UOp6skllIZ9PkR87DhQR0z79az9jyWc0/nK6+btRI+No6EH+lTONzpwsmlbqY5tbCx0/fYo804TEspYngnJJ9cUl1NJa28l0uydUKzAAgMjDn9TjNOsbhltZtJheWaG3barhM5Gf4j684pPE0cWkaJPptosT3jwl5QTjyx1yT61zci3Wh7ELr4tb/AJd/IwPGNrHdaVa3dwC2pSShpHDZJz1FbiyGKNBa33lReWNqMueg/lXO2d3JL9hXUYPtPmSDajcKFC4xxyTzV3VLZrO7GoWVgphjYLcWyscle5QHvz0p0nzS1McXDkgrnPapaPLKupThRcyvtf5Pvr02/Q1JbXcdzrD6LpsK2l0q7re5Cn5eOV9AKv26nV5FlYOjG6cLA4wYgBjafet9ooPDl/FcPEkeri2LhFHmO0Z7YHAPHf1roS5noeTUkktNGzjY2n0zxZZx3Wyz06+jWSV43JEr9ASQOoJzitk6BdW+kahqVlqcN79nmKSxytiN4mYYZOwZWyCK3r2+gupZ9QvdP+0IVjmVpF+eM4wVVRwPTj1zWBr+rNeeDrjT10y1i3XQmxExXy1HJJHc8jn2rZK78jkhZepx1+4kEx/eeUzlWJHTPQrXXeGktoYUtGw24ZMbcbSRx+JrD1LTbqbV4fs8S/YjChXDclh7etI12puVCxZFlKpG3u+fmJPepteNjGU25tnbeErZm11IjDMgj3TFZDu29hg969ZtpT5cfPykZ6fpXnvgWNp77UdRVw0MhWKLP3gRy34V3yscDKZA4Hoa3wsOWmcGNn7Sq/I8Z/afOV8M+xuv/aNeEV7p+02waPw1tGObr/2jXhdbS3MI7BX0h8MJvK+GGkMTxtmGM/8ATaSvm+vor4Zoj/DHTVZhlvNUL/22eok7J2NaUOeaRW1e8je7WSR5EeUmIBVJzH3IFU/DelW0Ev22zafzgzFhOu44Pbaf50eJGt7fUI2uZGSPJjyhxtGKdYpPa+HYLy1NxeRiUsjwKSRHnuP8a45v8D2YLXyNXT7dDC8beXbLtJeFRkZPIOK5rWtF1TV447jV4YvIwYkMTY8xuSm70Xtiqr61BHrNxKt1ciK5VUkjZgCnPTn1HpzUHim9vLhHj3z2mnbFwGbaS24bduetT1Q5Lc2tKEWniddIgzc+SvnW4HAfGCM9R9Ky9Wvbjw2XuJIZkupELLGvMfpuz3q94TuIrKaW61VS10m7bIxI3JwPm9zWNrlxc+I9UKW8fmXZ+WGEg9M8bfbvmhVGtFqNYf2t5S0F8GafptzK8VxMm+5Uyhg3BPU5Ht6V1+g2FksNzcPN50KIzwyt93I44FYHhvwWLCT7Ndqsl/NGzybQGEfoBXZaTpP2GMreSGWApiUMPlB7YHbFTJu7s9B3TjbbTZE+hXCskFxIiyyRL8olGB9f/wBdXb2d7jbeNuh88bHj24wR0rOv7dbC8jk3G4spVG0hsFfcg/zo1K8SO3jUEzW4I/jGR6daUVrdhdOKSKqxQ7g0TSQXIJBdRkuR9en9ami0ZLaCSd2nnmvVLTNIMlQPp/KsjWtUkgmhdTwwy8fUHHvXRaP4jiukY/Z0Zwnlht23aD2xWktdUZxckuV6md4akgukkglhQOw8rzsDc6dOnapdM0R7G8u4IbgPFkNHvHQdCK56bUVg8USkhktyVVnDZDN79vyrp4rqS6R4Gw64LCQKfpwe9UneOxpJcjuti42vJp8ghuj+9VQvzDCnHHX8qsSXMcPyMY3kuMOyoceWMZ615j4xgvgdQlt7nIt41MkbHcfwP4d6ueH7lH0a1u96kt8zHduYt34qFfdlJwbsjrtTa35ljdYSygF8csPUmsexuLW4a8inI8olcSZw0h6YNaNug1OB542Upsw+eox7dqqpaRbmRIwuOm7r9ayd07mi2sypDKnh62j/ALNSKGyQsVkxg5znPPft9K3fsV94k0svYJBvMYkVd4+bPUfX2rnLuZXUWUoZ4H+TjqH6hgfWuh8HzN58cl5O1q+5o1kixiXbnL7R2468c1orTTUjB+7axyPhSz1fwDq7eeXEN3LiQqrDZg/KT2wc8H2r1e3ur3U4X8+7NrHP8mx2SQt75xwPYUuom8v7JAVk1CxdgyzxAY3KejD+IdKpRS22m+O7DT7icRx3as0CGPkuB90dgKiUZ/Env8hKcfhtb8Ts7C4Gm6MlnZXECRRKT5x4RE7nFc9aTz63dRS+TNJa2soZZZV2xvzwwH8vrWfrd/c6rqV3DDElpp9kcefMd/mEdVSPp+Jq5PJqmtabZ25uBY6U2EWKD5pbg5HLOPug+1RJ307CjS5fee7NjWtVja2mhjnFzMGY3DR48tUQE7frnAwKxvB1s/8AYSNqNy5kaaR3Y/3mbO0ei9qvxadbWWqQaf5Wy0RJbdo0Pfhlx9Rmn2IE2mEg42HcYQO5PI+gxS1lLUTcYQ5Y+pcsbOCC/a6kDsiqACeeSc1UuryBdZvoo3yFjVtmOoPqfSq3ii6miWBbWbypJflAIyM1hb7KTxRcLLcSSsYUgTygHeVhywC9vcnilNpe6h04trnk+hzetwSTf2xAx+0TxXSu6IR86HoA3Yj0rYtraOKWOSd5IkRfMiy+4xYHf1HH51i+MWk0jxTO9raLDb3sW7YJSxkmXsQeAcY4qnrdyo02y1i/nezmiI8zyjucL12sPQt/OuiCHzXjY6K61+yTTjcXU5SURbkbGN6dmDdD9Kz7fU3kSSB2vJI7hgBEqgEJj5mbPTJ6GuZTxgNcHl3S2kVjEAv2ZFLNNxxhemPfPFdcJt/k+datbwuA6x8qBjjDMeWb1P5VtvoRa2pbfTWudMafzXcJ80cYOMD39aqCzukuS8cphm2YVEfJf03e1UvLS5tJhcyy4SUS2yHgq2ehPRvpW3DItpcRuIIBFLESzSSbZCR2A9vSj2SauNVZanHalZNHewz3V20BiWR4SkXHnDkAkcjI4z0rp9A1SO9Ux3SLJ5iDzOMYI9am1e2t5rSVbySLEy71dFDSp6exz0xXn95DLa6ncSR/avmULGxbarqByCy8E5z+lTy20L5lLU9R0JbDS7S5Swm8pXuGkCEAqhPf6cVHf6ha7/JtIFFxJHhzGML16/WuC026DJDdXaOkLDywqwl4lcjIwQ38+K6jTL3zo4HKB5ZR8rKBtGOgb8KmSZvScU73uT6tEmm6fDZ288cRuHysSvktgZLMfX2rOupEh0u7eZQ9xdtEiI4y+dwJ578KfyrTv7BtRiEl1GpjZ8BcfMp7sPY1zHjO2mHiLTbouUibEagHjhe3vWEu6R6cJcySbG6ONQXxJPF5hhhjG1JpU3JHzkH8efzrZOn3eranf3LXYiiVQrCLhZBj36Hp0qr4Wnn1+8lDRq1s2Dsc7jHjocetdC1iIA1vNnzmOEbbggDoWp0o2Wxji63vdmc/d6JdWySz5UzSbWMOcbiOjAf3qhXT5YtQi1OeSZp5wSBIcnB6k9vwrp7JWutQhu2lZoSjRhZVI3ODgnJ6VaubQkRiOJCsbFipJYH1rTl0OH2ivscBqOkQ3yzTeZKtzAhaIeaV+Ycis+dw94ba/dvJZFfzCuDu4yp9RXdX7WUO648o70l8sg42EEctjrnmuPvobeS/ubYBdrFUBb72T3B9QO1D9zULe0T0G30c4uIAmPICbt/TBrmtRgl1DVTaaWCb6chREvG31Yn2rqVUtpr2gk3ToSis45ODwau+BYBBdy3lxEhkA2CZhjKjqwrWG55VWfLHTc9A8LabBpVhaWMOWWFPnk7yMerVuu6eSAp4IJ3VWsok8pJUbKMuV44OauxxLGAqAbQAdoHSu6K0seY3rdnhH7QV217p/heZ7eS2Ym6/dydcfusE/UV4xXuX7TChF8OAdM3XfP8Azxrw2kykFez+GNa0/R/h5o0l1ITcBZWSNOp/fSdfr05rxivQdB01r/RdHjkUqjhtjE4Vv3j5z9MVzYmXLFep35ek6jv2L1pbXerwxTz3ZSW4uGuZEJztXsoB7V6FoV+F06BbSRDafdxGMkkdQMcVw14sllMHt3DQJJ+63LjJAxj8a1fCOrRR37xIzRJMzBIMYVD1JA9/WuSM+ayPWlTte2xel0WO7mla/slntbt2V1hTlS33Tns1P0KwvL/QbTTJkiRY5WjZyisdqnC7j3Na19fPPYmJLe4uYGDBY7XgkAcknPXrzWB4d1ZtFuGtmiurfSpWY2ss6kE45IJ7mtZPlREYOTfc29e8P3YNqgmY2cUm64JUEsFH3ifrjitxbDTbaJdaQqLhEAPmnadh7ZqhYa0t/btK8pMTNwVGQcdv0p+qLNc2Ci02s+7hX52oRnPvjripck1dEtTiuVk+jStNcPe3pjFxMAwjQcKvYD3rWtJY/s7wy7InlJ2q3P51l6XAlkYMLvUYyXGWPvV7XJUikEtqX8sD5egI+hpwWhDSbMzxTpn/ABL490ckrMB5ZDcZz9wZ9e1YVx4M1B9sNsF8vaP3MspyO5x7iuiu7lF0YzSSyv8AZ1z5f8TE9Ap9asafqEjW9s0sYEcmG3ZwFJ5APeqcVdjUpJHnOoeBdRS6VobovKSoAkHCEn1zzSR2Gs6PFqEVw1tJLbZZHjZWbHdh/hivSdXuje6l9gsjBbXVviR5yN29ecKPrzXKeMY7e0ttPvLaAT6l5u0xQjBkBHOWocZRVhKalq2cN4Sj1fWm1VzNAVUJIXmUgH0wR39RXRfbNd01dlxZSsYVJkNuuY2PYg+ldl4I02KxNzbyxskE8QkRc9X6/pXYwyQJbPbzRqwlUqy7ehNXZSWuhE7RdlqeM+HNGuLq/uNXkJX7fDsljddre/4EdPoKoT+G57S5d/DrW8Vgx2yJMxJjYDnbj16Yr0zUrBhbmG1doYY/kMZXv3APYen1rLRFs4ZY54g1sZA6AfMQw7fWlZbgm7+6U/hpPcSxTrqcKRNbMQ7E/fPbjvxV3XpFbViLbYVaPfg9DWhfSQNF9ogj8qULgkrhWHuPauW1S8VblXQxyy9wrcHPb61E9rG0G73Mu2u5XuLqTb5SoxO3bwT/AIVv+FTFa395fRW07eXHFKHXoW4Dp+WSRXItq0yzyyCF5AhJUbfv9sAd8Gus0a+votMayksCTfRkTI/PBzlxjp2ApQSS1FVu2j0XTNaju3lEGZUiQs7xjCRsf4Ae+OmfeuDkvjrPxHv9Su1UmwRLW1i279rsMlgPUDvXWeGZ4LfT1AjENuFMSwn5d/H3vfmue8MSwtNfzJDDAondprkvzIF+UBT19qmpNJGUI+/dGvZ6N/azL9ve4trNuiy/umkXPLSN1C+3U13elWtvBOkj5NtEPKh2DCgf3vxNcTBeK9oUikSK0Z2WRnOTOOwUda6HSm1K4RJYUISLG4yfKg4wBtrk9rFtRRtVhJK8nZFnxjZpY39vPHIgkk2lWLdHH3Tj8SD7Gsee/jttKu5iJIC5DSwk4ZfXB7jvV280qS8vit8xupxtJQAdD0wKbe6JFPaS2qxs25SoWWTO0+x61b5ruysc6nCyi2YWu6lZ3ljbxiY+eXHkOvUe/wBKz9MuI4rlLu1TzJtpE4Kj902e3eol0yBdN1L7ZBcTS2oXZFDJtYIox8v15P4Vd8FzaDHpVxNpt1LJqCHBjvoiGj5+6e5PpUWc3d7nXZQjZK6ubniqx07xX4Ua31Rja3ayIVnxh0Y/dIPfNeDwaG19d3OgzasWWzaRZ4tpQyOpOBvOc9K9g1e7l1iz1CVm2xLLDLBJ0VihwcDsevFeaeItEe+1LVru2nW2N0ysxZ8F8Dg57c9q2p1FF2fyMnTey07nNeHtT0vQ5xZXRDNljPJsyQRnCgnrXfx+LYNTdTKf9EZMRBiN2MckY4B+lc74hXR9b8L/ANp6w8tpOjeSz20AbZOF4LY/hbA/KuW0Fb2Lw9PfabcwzRWoxLC4ww38Ec8Ed67ILmXOupjKXLL2cuh1Wta1ay6nIdO+0rZRRiYlZOE9cDHJNWdQ1O41fTPP0lTPZKSskiphs4x8hPfn6VyPhm6QWzGSzEskR2AH5AF2nG0+vc5rrvCK6houjJYmONDNI00hLeZuB6Ef3adrEqTlZ20DwfDawq00kVxBqayGPN03mPIvIzzwB1GBWj4ksHF1NIZnnt3XZsiJIYnBztPQj+lUvD9le3GpM11PKITlolRAzgkn7xPqBnHbNdf5RtdLkuGleRo3I8rHIGKicdbo6KMraM8mjvtalvE0m1k8yPZi3AAXDj0PvjGO9dZ4Rtn0qOw1C0klvLGdWFzDONksEmeoPcVoz2F3Nbxmzljsbx1EyZVWynZsdyDmpPBeqXN3L9nFosZtQUkmbBEhH90ep6+1RJuxpHlTbRr67qUWn/v7m4+zeWpK+aPkIPsO9ch4qv08QNFHoV3DdbSJy6gqpk28xgdR1rutdsLe40q5aK2N3apGzmFuzBSefqa8n8OTw6RqyLZOiRSiOWYFeVODlR6Yz19qHors0U5O1i/4U16/06+uWntZXEgCxs3yEBepIHT6njivQNDvJNa1We6ARFVljdJCcPxkMD0GKy9O0AzXm3T7gNbSQI7u53Yz2HqTy1aun6Ld27taXV5DcmAYjKDaHjz0x6jinbsJ1FrzPUTV9NnuIJ0muDAWvFmxA38K8cH1xW9e3MaYMbs0aKfm6Z47isaWGJNQVr5bgGM+c678KMdDn+lZ9z4rjl1O8hWMy2irxIikmRiP5VaVtTJ+89Bl9B5jk+YGiIGcrkkda5mXYddZG2sVUuZV/i54PpUlzrkhkhMcWYEBEnzbX9MBf51QNzbNfJcwkpbNET5Q7sCcVnLXQqUvZxbvuOjjunlMVrEJ7ppGZC3y59cnsMV6JZ29tJZPayiLzEUYI74HasHwppkzWovrpAs04DLFj7i46E+p61sLZ7GdCzHBHzgc5rogmldnjVp88tOh0Xg2O6Ols1w7BNxWNT1Cj+lbjsyrxkZ79q43wtPJDqBh88Osmd2egx3+tdnu3KRkEA10Q+Gxyz+I8R/aW/1fhs9Mm549P9TXh1e6ftNKFj8MqMdbr/2jXhdD3Gtgr1vwHape6JpsdxcbQLacQxA8sxkf+leSV758M9MS78E6VNAES8VZQrt0b96/yn/GuTGRlKC5e56OWtKq79nYp+KYpEeNIIACqK/mY4bjGPY1y084hu7W8KlLmL5WAyAvv+Vd54x1QWlhDprK8VzI251YZBA6c/WuT1S2vLvS5JJI4QGwqEnDZ9x/WvNUnF6H0mHpXp801o9PuNzStctDbmAxSG9nYtGFYjYv8uateJEsrvTooppxdSKQE3yHKnvyOhFcLpdvqltp9xK8TPGuUMoTJTHb6e9aOgXBext1fYomch3fnIPUYrpVTp0OWVBNX2Zhxahd6QVhjuhdBnJfyN2Y8HoR7+tdtYeMrKOyzKzGYgjcPpxiuf1iCfXdUlg8PW2bWDEBmiIQ7j95mPUgdPwNQ+KdIXSLCAMzQTKp8pAQzHB5ZscHNaSpbPY5o4lyXLJN/wBdO/zOwt/GUMKSB+QsfyF26t/dx1pNI1+fXreW4n3vPaSKqwow24J+9j0rz3QoDqbR3urR3c0LExxwWCAPIQPU9BW74WstStZ2hWGSzF2xEDzR9QP4Wbsf0qXG2jZpCUZapNX6s9TebzNPcKVEqjcWK/eNYEF8948RjlMKy4GEOSQO23twKz7qK70y7is9QublHlyBFNndyMjbjqPeljspoLyHVNAnVrpyCzscK4AAwR0HU80+a+phycqOpsLFhrdxKzFEZFwrfwH1HqMGqni2O5uLVEsYiGiOVKkAZ6Bj6D1rYl1eORLX7fbrBMgPmY5OazfEuoStpkklkFd2RlQZxk+nHWtrtq5lGCfu9y34f1FbzS0F2Fa7tla3d7dsq7dytU9C8RXN1d3Vpbsh+zz7NzH5guODjvXF6tqAsoNK1PSbiT7ZMP8ATLMZbZxjeVHTFUNGkvND8SzG6RSNvly3LZCBTgrg+pzWfW5s4LV/1uekaibqRpyJZJHX720bSa5+6ur+ygjlt40khZsMx5z9fQ/zp8dymqMbKP7RHBGR5pQHnPOd3fryPpVbU1ksDMXd3sozjYiHOAO5Hf3p27EJpblEX12syraTFUY4fzlJ8sntWJrN3BY3piZhNqUzCNkQHAJ4DKemaUapEYPKWC6FzjBltySvPTkjk471Ak9tZ3EJms7qWeJgyEHduJ6qD0570cquOc7q6djtV0m6TSbMI8MFpKBGLhF3Oy/xBT79M+9dP4XttP0ZJnkvWaSY7UMp3sFx8oU9q85v7nUr2xit4L1IfsjtGsUIwyNjcABnnHQmsy0n1HXLpZtTuntLKUEExEfwjG0ejdPzpPRGf6nqWteLY/EGu22mWkG+2iXbdTQnHljoQp7sTRe2UOmWel2raVKulXN0tsbmI72jHoR2GepqLQU0nRNC8jSbdpdQjkAaJhlmLdST6e9XfD73tx51xc3EE77zvsWUlFYenoa5G/aytujeKVGN9jU03To44yzxbpopCkbjG1Ih3X1NdNBrVv5QS0MsrbgrZT73ua4GIQvdTxTWghjlUrLaF22sf7y+h+laul6xpGgpHZ5ghAPyheZCf5mslaLVtB1qftI3d2dbKbm2bzYYVW4cElvT39zXN3r39xdTN5sdnaf8tLg8sx9h60/VdcvJrd/It5UhIJM8ynYMew5PFcTc3H2qyNwjXurx55EJEMXXsOpH88VtLeyMqMNL2X9fgW7W5tYNTXTtGiuQJ2M813IdxfHVsn+VdRo0Au9Ut74QyLEzGB2lAGR18w+o9M1k6fciWG3MkM9gnl+WqTW+1segOMYPtW1Bb2EjzJci5kym0qWYL+YpRj1saVJ9Hv8Aea2r22jaPa3cty0KC5Y8F8KxPGAPWuE1qLTdQ0u8t5IoSsa43KvJ9wfWtLUtDivbK8tELR2qK0my4O6VJNp2gZ6AYBFcrpWoal9mskuYbVYbiP77MRISAAT6HBP6UVG+isOjHTV3Z5nZquo6dqkPnyiRWAUy8Iw3nG4f1qvZ3suga3avdQKlrOAzx27hldwcbsdMg44ruvGWix6HeWl/thvd5+eDODzwcY75wRTJfDvh/VdPSO3DSancMXhaSUgohA5PqRXTTq8rs+plUpqqlKD1QujT6e2pX0Ll3mSdTG5IUPvwSXHT8O1aOm2jpe6nY6dHFdJNK0gYSZWIDqCO3qK4S707V/CmoXEV+JGtpGUmZgGDlegLdq3ovElvJc/2hpdkILyaTEiqfLWUAc+xFbXvsZpvqdLbXYtYbiPCQzrn96eSzEY3AVZ0+7uL+4kt4LqErEVE8fdgRkNntXG23iaC+yThLpH8vy9u9cE4yMdKmOoR6cHN1aNlGaMvu2Fx1BHr9aTVty4tNabnU5huRd/YroM8SsZWjXmBQOgz+fFRQLa2mnabq+lxxxJcjy7xkJMcjjkHHVWPesrSJtV1OzEVlphtXjX/AI+WnXawP3QwHJzXWTaMul6BcaesyrPgXciIOsx6gDsBUykl8RSd2rEUOsz3cUqW3mRxShVNun+tbJ6f/Xrg2tk03VLiYIHuLeQK6bT5kbMTjA6MBgj8a9Ft9aMYgluNHbTWbB85sGQsBgkt/d9BWVY6hbSQ3+pMGJmlO5J0+dCOAyqe3cUrKT0ZspOKaaL2kX7aTGlreosQaJWVCf8AVE9F/PvUFxrBstbg1BCZGRDE0SPuVged3pmuZcajqX2qC+WOXC77cs2QVPY98VmtDNdQrp1x/o06HraOX2Y/iK9x6gGm9rExtu9T0PU/EUOr27iJA1vjBcEAZ9G9B715jrepyJ5v9mzSw3MBGPKOVA9Pf61jTNrek6nPp6Xlt5U6k+axxEV9eeh9qyc6paWBvWkEULsfLbYf3vY4OOn1xWqjJrVnLOtGLaSaL+pXkl3qNvJdOjXYXKsoILE9zXS+C9K/tDX7SK7ctDCCybOSzAc59OuK4rQ4ZL68Z5d08r7VVAeXJ7ew9a+gfCWljTLUbkVrmRQZCqYyaOX3uVHLVrNxcnob4gP2dhECpxgcDis+JmhgCyEAp94e/ars900aYGAMFsNxWVNdByM4+bnJHWt5WOFIj0iVLa883bht3GT0yfSu6hbenzLweB2H/wCquGa3fySWzGS3CgV2ti/k2Vt9okPmlAMdWop7hU7njH7TBBXw3jPW66n/AK5V4ZXuf7TLbl8NnB63PJGP+eVeGVT3BbBX0L8KWK+CNJYMMqJcA44PnPzXz1X0P8Kw/wDwgujkAeXibce/+uepaTVmVGTg+aO5211oGl+KYRZSR41Bj8sj5YA46/7NeX6rp11oE9xp2q73hGYlljGDuz6HpXoguJLO/S5iLbxxkelJ4mhg1Fzc3UZkV8bn/vH1NcNbDxktNz6LA5i9parqvPyPIfGXiWTSni0PStluhthFcMFO52bnlm7c9uKy7E7bCMx3Kq9uRnYMAoeuD9a9UvPDcN6XEthY3qogAlniAlUdhu74rz3xtocHhyKJkfzbWTPyjqDnkcdhWc1yqMLam9K8pzqymrav9TY8G6rFpkc4jYybo2cyOoDgk85HtxWBrLQatrUcSFH88hNxbJYjtnsPeqtrLLe2SSWtuWk6s3AUjpg/hUMFs1tr4WaIWymA+VGrhjuI4OexrRyclr0IVNQaaWjPZdD0qLS9GtIbfynmjP7xIz8wB7jt+NMkE93O8dtPNCGB3I45K9x9KZ4cP2i3083kWCsChXzgkn271oagdO094jPdOGmbyyjZyT9aucdPdOdtqbciN7DT/ENgGu4J47mEGKESSbXVR0KHqM+neuGv9P17w7aRT2tuXt7ltiKQOMnoPT3B/Cu7vbGW3jlaEutuwHmSuPu54GCPw5qDUNZsfsVvbW5uL+6jkUpBDh8MDlsjjOTgUKPNq9xOTWkXozltd1O5+wCe6ZPs0OD5ijk9se2KyI9YW60eW0068/0hDvQMAki+wGeB71V8YPaPPJJa6jd2QmYNJHPH99xwSYuec8Z9qboOiWt3qOoXes3MN2kCAQtETGHY9znB/pV2VtTGLlGS00MbxfqDW+oQXMEVxBqDLtnbzA0Uoxj5fU+tdJ4e8VjVdGisM26XNuwINy4CuB905x64BHeq0zQ6uFt7V4Ld7NSRNIxDiTOMIV5cVjSeG7vTIvt8USOTH+8NxuKBs8kY6/Q0vdtZhJTjNtK6/rY7jVPEKLZ5kwtwkm1oYztRT/E3GOO/NVvCt1ZanfMLqV7qdN0q723BlPRSuSMjrmuQl0u8tNMiv7i6T7PMoQ7G3KjZ+6yg9+OTU/hnQrGxnkk13zhA8X7m6t5wFjY85JB6gcYqlFJXRnzy5rNWPUbm9tI5UW4KqsIH7zgEfWo9VuNPudMntwJEVhjzApwSeeD61xehLoK3VzcSzyXU5jykcs5ZUU8cgdSevNauua9Z2OntAiKGlG2Py+cHsMdhUtXVjVPqcZpMXiCDULuazh+3G0RhtVhu284I9QD1A5PNa1olrfR6FPfBZYLhmZ2ibYwkzhVZR1wRjPpjNbfha5TQ9Ovbia1hmtjAZftE0mzDf3eOeteaQax5H2q4sLUJKwAYlyypk8kepb+lKzmrWMvaKnK99D2jT9ETU0u9SuZ2eyunkgFvECASvG/I6Lwao6H4evYLq7uo4Z9L025I221uxDuwGN5J4Vfej4fXWq6pqMWnW9u2nR4Lzxy5KgKB90Hoc8/jXTXFzaPrtzpcl7c3N2EJk3ttZl7D0C471xTTirJHZCSk+Z6nF+I9jx/ZILi8vLp3WNIQ0jZY9AZOBt7k5rV0/RdY0TV4rG+0CxlVEUibBJGe+7r+dWhek5s7CciK3lEu6GEyBD6bq7WPxF5mnTt9ke/ng+RJ1bDO2M7T/KiEk0TVjOL0RljxXb2kaJLYPPJIxhe3Y4dMDkK3QZ9DnNcvceIbCTUjon2m70lJHDJIwALHOQvTp2NQt4luNburzTp7SPTtQaSJ4o5CQWDYAHPUjnOPQ1Y1ezgh1K3nulkuBaw7XKchmwcHHp1/Srs47kxUZK6Rs2+qa7p0E1nft9u0mWU/ZY4f3jp7ZPQemK3tIjmEHmX1oI42wRufcw/Liuf0bUI/EUKnSryFhEAPLDcqf9odvpXWJdXiwos6qGjxvHYj1FUld6ilpsc34xkneJLqSSGNWZYpEhYl1QkDJPfineNYYV0W2i08KjWqsYW2/MjEcYrU1G3sroyRuh3pbi4RXHDruzkfSquuIlxstFVZPkNwZM8hQOn9acYK7Ypt+6jB0rR7FtJSa5jRr1Th57li+Wxkbc9vYfSsHVNMFpqFlcTEpuZgwI2MrdmA9Pauy8O6fKtsZ5bJrh2y4ml6AjkBc9Kg1SaS+tnN8gW683IWaQAK3YHHJHv3rBp2NI6zunoYmn6rpGvImnXs32bVIjiNymYbnB+6QflJ9q53xz8PrmRmbTJrABG80WqZjZs9cZ6AfWuh1Dwxdawsb7p5pmGFNtGCiN/sr1H1pk+j67HDDCBO3krtBuo2ZvrnrWsZSpq8QnGE/dbOR8N+ENU0+6P9oLb2ttdN5cEZn3LI45C7u2R0z1rpk0RWjaHVbOOZJP8AU7hlY/YE+prI1aW9ljaz1OJUlj2ujrkMMH7xIxj610vhj4j23mx2FxPHb3KDb5cmHikP1PrWkajm7szcVSjYl05o9LWGxFhK9wG3OFUFZF7bj/CBVzVbK6m0kLp1xNeM8oWacsFZc9xgdF6Vf+z5nmv7HVYothDNaiMZY+gPce1TJpd9e6ubiKd4YzHkwggKSfU98elTOnz6dy41FC0l0/MytXiivLaZPtt1HFMEilPyl1YAAFDjg5GTXL6xqP8AZHlf2teG8YMqSSCMAn/ayPoMiuibSLvSX1BrYSStKQVQtlCe5HpWJJHPdFob2N7eQMGglCg7COufbpVwXLsHNzIzL66i0vXJbm3vYJre9RCtvuDFdzfeTHathnjVt0y7inUj5cfX1riNa05fDl+rXdmbVg3mx3G3fHKeu0YHHt9a05tcudVijFq8NpLLgNLM33PfFU03qKMknZl/W7jSNRtf7O1HdbJMN0ckS/Lntmsi9/0Lwy1jbzQzwvMGd1GDwP5+tZmo299dXMiS3MWpSx/KjRfKuPWtPT9M0+xtjLqd0TMDv8i3G9ifftjtSs4lOdOa0WpreBrCRIbWcIQ9ySqKwAxHnkj0zXrsCJbQLwdpG0EdvX/PeuAsvlggu5kVLn76wpwIo8YA/Kuk1XUVOnRtHIqucFk29Rjp9K6aK5Vd7nj15c87LYszwS3OpRJtZUdflJHAz6mrX/CNy+YC0u9vQnt/ntT4M3tnFdg4/dhgV4IOK17OVJrBZd2MoWJYdvatlFS3ObmZnWukiXVnVbmKCG3h827mblYI/XHdj2FEmqanqB26Dapp2ng4jnn+aeX/AGj9fSq1oguvCWlSNMGGrXst1cMf+WgjO2NPoK3wSAI2Yqo449KOU0cuSyW54P8AtD2l1bDQGu7x7ppDcHLY+X/VZxjtz+leM17r+03nyvDJPUm6/wDaNeFUmraIV29WFfSXwmjDfDvRycdJev8A12fivm2vpr4Orn4daRwOkx56f66SmhM3ruOMhjznHUdqrIX+yyJlnT7wFaVym4lVxkjj0rM2GFwqjpn8aiauaUJ8k02Vbe9jS7hNxk5PyEHg+1ct8UdMudQs2u7eZVjscuUAzujLAMP61u6rE8M8O0AEMG554pdbska3bM7+XMhBC9Dkcg1z4iF4qS3R7+HnZ2ezPOhaSfYYfKYQWTuvyhhkH2/nVe70+aKBrlUOI8sjrjnnqT6+1a+oNHLpSWqjZJBJiWJuGAz95fUHip42jeGKy1QuqRNtLRkAgdjjsRXnxetj3K6926Wh1ng/Y2kWrFnmuFAPzdRntn0qbXrYXMhuYoTI65VB5h/kPSuLtdRi8M39zALqa7RhvUr29d3vW1FrtndWUd9cTyWzclS0bYb3Brug1bU8GvSk5XjsPk02/v42thqt3axlAzKHBXjk9a5KWyn1S8ubuC9E22MRxzmPbsKnsB7frVy/8RzX0V0uiLPtjOxnZflf1xmq+ifa/ssyWsLW7WoYmJ2CiXPXB6/j70pys7Izhe12zO1ZdaMKanLax3KKg8yUMCzjPbuOPyqPw9cXWr62Ilt4orXBlghcmSMnHT1YmqN/PdyvqEs90oYR+W0MZOUBwPwParun3+o+ClT7ZZYM6lLa5zkxoeoUevPWmlpYXO7pyenQ9B0nRJDpX2kwK7wjy1ggUB3PViQOn/1q03isrjRcSGS3ihXeBIuCpx824d6oJ4ovZrJZdJntrXVbaPMkcoHkXELdGU9d/wBe9c94qvjKPtTXw8uWNoBGn3i4GWIH1IAquWy0CU3fXQ5vx/BZr4naHR5Huo7qJZPJjbIc8EbiOo4NcZKoWAOpjRVwTCWJ3ZJ5Pv7elXdLEtt52qRfuZ4pPKiTGQzkEce4yDXb+FdAmm0B7u5tVN1M7M6zLzJg569s5/Sq5uRaHJyOs77f1oc3catJDp6nT9IW2tZIx5rqDhz6g9cUzTJ7hNWS0jso3mukCB2bO4dRtJ4X616CloPsbPel5Y2GzYxHGegC+lcNqVuE1WLSHkCpI6KJA2dhJwNp/nURk5dDepS5FdSPQtG0ezfQ8+NFi8m3cGC2D7VRBwzEj73J6+1ed6loNvJ4okWxins9MbBtGkGTLgDB/HOfpXtPhz4Xx6fNb/2kV1WBoPLM95c4jjbsFj7j61W8e2Og+CNRtVvtXjl1C5bbEYYiFtxtxvI6Y6L64NNcyvymbjCTTmyr4TgbS57JvtX2loYQt1cycsTnIjH0GPzq74t1zS/EfiKLS7dSEZh5skUeXZwOFyOg9e1ZulamjeKDbX9om2KzEasvAZzyx98/4Uuo38GgaVJZ6bpcVq0uXSdZcyPjkmuKzqPlR2JKm0xmqa3pOn3YsjPd2ptMb0hcTF/bGOK2LbxWoCyRrslnUhVuo9m4e2P5V5T4W8Rpa6zO1/GjwXB5ndMvH7+9dZYJfS3Cw/2rbX+kyFtqMNssB6hgOuPXHSuyNGMdDFT9orl3a7SS3Vugm1qIBYZZYSEjTuik8gY6GruvWt5Jo0Ym1FY2Z9sv2MB2Ydwx6iuh077XfaOI7xUMsa7UdPmFwo77ux9jXLrFbWk9w6Qkv0WIn5mbqc1Lik9EaxhCcdXqij4LhtrXxJHHLZy6ZYsyhHf78xAI+dhxyTXqUpjVFiuAxVMrvQZZAfWuTewXUtIhhkWeC6lDM0E4wQoOQfpU1jdTPGICskbyqV4O5lHcc9QetEtCfZrl3OgltxHphkZxPJFE6I6HIcMMdO30rlrVLmSyu5okdSieWZGOMr049ea2VvG0nT444FEkUYLfLySAM9P6Vnw3FgvhYXS3LZv3UruBc9c7FUdyc8dqh6JoT1kanhe/e50uO2klCqqMUI64z2/nUd9CumpH9ivLONjmVfNbLyN65PSsu4u7zTbi0stNSC3nnB4IzIigfeYdh2xWV/Yv2fUobi6MVyxX7TctMciMMwUNjuMdqi/3jgrGq2qRrPPv1PU4lxvMqKQrN6fSnQ+ItPubgx3PiC9kXZnbgjB+o61DrVtbWt48t9bL9iDBYlVnXOemAOefQ1aj02KWxmgt7aysJJwULMpd0XHVT60+eT924JQ+IsX15p93JHdWepTl1hMUsMkWd/oygj1zkd6o614V8P6zYT3cZtWk4aMqgC7s/Nu/lW/LqsVhpy2Wk3dtK6xqnmSW+SzYHUjoa43VZGt7q0huPsAmvboefD8yl48ZdlToCBVOnPexkppvfYSPQdOvrDfp+qDSboDCs0uYZfpmoLWbXI5ZraLWNPuJbYAFDIDkeuc1Z1LX/C1tLcW0gS7MSBoY/wCBBnkFf6VSsLDT9QuRqljodrZWQ+UyXKkeZ/sxjqf96n9Wkutn5Fe2XbTzLUPjOaBSssEVy6t8/wBll38d+O1LceNdHgugl3HNbIU3JJMnPuMCmXr6C0Sr9jgGoIDlYm2rMO24jo3uaprdQTyW5/s2xKlMx3FxKDlh/Dj+8KmPMtJMu3Mrxi2X9V8T+HdW0zErRywRsCymM43DGO1cCYLPWL+5s4JVaMP5scUCZCY7kn7v0r0S90SK/tkl1Bi0MnzCJFESN7k9cVA2nrBGLbT4YUifpb267R/vMep/GqUZy2RHMoL3rWOY0jS7Sw8+4Ub/ADRtYyjaAP8AZHaum8O6DHcr9otUKW6kM0h/5aewz2rc0zwXDNKLrVJpJnYAeWG+UAdBXWrZxw2SxIAqdEA/hFdMKF/j1POq4lbU9DhVtBbXb3eCY13Aknj3/XtVSTy9Qt0uLPe6OCVYnhf84rqLqNbb7RCUWSGRSdx5HzVLpNvZy2y2bL+9Vcjt8vbH6A1fL0Mee2pa0CGVtNhinJUPH0HH4fl2pviG+/svSY7aCRGYgxrlugPY1YmikjsXSBmWXHOOoPtWH4gjkmuVVkQx7QWbHJNaX5VoRFXepneFLm51X4UBLYbtQ8P3cokjX7xhZs7se1bPhC+kmnnW5bcWRSDycfWuZ8EajN4Y+KVmqxltP1ceRKg5APTJ9e1d3qehW+l65fSWMvkhJCJrU8L1yCp9Kz5tn2NnFzTS3PJv2mW3J4awTtBugP8AyDXhle0/tF3iXa+HlRdpjNyCM5x/qq8WrRu5lZx0YV9OfB0f8W40jpjE3/o96+Y6+mvhA234baQd2CBLjP8A13fihCZ10tuWYPHjcOMHsKp3NkA4KcEeh61q5PRsgf1qJxv4744OMUNEo5jUoPNWPIJ2scfSqUly0VqxbO9G4jbvXST22R7nsVrCuCPOKTxjYpIyV6j/ABrnqxstD08JXT9yRwvi22WK/gkkbBmUjCnlABxUenyrMFguWWQAb0Eg2lm6YJ9OOtdP4lihGnbhDAY2Yht52kA9DntzivPb0zKE2KzKuVweABn5hmvMnC0rH1eCqqpR5ZPYdqUt8PFUEUTE+YNilVAGwDJX3rW8RjVbfRIp5ItltNvjWGRcCE9jgdSewrH1OaJ73S2gYABGy4BYgAdPcirN0dQuokybuTUYh5kaSkLEIyMbxk471002rpHnYqnLllZ6J29NBLGG9n0G2sLdo7YFN9zNL8zEk9u+azdVtJ9MvJFuJ7ggjl42AY/4fSnTeJdR0cLoiR2yxxsR5kZ8zg88NWnZ6SJYd9xIpYN5oeRefXOT15re1tX1PKvz6LoQ2t7YwWVzbPol0J7zgln+UjHDE4zU1rfW2oyyWmEM8eEjjuCZHOB96M9MV2+i6HbfZZpZmMdwV82WVmyPUjHQDtXG3JF34kUWipaWtwXxdqMyNGB1A6hf50O1rdzSmpc1zMj0q3njEE0dxcPM+IYkGJWx6jsB3NNTSDYtcT6lqUNnDEWVLfd9pkQkZ7cD613/AIf02G0e4vI7cmAqscUj58x1PX6D2rjdZ027j1m5NvpLSxTEpKFOFPfI44qbqLsOadTU5eDzrhUt7MOIYJzcedKh+9jpiu7Xx1Nc6Z9pJhge0jVJoivzOemcdfSue8O2CXcllZW9xbWk0koTzLqXEbHacc8gHt70eIdJJlnhkuY0tbK48mSXaHaL3yPvd/zFVo7MmzhF2s2Yep6zO1/e3AR4ZZ3V1TO7Zx/hVGK6nupo5Z8O8bDkttOexJqrduwlePeHwSN3dxngmun+G9jYXOrt/aQDSgAwROOHOeT+FbciscDrSbt0NXw/Z+IrvUzbXGr3ih0VhiQsrgdOvFdhd6AjhX1W4lvp3UfNcfNtwMYH510ll4eZdXinUbcIQqr0xjsB/KptespbSwjnJDYyoTvj6/1pOOhHtG9LnAppUy3Ba1vZFEZO1S2VI/H8qU6TqN5G0UrL5atndjLD2Fdn4f0sX7GZjhWwSpXOOOmR/LvWrDpRildVOxBnp/Kko9Re1cdEzzy18HwGAiZRL2+Y1Z/sZbWSPyw8ciAhZY2w2CMHNehNYpCnX3NUtStUfKE5G3qPT1qnEmNSSd0zM8C6lZaJYrB9oK3BckiZsK49u1XPEukzKpvvDKpLG8nmTxAb2YY42+4NYl5olu88UhifdACFP1FR6Ut3p9zmzlkhYk5AOVPpmlpszojXadzf0LxK7X1zY+JG2XUg43jaYxj7o9K6EmybWI3tyXkW3LJIfuMAOBnpurlJoJ9fuN1rdxWWpr2uEDRyn/e6iqmjX+sWGrXNjfQfZNQRgHQj9zKPUdh+FHJfVbnVCqpGdf6xqMRW8kmhnjy8jwsPKbrjp3I9K3fBcEOlabLq97bt9vuv+PWFukW7oyjsx/QVyvjTU/OuFiURq8jfvgp5fHQZ9D/Sux0O5iumgN5J/oVjDvlJb70jcKoPqB/OuCcuX3TplHm1M2K5+wbpVsnYyzFJLncWeZgfmwT0A4GK37pbOOOOSa0Mt9clUaFQWKKDlU9PerWy1FzGsVqHtYsAxHnc5OQuPTPJrcnuhaI7SbobwhmVtobaT1qKVNy0FWrJWsjLfXby4a6E9lFASdsQzubAGMbjwKzLe0uprOfUBLA7RH7ksm1MehJ5qIaxcWNtKtzF56SEzJBn7xH8Z7/lVa003xLrGnf2rq0QsNKlbIe6Hlu49I4R0B/vPyfQV3RjFaLVo5N32XYx5tK1jxOkMMU8dnZ7z8tmD+9Gc7i/YV1PiXSbfR9NsIk2n7GAxlYB25GBh+oPqO4qe2klNrHaaWklna7SCduSR9e1Vrx1kWGz052muYXV5ZJc+TGM4LHP3m9BVWurs3j7jMq08PWt1DJLHYpbwSvuE0cRSRz3OTyc0axp1zd2z2clqptbbmNt53A/72evqBXReIZIGs0LyXMFyig8naSfxOBmuWt9VmDyRNIhkPJAJKqPQdcn1NVGhFqzbQOrZ3STZU1LRXuvDyvqUjWkqnC21sp2zHsC3eptKsLKOFXhsvs6xtmMuoYqx6kE9PwrXXz2uE+2SpcDb/o8LIV8tu5wev1rd0u0ihh8+5Jk8oZwAOPw9aapRVlDp1MKuKcFZ9ehSTTvtkivaRSQZA3SSsWJOOQo7Ct+x0iC1iPloob+Jyclvxq/bvHLHG8OQpXIJxz+NTksOPmAyQRjA59q3jBLU8ypVlPcqquC20IpGASDVXUr82kAL4WMMFYAdV7mpp3yyRgld4PI9qZfRRXFpNb3CnZIvJz3+tN9iFbqIlvC7NgF0Y5U4qtE9n/aEtmoInjTezBcH5qInmTAiHCkIVbsB6Vnaskza+k0RKBNgJjXJc+/+zgdKlvS40jf2h4mUjg9cHmq08VmLdWuxkDkZIyPYepPpV7TNMvtTgaaBkgtVGXu5vliX1wf4vw/OoTrenafJ5XhmJtY1JOG1GdP3aH/AGPT8OfejcqMG9XojM07wXLdeIdP1fWF/s7TbKfz4IjzcTnsCv8ACvuaseMtUlv9W+UgqzN+7jH+tzxtY+g71m65a+Jr6Q6gdcl+2D5kiRAsYPoQOfbrSDUBqNhYarFHHGybvtCgEbWBw6n6HmolC6OinNK/LueTftAWclpB4eMsilnNx8qLhVAEXA/OvHa9v/aUkEqeG3HQ/af/AGlXiFOyWiMOZy1YV9NfCD/km+jggYxLz/23kr5lr6a+D6j/AIVxo7EZ4m/9HvTQmdmw2xjr0FOUjO0c/iKYxAOD978/rTjxxyD3NMgjlxxnp06isXVbRSXZOCOd3HbvW+4P8LLx0qreRlg2Wzkc8UmrlJ2OOuJQ6vb3IQh1+7gHPpXG+LYNUk0+e5niDFCPMMShSYx3x3OO/pXoOrWabJCEAzjkDDZ9qwrhmMxikTzNoxIpPLx+lcNak17yPbwGKT92W/f9Tz2XXdPnsbWKzikQwtkgNjBPfPvV7QLnTINQluNR1KSOaCzeWzEKl8TdlA6A1i+KvDkOia5GLObNtdL5tuz8fKeqt7g1lpdy6aJllhDOylYpugU/3ge9KMVzXjqd31l+xcKml+q1E05fteoyz3tyY7hsuZJDyW9K6bT7/wAydY/tkTGM7drN1PUEZ6f41yZvrQpYoiM8saFJWl+6TnggDtg023s0neVY/s20tkM0u1lHGQM1vbXU8m6S5ofM9F8Sa2bTwpLE8iNO/DBHwWJ6ZxVfw40mn6bFqV69sk0iL98YZgfu89lHtjNec6hDwW82AmNQGVHzkn69T64q3p17JJDM91MZfLg8tFkOQB2AocNLhTr+80z1m88VWh1GWKK4isxKqqku5iZOPmKjoM9iTUeu+IpL2zjt7G8mRQpTKxAyzEjAx2x/OvIYWW7vbVXgYxg7cb/ve2TVtLy7lvHSFHDKNsaxAkL6fT60nG2hXt01/XYcwlmglDKBDauBPg7dpycbSehzmtCzt52lthPJNIk4GxlQtHGSeCwHLfzqk2k6pMWsrrEJjLSgN/Gx7kjrwOtbPhSTVw4h0++PzOIZHC8IG7K3vRNqMdBUlKrOz6mZqHh7UrS4v0nitR9ldVmRRwV6hwcZwfzrT8NanDqvjvSNtpDp0KYhSOInBPuT611OuTW9hpSaWJ5GJDSeUgBJPcyt1IyMgdap+DvB9zBc296YZZrmP5k4+7nnIHr6U6c+bVonFUY0LKMr3PclIik+Tbuzxh+1Z+twreQRxyMseDuJPUjP86w9NkuIroRSrIXb72f4c9//AK1TOVXzFd5GdNyZYdc8dfWtG7o4FGzNvQ4UtLNYw6bw2RtOAe1WLi5jbeqZZlyP/rVzGmuTcCKTJAwE+X0/zzW6kJnO5Vxzjp+Zpp6aEyWpOUDFWVgwwOp6cVBNAu3jkjpUd0DAQoWQu65wBwx/z+dXoopBDumK+Z2VR0HpQheZkSW/AGAuazpbQxMrLwPQn+VbskY5KhqintAbXKgk44IGM8dzRYq9jGurd4V+0x43jqD39jU1pfx63YtBe7sQnYZMYeH8Rzj3rVhgEtoARkY6HtXHoZtK8fafOp2W9wpimXPDjtketJqxrSqNMXxD4TnnsJ9Pd4dlwgNrdKOcqcjOPSsLTf7Ts3s9C1CynWS1b7VK6IX+0Y5UA453H9K9ovfCt5LFI+jSJNHJ86JKeY2/2T2rCvR4v0X/AEfUJ8xyAhGYfLz2D9iK5KqUlqerRmr6bmXol1rEnnC+sJbLLBv38gTIzw6g1Z8SXWiXs8MmreKhEYxgw2qb2yPXHWsTxZp19dxW95a5uLiWQRytvLMseOWwerdsCnaXbaPoSw+cDDeuflhkiJkduwJ9KqlB7L8SZu0rtfcaA8U2ek2pk8JaT9ovZEK/2hqjbQvpgHn8AK5K3v8AxFO0eoazeG81W6m/cMzboIogedqHgfiK32ltpyyWuiPc3JbmaQHEZ7gdqx9RtZpbhm1KaNY0IMVsjY2+xx1rq5OR2b08jHmW6NW41GQyFILl2IYPJIjcStjG0AdB+lW7K51S1ilEQSOWX5jIy7jGD3UHv2yag8OG2gvRKNLmu5zkBz8iR/QV0UWlSXV9Pc6i5w+GEMZ+QDp+NXz3furQxnWjDTc42DRRqdwC0FzelDuLSuTl/wC8SeK2RoU0ZjN5IEOQI1iXO0V2iW4CBY1CKOBjtinxQx+Zl1Un1FSqavcwniqkttDz/wATWN7b3lmdNYSEYSRpPvYzzt/wrotMtJ59OEN2WlUk5BPqeldKYIjhmVC2ck4z06E02TYEBXjPp1q+TW5jKo5EdlF9js4bcKwVBggnoanVsrlACoPAJPSqcAme5laY7F3bEVTu3qB94+hJJGPpU7ukKjkxjgiqXYzG4/eAkjpxntTL+dEiAYxgFgccfjitG20LU9aRks7Zoon6zyDYB7jufwqTUrbwv4QETa9dNquqIMx2cYzz/uD+bVLfY0jByKmn6fe6pKP7OtjJGBtM7Haij3J/lTNS1TQtCnZCH8Q6yp/494OII2/2m7/j+VZmseItc8SL5c7f2TpCji1tjh2H+0w/kKLO2t7W0jW2iCoVzgDBoH7sdtWVrm51PxK/m+JLnEC8x2UPyQxgdBt/i+pq/CUtvlhVRCoxtUYx70wlSyqu1gTtJPr606OIRyYVssOxGRihEyblqyyHG8hT8v8AWsc2T6bd3kkDW62d0wkkSbhQ2MFhz3HrWlGiqNkY4XJ4/nmq+oxrcXFv59mb9BDMxtdwUSkBcDP0zTauOnfmSR45+0M8RtPDSwOkkaG5AKYx0hrxevXPjuVMOgMunxaapNxi1jbcEGIu9eR1C1KlHldgr6Y+ELY+HOj4znE3/o6SvmevpT4RN/xb3RwTxib/ANHPTRLO13AOvXkc5708MpYZ2/Sow3qw3H0qQkMFOSD/AJ60yRJNu4Y2hu+KRlZsjjH86RuZl3ZwTTmYcEYAI/KgDO1CGSQABVxnjPSue1OELKJEAEq+o6jvXVSKWJwWLNwQfWsjULQ8nkxhTnPXms59yoys9DktS0+31iwMN1AsyoS6bm2SRH1U9/pVUeELbUrdLYjy9PX7/dlbHYdq3p7WGdowzHaBuBHDZFZGjT3miXMttcySXELMzRzH5ioP8LeorB0lLZ2PSp4u65Zo8i1zQJNOvpY08yaGMkFgvzLg9xWc9myjcpEnGSK9gvNLludXsL+yZil0WFyyDjZnk89xWL430zTNFt7hmKC4ChYmic7nY99p9upqY1ZX5Xuayw0FHn6PU89iSWzRPtEC+VcDIcqGIGeo960TFpl9d7YoJ4oUXAlUAbiO7Dt9akis72WxguriT7Pbtkw4AO7H3j7VqWmgTnSbSeZneOeU5VR1HYmtk7nLUgoW00e1zjZXbzWjSQsgOBg8YzW9Yaze6XZeTHaoofiKVk4H95v9o9PpXY+HfBifbbieWPbG2QoPHHqK07jw9eTN9nPlLaRnCHb8xBHT8OlNvTYxhKz3PMZdXuVWCeBnDxSAmU/xt1rooNY0pkikitpIJZU2lYn6v2OPrU9r8OtRjun88oIDkphtwPsRXZeEfhjp8N2s91LJM0RVlViNoPXmpdNT0No4qVN81zG8D6HqsrTi6tUEIfzEL4VpW9CfQfzr2fQoZDY2t1se2nw26IgDnp83tTU0qFX2xqFYfwZ/X8K0I3bCrI2Dg/nWsIcpyVKjm7shlihlmV3YRsG3kgfw9/xrKvreOUbonkIkyTgYwPatMoGB3AKRxj1qS3UkBiE3enUd8fSqsmZp22MyythboXdgWJBAJ5x2q3bSzqF+Tkk4Gev1/wA81bNvFk4VTu9V7+1PiMYbYWA28/d4JoS6Cv1KsJld/wB4FVgwbk8Ae1WpBuL7iGJPUilYBmAJbJyBn0p3IVj/ABA4600gMqdGBwvyjvzxU3luLTZu42cjd1/+vTpVMkmecL146VMq7bZlwMqMdP8AP/1qSQ2ylYbUQFuR0IxXL+PrFiljcxjdJFOGUgdR711FuPK+8cKDnqOfp703UYluYEXacl/X9c0mrjTs7nS+BNQfV9EF5bEw3CHa8e7PzL2rq7m6g13w3OkkSTK6sjDrhhx+YNeQ+CtVXw34tkgumK2V44jJJ4Vv4W/pXplrcQaNf3ETti2uH8xMdAxPIrllHldl1OuMubU4yHw9pWgaZM39prGS3mOrv8wPcgVzia9p6XEn2KKTVJ25MxX5n/4Ea634keGoL97TUIY4CkLeY6txvBrK020tVSN0RUGOPlwQf8aulBfZHVryW+phxy6vfxPFH5enWrOSY4R8wz1y3+FaWkeG7O2jC+SrSZyWbls++a3YokWRtoUHr061LIfKQt8u0jjJxjHWuiMLHJOpKW5DBaxR8kKrj06Ef4Vb85SNwMeD0OOev+earQ5uABbpLMPSNdx/PpVv+y5ly1ybazj24LXM4Uj6KOatLsTytjXfdhC+xO5A5NKrIqud2CeAoFQTXeg2zZvtdedlxlLOAtn23Gsm68XaDbNiz8OalqGD8xubnYCO/AptMfIzdadVxGc7gccHn8fep4LG+uGK29jcOCcDKY/yKfpvxD0C+uI9C8NaBqEl7PsSUxWwMduG6mR88ADNesZS3gAXG1RipbZSprqzhbHwPcTMHv7kRDusYyfzrUvrHw/4O0i61e9hLRWymR5XUyv+A/wqa88baJal1fUbMzJ95BMvH1NcfrnxP0yFx8x1JOv2SxiMhI9WZsDHtTVOX2ti1FLoYerfEHV/EO6LTZV0ixbgEAmZl+uPl/Csqw0qytN8yiWWWQ/PK6MzMT6sat3PxGv7gn+zPC6RqTkPO4B/ICsy/wDGPjIW++3s9NhVicrsLYPrQ1Hq0S/e0bNu5dFRflcDsNn60gju5I91vYXkgx0WEkfga5ya48V3RUzaokSEAbYYVznr+VNkstfbIGv6jjbvO2bYp9ql26C5YdzoIbXVPMdDpF6EJzuMeM1aNrfgjGmXxHRjsHA/OuLt9F1C8h8yXWdTPJwpnbkVbt/DCqN02oajyec3L/40lfoD5PM6yC0v3O3+zLsE8hmAFJf+FLrV7GRL2PUIjGCY47RBuz/eLE/pWB/YNqpJ+1X2TjGLh/8AGkk8PxumYNQ1KF8fKyXLZB/OmuYacE72Z5T+0JoEPh6Dw5bRR3kbk3JcXP3j/qv8TXjVer/HG91R4tG03V7qS6awluRFJKcsUYQkZP4V5RUpW0HN3dwr6Q+EZ/4t/pAPcS+v/PZ6+b6+j/hMdvw90rIzxLjj/ps9CIZ2sffJOT7mnjgAtj2NV1O3dsBNSu+QMLg+w6VRIox5mPlIPXIqVU+ZewH41Av+tBXueuafnLA+nH+NJAPKgybiAM8cioZ7dZUIVsdfc0uGI+Ths56imLI/mvuGAMYVTz+NDBXMk26plncOCdu0e1VZ7FtudmdvB4rcgtW3F5fL3K5ZQpOAKlkhQo6LjDe5qFC6Lcjj5dOuJLMwwMYomOSRnK85+XHfOK8t1/wbq91e311EGvcHADyHeOnIJ4P0r39U+XHHTHFJFaRlmwAoY8j6UlTs7rcp1ZOKi3ojxHStIU2llZ6us1vaRMZDI+SykgZQY4AzXdeGI/Ou5dPjUS2EQD29yOBnuv8A9euwm0m2lhKyRqy53GprO0jhKmNVAA4GMU1Bp3NamJ9pFJohSxjQbTzlvSpGtI2wcfdAA5q/IFJDYGQeCTzSACNweueAfWtDluRpZoEXOC3uKngEaNtUcE9h/SpZuLdSrBiTxjjHtUTZ2BmGSD6mi1guPeRMgc5PpU3ml1xuKooPLVW53E4JwP509nXaDnh+nY59aaAjlkckqHBwME5oiVgFZW3HBB96WaBHjbhvUrzg/lT7ZNgGwFVIotcdlYlQltpA5pQFDkkjIA680bSpB/nTlAJJUHHXOetOxNhoctzjA9/1p6yMq9Buz3p0YDqxA96guEJZUBPXp6U7BuRlNzDJKqP8KlaPERKkYI/OkUbVA+nAHSllLsAucKvFIDLkVvJMSABgc5bkVYgWNVg4G8nJBPeo5kduDhQvUetPi/eTRM3AX0NR1K6FLxPpkV5ZTSCJTIoz8wOc12fhaNdZ8LWElwFdmhAOT0YDFZJiD70+8Cu3JrndF8RP4ahu9OkDGPzm2N02buf51nVj1NaF5S5Ud4umvMW06UNegKG8tRuwp9T2/GqGpafHFOI7XybaUcFWcMWx22jP9K4a1urwQG6k1Fi5QmWOKYiOVtxO5gOpA4A6Cuu8L6dLqUMV5CyGPoyE4I96yvGmr9TsnRuryegksF3awSyfZNQuUTn91tjX8OrVixeIpJGY6fYWcbdPMlBlbPvngV63YWssSqjGPZjoByT9a811u58Oyamz+HpWlmlnaGXyU3QGUdQW6A1qqtleWiOb2bd+RGVJda3dHZPfShDyEhOwY/Coo9CWR/MnfeuPmZiSfrWtcXOn2ikXuoW+9R80Vv8AvWx6HHANZsvikqxGl6P5jj/ltdtnk/7Iros/tMxtLqXbHREkO2zt3mkGPuRnA/HoKZrmnaXZLt1XWbTTuoMUB86c57ADgfrWbcTeItWwL3UZIbfGDDb/ALtPpgVNp/h22tB5hjUsf4sjJ/HrS91bK/4f1+AtF1NnTviCdN0yPTfBmiBLeNdgubz5Sx7sVHJPuTWVqUuva9n+3tYuXiY5+zwnyovpgdfxq/FBFHgLt2+uehqZfLVCFC5JJ4U/5xTTa209P6uHO+hk2fh/TbdR5VuhPrjPSrqW8EcnyxoFPqP8KZNJhm6DA7f5/WiJmWTkkZ4JC8g+tRoT5ltI0BHK7V4AWpSy7QVCgfnVFZW2hQTu6BhjmplJyGyd2ckD+VUIkmIVC5K8Hp61W1Cxt9Si8qcSFCMHY5XcPTipmXexwSwxj6U2MujcHA6nPIoBO2xPGEWIBNxVVwpB5wPeqs0wB2AENnJ46VZDDOeACearHaZmY8tjA54o9BofCBGPlynOckcVPvITJBUjjqD+NQnhjk8Hn6U3PQ5BU8e1AjxD9oXnVtLYD5WSTB9cbB/SvI69n/aLQBvD8mPmYXAP4eX/AI14xUS3NAr6M+FGB4A0kkjpL1/67SV8519FfCpj/wAIDpHoFl7f9NpKQM7HOAMduvNSIxCgfz70xcgZZc8dqViSeSMjpjvTIJEI35Ixg/pS7hgncR2APU0xSCcbvem5OTkihAPVv3hVvTP+TSg/MSyNkDBqIllYEHB7U4kFssxP6ZoAdnyyTzuPYDpQJTxk5IORxTifM4BPsajx1BPenYCSNiQdyDPtVoIGBJAHbr61UVgr4wTj04pyu5JyfyoAlYEKEXnpzik3KoOBgDINRtJtRiW4PvyKYcv6kZ/zmmIt5DHnJI7eh/z2oSMOzOuTzwKii3EdOc8AVNGzqxAbHHPFAmyVdgTJVhn15pzsqjkAj3GKjUr3PPbn9adyFyD7DPeqQIAwL7iB8x+n4UTRIQSAFOOh/wA9KjBA2knHc45zVnEbc5Ynvxxmp3C9gVR5a4kAK4AAp4bkE/d6cjvUaDAbp/j61taLFaSaff3N6k0gt2jVUjfb97dzkg+lUtAMwj1xj/PanADB5XcBkn1Fawm0RlGLG865/wCPkf8AxNWr+HRrVbV2s7xjcQib/Xj5ckjH3efu0xnNxSYX5RkHnP1601mBBJUFs9M10emx6Jf30NstpeL5sgTcZxxn/gPvVK5k0RZTGbK+O0nkXKj/ANkpXAwGboBjAPUnFLuyhPUV0kEWiTade3X2K+AtdmVNwvzbjj+7VAXfh8r/AMeF/gdvtK//ABFILGBKAM8Y4wCTUMS+WzY6ZyK6/VI9BsY7NjZ37m5gE4H2gDblmGPu/wCzVTTW8PX2p2toLK/Rp5Vi3falO0sQM/cpFIxDdKhZiCB2AH+fyrm9ejiuGLyA52n7v9a7a+k8PQXM0LWGoNscpkXa84P+5UYs/Dd3pOoXx0/Uwtp5eUF2vzb2x/c4xilLXQcdDxq5jt5LB7aW9vbG7S4DrdIA6mLnchTuehB+tbGg/F6w8LXkenwpqGq2vCmfyliY+4XNdHeReD2P7zRdVYsMk/b15/8AIdRat4Y8D6bBpd2dF1eRr6A3GBfICnzsuD+75Py5qXCNtjb2smrNnT6x8QrXWNNsxpv2yJGffMgjKyFccL6YJ61ymqaxfXkSQW1kmmWuMFY9vfrwOMn161u+F7fwrd6lZ2EWl6rCbmZIgzXqtt3EAH/Vj1rUm/4RuK4lgbTdSIjYpk3a84OP7lZxp2epbqaWOFsLNVOf3ZDdR65retI1yQoDAdR17/rXUWNh4cu9Ov7pNPv1FpsbYbpfm3NtznZ24/Oo0fw9CuV03UQAOguh/wDEVrHQ5pGdbhicMV6Zx6VPKkYRSvJPHI610F3HodtaWMv2K9P2mIyhRcKCvzFcfd56VFpqaFe31vbLY3yiaVYt32lTjcQP7tUZ2OfRMjcoOCeAcD8aRUIzljyOfT8K6G5fQ4JZEayvT5bFCTcjsf8Acqa2TRLrT764+xXo+zIjlftC/MWYL128Hmi4HIMq7sq3U9Cf50uWbluSDj8a2jNoGGP9m6hjP/P0v/xFWr6HQbOzspjZX7i6iMgT7UvyjcVx9znpQUc4ItwZdwA7YNG0ovzMSfbv7Vvae/h+8vIIBY36NJKqAm6Xgk4z9yn6g+hWl7PbPYag3luUyLpcNgkZ+5TFY55nccrycfxdaeoDHAPfpjrW5JBpV3o2o3NlbXkE9qiMpknVlbc6r02jsa5x85U/P0Gfb2xQBZJWNT8oz2xULOpyfug4OfekLl1PIPpk9f8A6/vTSpwOeR1oAl3dDk9Dn6+lVht8xRubgbjTmAA+QcY/Cgv5Y+7z19fxpMaPJP2hyDH4e5zzc/8AtKvGa9j/AGgmLJ4fJxnNwDj/ALZV45UspBX0L8LXx4C0kcDAl59f3z189V9A/DAk+BNKUE9Jf/Rr0hnaRScdevQVPncv8I47VTiJbGXOfarSk4IJJ3e/5UEsahAVyAPyqVSWVcKM+gqvAShILMQT61KXKhWGdozwec00A/cDxj5fQn/PFRu5f1yeetIpLSnllzx05z/jSjaEJIJ9D2FMRIhyq4xnpwKVlGAckc+nNQMVTpjPUAHFKZFwT6elFwJ0JbAIxkHPFOjlJYhuD049ageVUADD73btTBIoYsv3ex96LgWmKswAGMd8EUM25TksR6H1qJZMHIOee3ajeAc85znmmBNC3DFhkDtVhZOM9SOnPT/69QDooAOCP4ef/wBdLECUb5jjr+v8qaJZIG5B6AflUxJIJB7dh0qLC8DacnqWxzQhTfjqOh5xQCJlX5AG79wP6U5mMagHjHUZ7VE7Krjb0PA9qR24b0PYrx/n+dNDepMXyF+bt+XpVy2vZLfT7m1MYK3DRsxPVSucYH41SDABQPwIpTJg5YjkcE/ypgWonBGffkY6fjWhqlxNMlms8JhKW6xpuyN6ZJDD8z+VY0UjJKreYI23DD7jge/HNbviy6t742FxDfC6khtUgkKh87xnLfMoznP1ouOxnaZdtp9/DdBQxhfeFPc5zj/PSqzvvkdjnLEnGarF1DcEgD+I96OvXkepFIDVtFvl0W9VLGaS0uAu+cRsVXY2eo4/wrJkQKeBxnPPfium8P3tlp8MklxeLue2kjChZDNGTnhOseD1yfWuWdA3JBwevTFIC5qN+b6O0Uoq/ZoBCCMnIBJz/wCPVFoIuhq8M9hay3U1u6zCNELE7SD25xUQUkcKOPyAq34emaw1G4eG+ispHiKbpYvNVwSMqRhuvrg9KTQIp6lDdrdS/bLeS3mkcv5cqFSAeehqOG8eDT7+y8pSLvy9x542HNanimWxudSZ9LjRIQqg+WmxXcD5mVew/KsR1LSAsCCATxj/AD/hTRSMue1MpChW3FsDA6nPQe9bOuabqbWGnDUNKu7e3sofIDvA6hsuzckj1aq7wBs7MDB9cjH+e9bes6haf2ZZaLpM3mQRj7RcyhCvmzNxjkD7oGBQ0O5z2kONO1K1vURWa2mSUKeMlWBwT+FTvJ59xLKygGR2bAOepzS+Sc5Xgjv608R5AIbAycgUrDubGi/bP7N1KO0s5p4ZVRZJEjJ8vawbnA9qrRCORehBznArqPC2s2dnp9st7JsFpcNPGI2YPISuMEbCpByR95f8efe43yysAFV2zjGdoppGcizd3Dzw2UTBUS3iMakc5G4tn9aTTzNFcpcwwvILZllbap4AOQSR05qKHDZGRn3ra0S8gh0jVLa61BIBcLtjidZCu/IO7CqQMgY9eKbEtTGuvMu5Li8EDmIyFnKodqFjnGaLe7+zWl7boMrdKqtzyu1g3H5Vr2V1C3hW9sbi/QSSsjwwsJCF2kkj7pAzxzn64rni6hirfKO3b86kllctulCL8zngKOc+31q7e/2jqBtbCPTrhrmyjMZjWJi+NxOSuMj72Kj0q4+zatbzG7+yhXyZ8twO/wB0E8jjpzmtbVLiwu/EmoXaanatazMJVjmSYRydtrbQGBHXHT3oGc3bS3Gn6jEzxMs1vKrmOQbTkHOMdanmuhdXNxcOqo0sjOVU5wSc8fnU/jK8g1LxHeXFpNI8UpXYzJgk7QPy44zzWYmIlIzuGOeDTQzatZri1026jW1dob3bErlGxlWDEKeh6dPeq97pt9ZxmW+s7uCHO0PLEygn0yR1xn8q2bzULa48MabavqiSXdtLvKskjFEOAACVxlfTOOOKi8R6laXuk4nuLe/1Zrjf9qgtzF+7AxhsquTnHr9aVwOdGACVXg98f5/KoldjkbSPqOtHmKQylPSoskkDaGHUE8c/5/OmCHMWLDIx9Bx9aeihTliQR2ApsWNxUZzjOcdKFCBwHQfKeDn9M1LGjyb9oM7hoJGMZuOn0irxyvYf2gCCmgEf3rjv/wBcq8epMpbBXv3wyB/4QfSiOBiXJ64/evXgNe9fDQkeCNLO04xLyOP+Wr1LGdakmSegUdCMkVYDuwPdh2GeKqgLIoYL0zwP1pyEbV3ZU9qEwLEBJO75Vx371ZXkcL2qnAdyOpBJHelZigGFG48U0xNDncxFiSuDxjrmpLd98IfqCOmMf5+tU1DFsEZA/PNT27kIAO2etC1BosEEZyRtP04pAMMQWJznAFMznOTknvnpSSF+h4PbBpsRI24ZO8ng4qMeYWByGA44Hb/P5VLEzFflXr1OaEJJzxg+9MQqnu2Ae4A4pWZflO8HHanBGBOOO+f8/wCRUZU9C20dvXNAF0lHxjr9cVFLIYVCsQTnsM4yarpMzXCoNxXnkdqsTA7Sx6noR2FCegrWLAHygHnPcdqcpP3XYFsHByKr+c2M5x755pFmGAOGx1OaoLEu8I6qWPX2/T/CpRIkhIYgjHY5z/n9KoTXA3NgDPTJ55otGIaUOSc44x0pJ9h20uWgSblSdoQ+vf0ra0/TheadqN0Ziq2kavsC535OPXj9axJGGQyNwvYdvpWhpWsPp8F1AlvBcQ3SKkiy7ugORyrA0xepbsdHv762823tt6EtsLOoL4HO0E5bA9AcVMujal9k+0CAeV5IuOJVz5fZtuc4/DiktvF13a2otIooo4EctGiSzIEJ6jKyAkZ55J61DH4ovFUIYoMCxOn52n/V9d3X73v09qLsqxdXw1flUaWJEXMe9mlTdGHOASucjOe9W5vC3lR6xH9o825s2hWEiZEVt7EfNknaeOhIP5ii+8VwSaVdhA7ahcLCJJ2iCD92cg43tk8eg96y5fE9zcPek29qn29o2mKq2d0ZyDyxwfXt6YNGoWKkOmXL60umTpOtxv8ALdVCkg+2SB+tTr4d1R4/Mgt1ZHEjR5lQO6ocMQuckj2pH126bXl1cJD9q8wSbADs9Omc/rV6DxPfItq6R2x+zCYLuVukhyc8/l/WnZiMfTNPur/zvskQxEN0ju4RVHTlmIA/Gpbfw/qU0bSJCrRgsQUkjO/b94pz8wHcjNVU8TLpCyW7xxXEV8oWSJkYqwU5BJBBBB6c1qWHiu8itPskccaWqbjGqTSpsDHJGVcEj03ZpBYaNA1EQCcwRCPylmyZUz5bdHIzkD3PTvT9X8Lvp+oahAtwZhawefmIJnGFzuXfleo9SeuKbL4jvmgdBFbtmyWx4DfcHfr19e3tUV14mvbi7u52t7QTXVv9mndVf5x8uGxuwDhR0/KjUpWETwtrStIktuiSiUREGeI7WIyAfm4JBGM9ajtvDWqSyyCGzIZWaHazopZ1BJCgkFsY6DNWpPFd/Pc3MssNsrz3EVywCtjdGAAB83T5RVhfGGohZlKoySTNMQkkse1mOSAUdTjnoSaaTAhvvDF5GmnfZ5EuJLuISmNXUFOuc/N0GOW4HaoofDGsSzmGCzDt5ayjZKhBRjwQc4Iz6dKntfFF9E1pLHHAZrSMxLLtbcyHOVPzdPcYPHWo5vEd7cpcoY0/0iHyHDSSyEANngu5xz+HtTswIJdIv7K2+0XcMccZyyh50DEZxkLnJH0HvUIBclmbCjvzWlHrN2ujNpaxxC3KqpJMjHg5yAzlVyeflAqnAAIyXwDk4/z/AEoJbEKRjG0cg9MU10XHzcnp7D2/+vT3cFsnPTGR2qokj7ijdAODj/PFSSPdQdrAE98Y/mP6VBLkyK3Ib6VK7MABnhjksO59ahZxnBHt9KkOg1woX1zj5v5fhULjdtYDlTzk8g/401S4cqSduOMGo3YnAHzD681QWHSfOo459c5pwxyM9ueahjjZiDnkHpnipGCqeeM+goGkOLbl+Yg9uKRmUFeFyw4z0z71H5mVHJUnGcigoS+cHPbPY0mAFhnc4A5xTnfIBDLjqOlQyOoUq2QpxxjpSRjYCpOTnOCO/wDjQOxM7DdnJBP8Pce31pN6u+c78cfLiomXg5YhSMcjNRSzpb/OGx3P+NILHl3x+J8vQQT0a54/79V5BXrnx5YNFoDDubj/ANpV5HU3uWgr3b4cn/iiNLGD92XHPfzXrwmvcPh2+PBuljGRiQYB/wCmr0mNHWW0uGPYDj3p7SoBlhnPQ561SEpVgoyyg8Z4P51I8gCfLyfqKm4zSt2UgkgE5zjOKlU8Yzgnjjt7/wD1qz7KQeVtJ5z0x1q0JNq4Y49sdPx/rVJktE2R5i7RtX2PWhcliWyD/nFRLIp5yCMjGRTpJGRgEUnJODngVQibpgAcHk4FNJAAHLDPQjpSb8nAbDAA9etRlj82Wwfc5oCxYRQUIHBz0qSPkFucdRx/IVSim5wXxx65qdJE34ZmGBxlqaCxcJTbyMe9QyBDuCnAPJNNDo+SJB6f5FMZsqWyPQnNFyRqswlHy/d75/nVnzSo5OTjAGcZNVmkIbYG56f/AK6A2Dw2R9e1AyYsMEdc9sUrYztwUJ4yKi34VmUqSSOP8/561X87O/OFIyMetDaAn2KMN0UdP61ICEYdcHsewqj5wc4JAOcDNPWUeZjGWxzjmhDNDeWHXAHI+tPRvlzxxniqTyDYfmJB6+9NNzggKWw3H19qdyS00wVfvA89MZpEnCsMtWdNcruzk/n1qCWcliUHI469aLlJHQCdWb72AQScDk0sjLgEdc4HPWsVLqTGMbfQipHvXMeWThepzzRcHE2Y5CcdvX3qUPkDI3Ln8qzrOZXTrhqk83aMBSCDjr2qkyS+5WSMhtv+NRopWTAXg+3SoC/ygrwc85qaWYEKCy/h2piT6FgbdhJI3HjAz+VVZjuIEeCAOSOv/wCuoy6h2Xk5wTzQJ1MjnsOSR3ouFxyh3fOO/G3jirALKBxx7/yqCOcAElfz7fWpJLmNix2bWzxmmh3EVtzOq5AGMEVatxhwD3GSaoRS7GweOOOOP8momumyWClTjoDUthuawcRO2COM7fpU0c+I9yMMY6f571z8d0UYs5BGe9Si55HlsApycg9KBWNRmWTeSwB9qgLEYCZYjvnqKjhnUxEOQGIPeoTcbioAzzgEUhF0S7oztB9eR3qB2Rwxcn24xVSa4VEOD07DrQlwjZRv4h1BpBYc33R5Y+UdPp6UmArFmyCPQ04MiqTk46DOP8/hUFxKpjx8oB4wTx/+qmNEzOOCoA45yOopxAdcDI7gkj/OapxTI7cHJ6cHoanZcryU2j5s89PajcY6Xcn3G5x0J/z+VOZsrk4JxwOelQlxtBDA/LnOOppqsSu5higRZORGoCjPr71AR/EH+ZeCPapEkJyD81RFs5wAxHPXHH1pAMClvmZ8dyM4z75qO4hA3bwCDjr1pQzEYPPPHH8/8Ka8ysSCBnH1pNFLc8t+O+BFoIA4BuP/AGlXktes/HV98ehHPe4/9pV5NUlBV631XUbaFYre/u4olGFSOZlA5zwAfUmqNFAGkdc1YnJ1S+J9ftD/AONH9u6t0/tS/wD/AAIf/Gs2igDTXXtXX7uq34zzxcP/AI0o8Q60OBq+o/8AgS/+NZdFAGp/wkOtdf7X1HP/AF8v/jSjxFrYGBrGpYP/AE9P/jWVRQBq/wDCRa3nP9sajn/r5f8Axo/4SLW8/wDIY1L/AMCn/wAayqKANX/hIta/6DGo/wDgS/8AjR/wkWt/9BjUv/Ap/wDGsqigDXHiTXB01rUx9LqT/Gk/4STXP+gzqX/gU/8AjWTRQBrf8JHref8AkM6l/wCBT/40n/CRa1/0GNR/8CX/AMayqKANb/hI9c/6DOpf+BT/AONN/wCEg1nP/IX1H/wJf/GsuigDU/4SDWc5/tbUM+v2l/8AGg+IdZJydX1HP/Xy/wDjWXRQBq/8JDrWMf2vqOOmPtL/AONJ/wAJDrX/AEF9R/8AAl/8ay6KANP+39YH/MW1D/wJf/Gl/wCEh1n/AKC+o5/6+X/xrLooA1R4h1odNY1H/wACn/xo/wCEi1rGP7Y1HHp9pf8AxrKooA1V8R62v3dY1IfS6f8Axp3/AAkuu/8AQa1P/wACpP8AGsiigDXPibXT/wAxvU//AALk/wAaP+Em17ORrep5/wCvuT/GsiigDY/4SbXgc/23qmf+vuT/ABpB4m13JP8Abep5PX/S5P8AGsiii4Gx/wAJNr3/AEG9U/8AAuT/ABoPifXz11zVD/29yf41j0UXA1z4l104zrWp8f8AT1J/jSf8JJrnH/E51Ljp/pT/AONZNFFwNY+I9bIIOsakc9f9Kf8Axpf+El13/oNanx/09Sf41kUUAa//AAkuu4x/bWp4/wCvqT/Gj/hJtdyf+J1qf/gVJ/jWRRQBq/8ACR63nP8AbOpZ/wCvp/8AGgeI9b/6DGpf+BT/AONZVFAGv/wk2vY/5DWp/wDgXJ/jR/wk2vf9BvU//AuT/GsiigLGr/wkWt/9BjUv/Ap/8ad/wkuu4x/bWp49PtUn+NZFFAGsfEetkYOs6kR/19P/AI0f8JJrn/QZ1L/wKf8AxrJooA1v+Ek1zOf7Z1LP/X1J/jSjxJro6a1qf/gVJ/jWRRRcDVPiPWzwdY1Ij/r6f/Gj/hIta/6DGo/+BL/41lUUAW73Ub2+CC+vLm5CZKedKz7c4zjJ4zgflVSiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Velamentous umbilical cord insertion of a bilobed placenta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Pathology Department at The Valley Hospital in Ridgewood, New Jersey.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Velamentous cord insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diamnionic, monochorionic twin placenta with the intervening amnion rolled in the center. Notice the haphazard vascularization (large arrow). The velamentous cord insertion (small arrow) of the smaller twin of this discordant pair is not an unusual finding in monochorionic twins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mhairi G. MacDonald, Mary M. K. Seshia, et al. Avery's Neonatology Pathophysiology &amp; Management of the Newborn, 6th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42458=[""].join("\n");
var outline_f41_29_42458=null;
var title_f41_29_42459="Differential diagnosis of abnormal adult behavior";
var content_f41_29_42459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of abnormal adult behavior",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Life-threatening conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wernicke's encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS infections (meningitis, encephalitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage (eg, subarachnoid, subdural)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epilepsy (eg, nonconvulsive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication adverse effects and interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication withdrawal syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrine disease (eg, thyroid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke without focal motor deficit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS mass lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42459=[""].join("\n");
var outline_f41_29_42459=null;
var title_f41_29_42460="Precip factors ADHF";
var content_f41_29_42460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common and uncommon precipitating factors associated with hospitalization for ADHF",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dietary and medication related causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary indiscretion - excessive salt or water intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonadherence to medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic volume expansion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Progressive cardiac dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression of underlying cardiac dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical, emotional, and environmental stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac toxins:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricular pacing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac causes not primarily myocardial in origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac arrhythmias:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial fibrillation with a rapid ventricular response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Marked bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduction abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valvular disease:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Progressive mitral regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-cardiac causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary disease - pulmonary embolus, COPD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia, from bleeding or relative lack of erythropoietin or bone marrow suppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic infection; especially pulmonary infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adverse cardiovascular effects of medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cardiac depressant medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nondihydropyridine calcium antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type Ia and Ic antiarrhythmic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Sodium retaining medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Steroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonsteroidal anti-inflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Medications that reduce contractility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anthracyclines and other chemotherapeutic agents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Heart Failure Society Of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006; 12:e86. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42460=[""].join("\n");
var outline_f41_29_42460=null;
var title_f41_29_42461="Paramedic thrombolysis examination checklist";
var content_f41_29_42461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paramedic thrombolysis examination checklist",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"centered\" colspan=\"5\">",
"        <p>",
"         Wilkes County Emergency Medical Service",
"        </p>",
"        <p>",
"         Advanced level practical skills examination",
"        </p>",
"        <strong>",
"         Thrombolytic therapy",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"5\">",
"        Date:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Candidate name:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Examiner signature:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Level:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- EMT-P",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Automatic failure = critical critera",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Cumulative failure = 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Exam series:&nbsp;&nbsp;&nbsp;- A&nbsp;&nbsp;&nbsp;- B&nbsp;&nbsp;&nbsp;- C&nbsp;&nbsp;&nbsp;- D",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Time start:",
"        <br/>",
"        &nbsp;",
"        <br/>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Time finish:",
"        <br/>",
"        &nbsp;",
"        <br/>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Yes",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Takes appropriate precautions for personal protection [may verbalize]",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Assures that all steps on chest pain/suspected cardiac event protocol have been completed",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Assures patient has two (2) patent IV lines or has twin catheter that is functional",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Correctly interprets 12-lead ECG and transmits [may verbalize] to ED for physician review",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Performs history and assessment of acute MI signs and symptoms",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Repeats 12-lead ECG and correctly interprets 12-lead ECG",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Performs neurological assessment for thrombolytics",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Completes thrombolytic therapy screening form",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Performs [may verbalize] rectal exam using hemoccult slide and developer",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Contacts medical control and provides patient information and requests permission for thrombolytic therapy",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Ensures that all needed adjunctive medications and therapies have been administered",
"        <em>",
"         (according to WCEMS protocols)",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Administers enoxaparin (Lovenox) with correct dosage and route according to age and weight",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Properly reconstitutes tenecteplase (TNKase) for administration",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Administers the correct weight-based dose of TNKase over 5 seconds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Verbalizes need for frequent assessment of patient clinical status",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Verbalizes need to contact medical control for patient report and transmission of repeat 12-lead ECG to ED for review",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Verbalizes need to document&nbsp;patient information&nbsp;with 12-lead ECG tracings and screening form",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        At the completion of test submit this form to the examination representative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Critical criteria",
"        </strong>",
"        <em>",
"         (document rationale for critical criteria on reverse side of this form)",
"        </em>",
"        <ul>",
"         <li>",
"          Failure to assure two patent IV lines or&nbsp;one twin catheter",
"         </li>",
"         <li>",
"          Failure to perform a neurological assessment",
"         </li>",
"         <li>",
"          Failure to complete thrombolytic screening form",
"         </li>",
"         <li>",
"          Failure to&nbsp;provide all needed adjunctive medications and therapies",
"         </li>",
"         <li>",
"          Administers incorrect dose and or uses incorrect route of enoxaparin",
"         </li>",
"         <li>",
"          Administers incorrect weight based dose of TNKase",
"         </li>",
"         <li>",
"          Failure to verbalize need to reassess patient after enoxaparin/TNKase administration",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        <em>",
"         OFFICIAL USE ONLY - DO NOT WRITE IN THIS BOX",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Candidate result:",
"       </td>",
"       <td>",
"        Pass",
"       </td>",
"       <td>",
"        Fail",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Failure due to:",
"       </td>",
"       <td>",
"        Critical criteria",
"       </td>",
"       <td>",
"        Cumulative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Representative:",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henderson McGinnis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42461=[""].join("\n");
var outline_f41_29_42461=null;
var title_f41_29_42462="Melker cricothyrotomy catheter";
var content_f41_29_42462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Melker cricothyrotomy catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cricothyrotomy catheter is pictured above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from COOK Medical. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42462=[""].join("\n");
var outline_f41_29_42462=null;
var title_f41_29_42463="Finger pulley system";
var content_f41_29_42463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Finger pulley system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 169px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The retinacular portion of the finger tendon sheath consists of cruciform, annular, and transverse tissues that facilitate smooth gliding of the tendons and form a pulley system that enables effective finger flexion without displacement of the tendons (ie, \"bowstringing\"). The retinacular pulley system is comprised of the palmar aponeurosis (PA) pulley, five annular (A) pulleys, and three cruciform (C) pulleys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Doyle JR. Hand. In: Doyle JR, Botte MJ, eds. Surgical anatomy of the hand and upper extremity. Philadelphia: Lippincott Williams &amp; Wilkins, 2003:522-666. Copyright &copy;2003 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_29_42463=[""].join("\n");
var outline_f41_29_42463=null;
